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Abstract 
 
Glucagon-like peptide-2 (GLP-2) is a peptide hormone, secreted 
postprandially from enteroendocrine L-cells. GLP-2 has emerged as a central 
physiological mediator of intestinal growth and integrity and has recently 
shown promise as a therapeutic agent in patients with short bowel syndrome 
and inflammatory bowel disease. 
Reliable methods for GLP-2 measurement are not widely available. In this 
work a radioimmunoassay (RIA), using the GLP-2 antiserum (FT-17) has 
been optimised and validated. Cross-reactivity with GLP-2 precursors and 
degradation products was investigated using column chromatography. It is 
shown that accurate estimations of active GLP-2 secretion in response to a 
physiological stimulus can be made using this RIA.  
Plasma concentration of GLP-2 and other hormones, secreted from L-cells, 
were investigated in patients with short bowel syndrome (SBS), morbid 
obesity and in those following Roux-en-Y gastric bypass (RYGB) surgery. It 
is shown that, contrary to current thinking, SBS patients with a retained colon 
can be GLP-2 deficient despite increased L-cell activity as indicated by raised 
levels of PYY. Differential regulation of peptide generation in L-cells, 
depending on the residual intestinal anatomy, is a possible explanation. 
Secretion of PYY and glucagon-like peptides may also differ in obesity. 
Despite a previously documented attenuated postprandial PYY response in 
obese compared with normal weight subjects, no difference in glucagon-like 
peptide secretion was found in a series of test meals. In obese patients 
undergoing RYGB, an exaggerated postprandial GLP-2 response was noted 
as early as 2 days following the procedure and persisted for at least 2 years. 
In diabetic patients this adaptive response was delayed. 
Enhancing endogenous GLP-2 secretion might serve as a therapeutic 
strategy for patients in whom intestinal mucosal regeneration is impaired. It is 
shown that bile acids and glutamine act as effective GLP-2 secretagogues in 
model L-cells and that diversion of bilio-pancreatic secretions to the distal 
ileum leads to increased plasma concentration of GLP-2 in rats. 
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1.1 GLP-2- Physiology and clinical applications 
1.1.1 Preface 
 
Glucagon-like peptide-2 is an important growth factor secreted from the 
human intestine. Since its specific intestinotrophic properties were first 
described in 1996 by the Canadian research group around Prof. Daniel J. 
Drucker (Drucker et al. 1996), the body of research investigating GLP-2 has 
grown exponentially and there is now an increasing understanding of its role 
in intestinal physiology in health and disease. At the present moment it 
appears that GLP-2 may become a useful therapeutic adjunct in the 
treatment of short bowel syndrome and inflammatory bowel disease and first 
clinical trials in such patient groups are underway. Therapeutic application 
might however expand to other causes of intestinal injury like ischaemia, 
radiation or chemotherapy. Some nutrients, known to be important for 
intestinal integrity and growth, like glutamine and short chain fatty acids, 
might in fact mediate their effects via GLP-2. GLP-2 also appears to 
influence bone metabolism and could therefore provide a new treatment 
angle for patients with osteoporosis. Even though a major future impact on 
daily practice is not yet certain, GLP-2 is moving from the obscurity of 
research laboratories into the clinical environment. The introduction to this 
thesis is therefore dedicated to exploring our current knowledge of GLP-2 
physiology and analysing its use in the clinical environment.  
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1.1.2 GLP-2 - Part of the proglucagon derived peptide family 
 
Glucagon-like peptide-2 is a 33 amino acid peptide hormone with an 
estimated molecular mass of 3765.8 (Hartmann et al. 2000). It is formed 
through cleavage from a much larger peptide, proglucagon, a prohormone 
that is mainly expressed in pancreas, intestine and brain. In 1983 Bell and 
collegues first isolated and sequenced the human proglucagon gene (Bell et 
al. 1983). The mammalian gene is 9.4 kilobases in length (White et al. 1986; 
Irwin 2002), comprising 6 exons separated by 5 introns (White et al. 1986). 
The gene has been mapped to chromosome 2 (segment 2q36-2q37) 
(Schroeder et al. 1984; Tricoli et al. 1984). The initial translation product 
preproglucagon is a peptide of 21 kDa, containing 180 amino acids. It 
includes a 20-amino acid signal peptide that is cleaved to produce the 18-
kDa proglucagon (Lopez et al. 1983). 
 
Proglucagon contains three homologous hormonal sequences, glucagon, 
glucagon-like peptide-1, and glucagon-like peptide-2, separated by two 
intervening peptides, IP-1 and IP-2, and preceded by an N-terminal 
extension called glicentin related polypeptide (Rouille et al. 1995). 
Alternative, tissue specific splicing through prohormone convertases leads to 
the formation of additional, extended peptides. In intestine and brain GLP-1 
and GLP-2 are produced together with glicentin and oxyntomodulin, which 
contain the glucagon sequence. In the pancreas, glucagon is secreted 
alongside the large major proglucagon fragment (MPGF), which combines 
the sequences of GLP-1, IP-2 and GLP-2 (Rouille et al. 1994; Rouille et al. 
1995) (Figure 1-1).  
 
In older literature, the terms enteroglucagon or glucagon-like 
immunoreactivity are commonly encountered. These in fact represent 
glicentin and oxyntomodulin. Because both peptides contain the entire 
glucagon sequence, they were detected when intestinal tissue was 
incubated with antibodies against glucagon.  
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The term glucagon-like peptide is derived from the observation that both 
GLP-1 and GLP-2 exhibit considerable sequence homology to glucagon 
(Figure 1-3). It is assumed that these three peptides originated by triplication 
of an exon that encoded a glucagon-like sequence (Irwin 2001). The GLP-2 
peptide sequence has undergone significant evolutionary change in its 
amino acid composition and possibly also biological function. Within 
mammals the sequence is highly conserved (Irwin 2001); for example: 
human GLP-2 amino acid sequence differs only in one position from rat 
GLP-2 and in two positions from mouse GLP-2. Recent reports show that 
porcine GLP-2 comprises a 35 amino acid sequence with C-terminal Serine 
and Leucine, in contrast to the 33 amino acids of human, cow, rat and 
mouse GLP-2, although it retains similar effects in vivo and in vitro in spite of 
the structural differences (Pedersen et al. 2008) (Figure 1-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1: Differential processing of proglucagon in pancreas, intestine and CNS.   
  (Partial processing is indicated by dashed arrows.)  
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Pancreatic α islet cell 
Glicentin related pancreatic peptide   PG 1-30   GRRP 
Glucagon      PG 33-61 
Intervening peptide 1     PG 64-69  IP1 
Major proglucagon fragment    PG 72-158  MPGF 
Glucagon-like peptide 1 (1-37)    PG 72-107  GLP-1 (1-37) 
 
Intestinal L-cell  
Glicentin related pancreatic peptide   PG 1-30  GRPP 
Glicentin      PG 1-69 
Oxyntomodulin     PG 33-69 
Truncated Glucagon-like peptide 1 amide (7-36)  PG 78-106  GLP-1 (7-36) 
Truncated Glucagon-like peptide 1 (7-37)   PG 78-107  GLP-1 (7-37) 
Intervening peptide 2     PG 111-123  IP2 
Glucagon-like peptide 2     PG 126-158  GLP-2 
     
 
Figure 1-2:  Main products of proglucagon processing.  
 
 
Glucagon     HSQGTFTSDY     SKYLDSRRAQ     DFVQWLMNT 
    GLP-1     HAEGTFTSDV     SSYLEGQAAK     EF I AWLVKGR G 
    GLP-2     HADGSFSDEM     NT I LDNLAAR     DF I NWL I QTK  ITD 
 
Figure 1-3:   Sequence homology between Glucagon, GLP-1 and GLP-2.           
Underlined, bold: positions shared by all peptides.  
 
 
 
      Human     HADGSFSDEM     NT I LDNLAAR     DFI NWLIQTK  I TD    RK 
      Rat      * * * * * * * * * *            * * * * * * * * T *        * * * * * * * * * *             * * * K* 
      Mouse      * * * * * * * * * *            S* * * * * * * T *        * * * * * * * * * *             * * * K* 
      Cow      * * * * * * * * * *            * * V* * S* * T *        * * * * * * L* * *             * * * ** 
      Pig      * * * * * * * * * *            * * V* * * * * T *        * * * * * * LH* *             * * *   SL 
 
 
Figure 1-4:   Sequence homology of proglucagon 126-160 between mammals  
 (adapted from (Pedersen et al. 2008);  
The last two amino-acids are the cleavage site (PG 159-169) which is altered in the 
pig sequence. 
* Amino-acids identical to human GLP-2. 27 out of 235 amino-acids have been 
completely preserved among the 5 species. 
(See Appendix 3 for code of amino acids)     
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1.1.3 GLP-2 - synthesis  
 
Under physiological conditions, intestinal GLP-2 is produced in L–cells, a 
subset of enteroendocrine cells. It is released synchronously and in 
equimolar amounts with GLP-1 (Orskov et al. 1986). The glucagon-like 
peptides are partly co-localized with GIP (“L/K cells”, primarily in the upper 
small intestine) and PYY (primarily in the lower small intestine and colon) 
(Eissele et al. 1992; Mortensen et al. 2003; Theodorakis et al. 2006). L-cells 
are the second most abundant population of endocrine cells in the human 
intestine, exceeded only by enterochromaffin cells. They are thought to arise 
from pluripotent stem cells in the crypts. Most of the L-cells reside in crypts 
of Lieberkühn, but a few cells can also be observed in the intestinal villi 
(Kieffer et al. 1999). L-cells are open type cells. Their microvilli reach into the 
intestinal lumen; the endocrine granules are located near the basement 
membrane. This design permits intimate contact with the luminal milieu, as 
well as proximity to the enteric nervous system and microvasculature and 
hence allows hormonal discharge in response to nutritional, neural and 
hormonal signals. 
  
A high abundance of L-cells is present in the distal jejunum and ileum. Along 
the colon, the L-cell mass increases from the proximal to the distal segments 
with high concentrations found in the rectum (Eissele et al. 1992). The 
highest tissue levels of GLP-2 are found in the ileum. In the colon, the GLP-2 
content increases from the ascending colon to a maximum concentration in 
the rectum (Caddy et al. 2003; Schmidt et al. 2005). Recently it was 
established that L-cells are also present in the human duodenum 
(Theodorakis et al. 2006).  
 
The concept of distinct cell populations, dedicated to the synthesis and 
release of separate peptides, has been questioned lately. Instead, highly 
specialized enteroendocrine cells might originate from a multipotent cell 
population, able to produce peptides according to stimuli in the metabolic or 
biochemical milieu (Theodorakis et al. 2006). 
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1.1.4 GLP-2 - secretion  
 
The complex mechanisms of glucagon-like peptide secretion from the L-cell 
are not fully understood as yet. Both GLP-1 and GLP-2 are produced 
simultaneously and co-secreted (Orskov et al. 1986; Theodorakis et al. 
2006). Accordingly their concentration and diurnal profile are highly similar 
(Hartmann et al. 2000). This also means that data relating to GLP-1 
synthesis and release is largely applicable to GLP-2 and vice versa. Basal 
GLP secretion appears to occur in a pulsatile manner, with 5-7 pulses per 
hour (Balks et al. 1997). Nutrient challenges produce a rapid rise of 
glucagon-like peptides (Balks et al. 1997). The postprandial profile seems to 
follow a biphasic pattern. A first peak occurs within 30-60 minutes and is 
followed by a second plateau within 90-150 minutes (dependent on the kind 
of nutrient ingested) (Balks et al. 1997; Xiao et al. 1999). It is believed that 
the initial rise of GLP-2 is caused by early indirect L-cell stimulation through 
neurohumoral signalling which is followed by later, direct stimulation through 
nutrients reaching the distal intestine (Brubaker et al. 2003).  
 
Nutrients play the predominant role in GLP secretion. Meal-related GLP 
secretion depends on nutrient composition and calorie content (Xiao et al. 
1999). Luminal carbohydrates are well documented GLP secretagogues 
when given as a meal or intraduodenally (Unger et al. 1968; Kreymann et al. 
1987; Elliott et al. 1993; Qualmann et al. 1995; Balks et al. 1997; Kong et al. 
1999; Xiao et al. 1999; Feinle et al. 2002; Henriksen et al. 2003). 
Conversely, intravenous glucose administration has no effect on GLP 
secretion (Unger et al. 1968; Nauck et al. 1993; Herrmann et al. 1995). 
Lipids have also been established as potent GLP secretagogues in humans 
(Elliott et al. 1993; Layer 1995; Hartmann et al. 2000; Feinle et al. 2002; 
Feltrin et al. 2004; Feltrin et al. 2006). The effect of fatty acids appears to 
vary depending on chain length (Feltrin et al. 2004)  and saturation 
(Brubaker et al. 1998; Feltrin et al. 2006). Recently, Hirasawa and 
colleagues  have demonstrated in STC-1 cells that GLP-1 secretion in 
response to long-chain free fatty acids is mediated via the specific G-protein 
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coupled receptor GPR-120 (Hirasawa et al. 2005). A number of studies have 
demonstrated a positive effect of short chain fatty acids on proglucagon 
mRNA abundance (Tappenden et al. 1998; Drozdowski et al. 2002) and 
GLP-2 secretion (Tappenden 1998; Bartholome et al. 2004). The evidence 
for the role of protein in the regulation of GLP release is not conclusive. Xiao 
and colleagues have reported that levels of active GLP-2 do not increase 
following a protein meal (Xiao et al. 1999), other authors however found a 
positive response in GLP-1 (Elliott et al. 1993; Hall et al. 2003) and GLP-2 
(Henriksen et al. 2003) levels. A recent report has indicated a strong 
stimulatory effect of glutamine on GLP-1 secretion (Reimann 2004).  Even 
though Cholecystokinin (CCK) does not appear to influence GLP secretion 
(Brubaker 1991; Plaisancie et al. 1994), there is increasing evidence that bile 
acids play an important role in GLP release (Adrian et al. 1993; Plaisancie et 
al. 1995), possibly mediated through the novel bile acid receptor TGR5 
(Maruyama et al. 2002; Katsuma et al. 2005).  
 
The rapid postprandial rise of glucagon-like peptides is widely believed to be 
subject to intricate interaction of neural and hormonal mediators. Research 
in rodents led to the hypothesis of a proximal-distal neuroendocrine loop 
whereby nutrient induced release of gastric inhibitory peptide (GIP) initiates 
afferent vagal stimulation, which in turn leads to efferent signalling via the 
coeliac nerve to the ileum. In the enteric nervous system gastrin releasing 
peptide (GRP) is released via nicotinergic synapses, which in turn stimulates 
muscarinergic receptors on the L-cell to release GLP (Rocca et al. 1999; 
Anini et al. 2002). However; even though cholinergic transmitters are known 
to stimulate GLP secretion from L-cells (Brubaker 1991; Herrmann-Rinke et 
al. 1995; Brubaker et al. 1998; Dumoulin et al. 1998; Reimer et al. 2001; 
Anini et al. 2002; Anini et al. 2003), there is no conclusive evidence that 
efferent signalling through the vagus nerve is important for GLP secretion in 
pigs and humans (Wojdemann et al. 1999; Hansen et al. 2004). Instead it is 
possible that parasympathetic innervation mainly mediates local reflexes in 
the intrinsic enteric nervous system (Hansen et al. 2004). Equally, despite 
evidence of a direct stimulatory effect of GIP on L- cell models (Brubaker 
1991; Brubaker et al. 1998; Damholt et al. 1998) and in rat intestinal explants 
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(Plaisancie et al. 1994; Herrmann-Rinke et al. 1995), its physiological role in 
GLP release in humans remains unclear (Kreymann et al. 1987; Nauck 
1993; Nauck et al. 1993). Given the close proximity of K- and L-cells 
(Mortensen et al. 2003; Theodorakis et al. 2006) it is possible that, GIP 
related effects are mediated in a paracrine rather than hormonal manner.  
Somatostatin, which is produced in D cells throughout the intestinal tract, 
inhibits secretion of PGDPs in various animal models (Brubaker 1991; 
Hansen et al. 2000; Chisholm et al. 2002). Both GLP-1 and (to a lesser 
extend) GLP-2 have been shown to stimulate somatostatin secretion  
(Chisholm et al. 2002; Hansen et al. 2004), implying that L- cell secretion is 
subject to negative feedback mechanisms through glucagon-like petides 
themselves and via paracrine somatostatin activity.  
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Figure 1-5: Mechanisms of GLP-2 secretion.  
Enteroendocrine L-cells and K-cells are stimulated through different nutrients 
reaching the duodenum (A). Subsequently, L-cells in the distal ileum and colon are 
stimulated, either directly through nutrients and metabolites and/or neuroendocrine 
stimulators (B). GLP-2 is released from L-cells and stimulates GLP-2 Receptor 
carrying cells, located mainly in the proximal small intestine but possibly also on 
osteoclasts and pancreatic islet cells (C). 
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1.1.5 GLP-2 - metabolism 
 
In a similar fashion to GLP-1 and GIP, active GLP-2 (1-33) is degraded by 
the ubiquitously expressed proteolytic enzyme dipeptidyl peptidase IV 
(DPPIV) (also known as CD26). Cleavage of N-terminal histidine and alanine 
results in the formation of the GLP-2 degradation product: GLP-2 (3-33) 
(Brubaker et al. 1997; Tavares et al. 2000). In vivo half-life of intravenous 
GLP-2 (1-33) has been reported at 7 minutes,  in vitro half-life is 8 hours in 
plasma and 3.3 hours in blood (Hartmann et al. 2000). Substitution of amino 
acid alanine with glycine at position 2, as in teduglutide (GattexTM NPS 
pharmaceuticals, Bedminster, New Jersey, USA), renders GLP-2 resistant to 
DPPIV-mediated degradation. This technique, or the adjuvant use of DPPIV 
inhibitors, extends the GLP-2 half-life (Thulesen et al. 2000; Jeppesen et al. 
2005; Marier et al. 2008), and confers greater biological potency (Drucker et 
al. 1997; Hartmann et al. 2000; Jeppesen et al. 2005). Renal excretion 
plays a key role in GLP-2 clearance. Injection of I125 labelled GLP-2 has 
localized renal uptake to the proximal part of the tubules, consistent with 
glomerular secretion (Thulesen et al. 2000). Increased GLP-2 levels have 
been demonstrated in nephrectomized rats (Tavares et al. 2000) and 
humans with chronic renal failure (Brubaker et al. 1997). However, since 
some clearance can be observed in nephrectomized rats, other organs and 
mechanisms are suspected to contribute (Tavares et al. 2000). As uptake of 
injected I125 GLP-2 is also high in the liver (Thulesen et al. 2000), it is likely 
that this is a place of GLP-2 inactivation and possibly clearance. 
 
1.1.6 GLP-2 - receptor and downstream mediators 
  
GLP-2 acts through a specific receptor (GLP-2R) that belongs to “Family B” 
(also “Glucagon/Secretin family” or Class II”) of G-protein coupled receptors 
(GPCRs). In 1999 Munroe and colleagues were the first to clone and 
characterize the cDNAs encoding the rat and human GLP-2 receptor 
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(Munroe et al. 1999). The human GLP-2R gene has been mapped to 
Chromosome 17 (17p13.3). It encodes a polypeptide of 553 amino acids.  
 
The highest GLP-2R concentrations have been described in the jejunum 
followed by duodenum, ileum, colon and stomach with undetectable levels in 
oesophagus, adipose tissue, heart, kidney, liver, skeletal muscle, spleen, 
testis and uterus (Munroe et al. 1999; Yusta et al. 2000). There have been 
recent reports of GLP-2 receptor presence on osteoclasts (Henriksen et al. 
2004) and pancreatic islet cells (de Heer et al. 2007). Detection of GLP-2R in 
brain and lung tissue requires more sensitive techniques like real-time PCR. 
The relative abundance of GLP-2R expression in the jejunum is at least 20-
30-fold higher than in the brainstem (Yusta et al. 2000). Small, focal areas of 
GLP-2R expression have also been detected in samples of human tumours 
including intestinal carcinoid tumours and colorectal carcinoma (Yusta et al. 
2000; Koehler et al. 2008). Moreover, GLP-2R cDNA sequence tags have 
been detected in large cell lung- and cervical carcinoma cell lines, as well as 
in the normal human cervix (Koehler et al. 2005).  
 
The precise location of the GLP-2R at a cellular level within the GI tract is the 
subject of ongoing research. Even though GLP-2 exerts strong stimulatory 
effects on epithelial proliferation, there is no apparent expression on crypt 
epithelial cells or enterocytes. Instead, the receptor has been demonstrated 
on enteroendocrine cells (Yusta et al. 2000), enteric neurons (Bjerknes et al. 
2001; Guan et al. 2006) and subepithelial myofibroblasts (Orskov et al. 
2005). This implies that intestinotrophic and other effects of GLP-2 are 
mediated through other downstream effectors (Figure 1-6). Insulin-like growth 
factor-1 (IGF-1), which is co-located with the GLP-2R in subepithelial 
myofibroblasts, appears to be essential for GLP-2 induced intestinal epithelial 
proliferation (Dube et al. 2008; Liu et al. 2008). Other growth factors, like 
vascular endothelial growth factor (VEGF) and transforming growth factor-ß 
(TGF- ß), have been linked to GLP-2 induced wound repair (Bulut et al. 
2008). Anti-inflammatory effects appear to be mediated through release of 
vasoactive intestinal peptide (VIP) from enteric neurons, independent of 
  26 
proliferative action (Sigalet et al. 2007). Nitric oxide (NO) might be a key 
mediator in GLP-2 induced up-regulation of intestinal blood flow (Guan et al. 
2006). 
 
 
 
Figure 1-6: Proposed model for the indirect mechanisms of GLP-2 action in the intestine. 
Expression of the GLP-2R in (A) enteroendocrine cells, (B) intestinal subepithelial 
myofibroblasts (SEMF) and (C) enteric neurons, suggests that GLP-2 acts indirectly 
to produce its diverse actions in the intestine. IGF-I is critical for the ability of GLP-2 
to induce intestinal growth and activate crypt cell proliferation and ß-catenin 
signalling. Other SEMF-derived growth factors may induce complementary actions 
to those of IGF-I, such as keratinocyte growth factor (KGF) in the colon. GLP-2-
mediated enteric neuronal signalling enhances intestinal blood flow through a 
mechanism involving NO production and has anti-inflammatory actions through 
vasoactive intestinal polypeptide (VIP), although the target of this VIP effect remains 
undefined. Neural GLP-2 receptor signalling may also influence the crypt epithelium 
and gastrointestinal motility.  
 
Reprinted with permission (Dube et al. 2007) 
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1.1.7 GLP-2 - physiological role and pharmacological effects 
 
GLP-2 influences multiple aspects of gastrointestinal physiology.  Studies, 
utilizing relative GLP-2 deficiency models, have demonstrated that GLP-2 is 
one of the causative factors for regulation of intestinal growth (Hartmann et 
al. 2002; Perez et al. 2005; Shin et al. 2005). Recent studies suggest that 
GLP-2 plays a physiological role in control of local intestinal blood flow 
(Stephens et al. 2006; Bremholm et al. 2008) and bone homeostasis 
(Henriksen et al. 2003; Henriksen et al. 2004). GLP-2 may also have 
importance in foetal intestinal development (Amin et al. 2008).  
 
In addition, there is a large amount of correlative data linking GLP-2 to 
intestinal growth and adaptation in various pathological conditions, like post-
resection intestinal adaptation (Jeppesen et al. 2000; Ljungmann et al. 2001; 
Topstad et al. 2001; Dahly et al. 2003; Paris et al. 2004; Martin et al. 2005), 
coeliac disease (Kilander et al. 1984; Caddy et al. 2006), TPN induced 
intestinal atrophy (Burrin et al. 2000; Niinikoski et al. 2004) and inflammatory 
bowel disease (Schmidt et al. 2000).  
 
Pharmacological administration of GLP-2 induces mucosal growth in small 
and large bowel (Drucker et al. 1996; Brubaker et al. 1997; Drucker et al. 
1997; Tsai et al. 1997; Litvak et al. 1998; Kato et al. 1999; Ghatei et al. 
2001). Intestinotrophic effects of GLP-2 are mediated not only through an 
increase of intestinal crypt cell proliferation but also through a reduction of 
villous cell apoptosis resulting in expansion of villous height (Drucker et al. 
1996; Chance et al. 1997; Drucker et al. 1997; Tsai et al. 1997; Benjamin et 
al. 2000; Jeppesen et al. 2005) and crypt depth (Drucker et al. 1997; 
Ramsanahie et al. 2004; Jeppesen et al. 2005). Epithelial cells undergo 
morphological changes; become narrower and longer with elongated 
microvilli (Benjamin et al. 2000). The trophic effects are more pronounced in 
the proximal small intestine (Tsai et al. 1997; Scott et al. 1998; Hartmann et 
al. 2000). A single injection of GLP-2 appears sufficient to promote crypt cell 
division. On daily treatment, effects are persistent at 3 month; after treatment 
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cessation however, all changes of intestinal morphology rapidly reverse (Tsai 
et al. 1997).  
 
The GLP-2 related increase of intestinal mass is accompanied by enhanced 
intestinal digestive and absorptive functional capacity as evident in 
enhanced expression and activity of brush border enzymes (Brubaker et al. 
1997; Kato et al. 1999; Kitchen et al. 2000; Petersen et al. 2002) and 
absorption of nutrients (Cheeseman et al. 1996; Cheeseman 1997; 
Cheeseman et al. 1998; Kato et al. 1999; Au et al. 2002; Guan et al. 2003; 
Meier et al. 2006).  The effect on glucose uptake is inhibited by L-NAME and 
therefore possibly dependent on nitric oxide (Guan et al. 2003). The rapidly 
increased hexose transport is facilitated through upregulation of membrane 
expression and activity of transporter proteins SGLT-1 (Cheeseman et al. 
1996; Cheeseman 1997; Cheeseman et al. 1998; Au et al. 2002; 
Ramsanahie et al. 2003; Martin et al. 2004; Cottrell et al. 2005) and GLUT-2 
(Au et al. 2002).  
 
GLP-2 reduces gastric acid secretion (Wojdemann et al. 1999; Meier et al. 
2006). In animal models GLP-2 inhibits gastro-intestinal motility 
(Wojdemann et al. 1998; Bozkurt et al. 2002); results of human studies are 
conflicting (Jeppesen et al. 2001; Schmidt et al. 2003; Nagell et al. 2004; 
Meier et al. 2006). GLP-2 stimulates glucagon secretion and inhibits the 
glucagonostatic effect of GLP-1 (Sorensen et al. 2003; Meier et al. 2006; de 
Heer et al. 2007)  
 
GLP-2 has shown a beneficial effect on intestinal barrier function in rodent 
models of type-1 diabetes mellitus (Hadjiyanni et al. 2009), necrotising 
pancreatitis (Kouris et al. 2001), psychological stress (Cameron et al. 2005), 
food allergy (Cameron et al. 2003) and thermal injury (Chance et al. 2001). 
  
 GLP-2 infusion causes rapid up-regulation of portal blood flow (Guan et al. 
2003). The increased portal flow mainly derives from a GLP-2 related 
perfusion increase in the proximal intestine and pancreas, whereas flow to 
the distal intestine, stomach, spleen and kidneys remains unchanged or is 
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decreased, indicating flow increase in the superior mesenteric artery (Guan 
et al. 2006; Stephens et al. 2006).  The mean arterial blood pressure is not 
altered during GLP-2 infusion indicating that the vascular effect is locally 
restricted (Wojdemann et al. 1999; Guan et al. 2006; Stephens et al. 2006).  
 
Nitric oxide (NO) appears to be an important mediator of the GLP-2 related 
vasoactive effects. The NO-synthase (NOS) inhibitor L-NAME suppresses 
GLP-2 increased portal blood flow (Guan et al. 2003). The GLP-2R has been 
localized in neurons also containing eNOS and GLP-2 infusion increases 
abundance of eNOS mRNA and protein. It is speculated that NO, following 
GLP-2 mediated release, diffuses locally to the vascular smooth muscle to 
activate cGMP synthesis and stimulate arteriole dilatation (Guan et al. 2006). 
The GLP-2R is also co-localized with VIP in enteric neurons and with 5HT in 
enteroendocrine cells (Guan et al. 2006). Both substances are known to 
have a potent vasoactive effect on mesenteric blood flow (Ganz et al. 1986; 
Hansen et al. 1998) and could represent downstream mediators of GLP-2 
action. 
 
In various animal models of inflammatory bowel disease GLP-2 improves 
outcome and reduces expression of inflammatory cytokines (L'Heureux et al. 
2003; Ivory et al. 2008; Yazbeck et al. 2008). The anti-inflammatory effects 
appear to be independent of proliferative GLP-2 actions (Sigalet et al. 2007) 
and do not depend on Interleukin-10 (IL-10) (Ivory et al. 2008). 
 
GLP-2 also affects bone metabolism. A dose dependent reduction of bone 
resorption marker s-CTX and attenuation of the physiological nocturnal s-
CTX increase has been shown in healthy postmenopausal women. 
Moreover, the detection of GLP-2R on osteoclasts suggests that GLP-2 may 
form part of a “entero-osseous axis”, coordinating nutrient dependent bone 
turnover (Henriksen et al. 2003; Henriksen et al. 2004; Henriksen et al. 
2004).  
 
Glucagon-like peptides, including GLP-2, are also liberated in the central 
nervous system and are likely to play a regulatory role. This aspect of GLP-
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2 action, not yet well explored, is an important area for future research but 
will not be covered in any further detail in this thesis.  
 
For practical reasons, GLP-2 and other intestinal mediators are often studied 
in isolation. Undoubtedly however, GLP-2 secretion forms only a small part of 
a complex intestinal response to nutrient intake and will act in concert with 
other gut hormones (for instance GLP-1 and PYY which are also 
postprandially released from the L-cell).  
 
A number of other factors are known to affect intestinal growth. Even though 
the individual growth promoting properties of these factors have been well 
documented, less is known about how they interact. Several, including 
epidermal growth factor (EGF), appear to act synergistically with GLP-2 
(Drucker et al. 1997; Kitchen et al. 2005). Nutritional factors like glutamine 
and short chain fatty acids (SCFAs) might exert their growth enhancing 
properties by facilitating GLP-2 production and release (Bartholome et al. 
2004; Reimann 2004), whereas keratinocyte growth factor (KGF) and insulin-
like growth factor 1 (IGF-1) probably act as downstream mediators (Orskov et 
al. 2005; Dube et al. 2006).  
 
 
 
Growth hormone  (GH) 
Glucagon-like peptide 2  (GLP-2) 
Insulin-like growth factor 1 (IGF-1) 
Epidermal growth factor  (EGF) 
Hepatocyte growth factor  (HGF) 
Transforming growth factor α  (TGF-α) 
Keratinocyte growth factor  (KGF) 
Neurotensin 
Leptin 
R-Spondin 
Glutamine 
SCFAs 
 
 
Table 1-1:    Intestinotrophic growth factors 
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1.1.8 GLP-2 - clinical applications  
 
Short bowel syndrome (SBS) is a highly disabling condition that typically 
arises after extensive intestinal resection. When the remaining functioning 
intestinal mass is insufficient to maintain the nutritional needs of the 
individual, long term parenteral nutrition (PN) becomes mandatory. Although 
PN has revolutionized SBS treatment; it reduces quality of life and carries 
significant risks, mainly hepatic failure, central vein thrombosis and recurrent 
sepsis, which can reduce survival. SBS patients with end jejunostomy and no 
colon, known to have poor intestinal adaptation, have a markedly impaired 
postprandial GLP-2 response (Jeppesen et al. 1999). In contrast, patients 
with a preserved colon can exhibit increased fasting GLP-2 levels with a 
postprandial profile comparable to healthy controls (Jeppesen et al. 2000). 
These findings, combined with evidence of a correlation between GLP-2 and 
intestinal adaptation in animals (Scott et al. 1998; Ljungmann et al. 2001; 
Topstad et al. 2001; Dahly et al. 2003; Martin et al. 2005; Koopmann et al. 
2008) have raised hopes that GLP-2 therapy might increase intestinal 
absorption and reduce PN dependence, through enhancement of post-
resection intestinal adaptation. 
 
In small, uncontrolled, open label pilot studies of SBS patients, native GLP-2 
and the long acting GLP-2 analogue teduglutide caused significant 
improvements in fluid absorption. Increases in energy absorption were 
relatively minor. Similar results were achieved in patients with and without 
preserved colon, implying that supra-physiological GLP-2 concentrations may 
exert additional benefit (Jeppesen et al. 2001; Jeppesen et al. 2005). Results 
of a phase 3 multi-centre randomized controlled study of teduglutide  
(GattexTM NPS pharmaceuticals, Bedminster, New Jersey, USA) have been 
published in abstract form (O'Keefe et al. 2008). In  86 patients with stable 
post-resection SBS a reduction of parenteral nutrition requirement (> 20% of 
weekly requirements) was achieved significantly more frequently following 24 
week daily treatment with  teduglutide (0.05mg/kg) compared with placebo 
treatment (45.7% vs. 6.3% responders; p=0.007). Interestingly, this benefit 
was not seen in a parallel group who received teduglutide at a higher dose 
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(0.1mg/kg). Plasma citrulline, a sensitive marker for enterocyte mass and 
function (Papadia et al. 2007), increased with teduglutide treatment but not 
with placebo, indicating intestinotrophic effects (Messing et al. 2008). 
Accordingly, increased villous height was documented (Tappenden et al. 
2008). A 28-week extension study established that long term treatment with 
teduglutide was safe and that parenteral nutrition reductions could be 
maintained for up to 1 year in the majority of patients. (Jeppesen et al. 2008), 
4 subjects were able to be weaned off parenteral nutrition completely.  
 
These results indicate that GLP-2 treatment can achieve clinically useful 
reductions of PN requirements in SBS patients, considered to be stable on 
optimal conventional management. However, SBS comprises a 
heterogeneous group of patients with regards to nature of the underlying 
illness and amount and quality of the residual intestine. These factors may 
influence treatment response and optimum treatment dose. It has been 
shown in rodents that GLP-2 augments post-resection adaptive growth 
predominantly in the proximal but not distal intestine (Koopmann et al. 2008). 
Timing of treatment initiation might also be of relevance. Recent studies 
suggest maximal effects of GLP-2 on post-resection intestinal adaptation, 
and in particular on intestinal stem cell expansion, in the early post-operative 
period (Garrison et al. 2008; Kaji et al. 2008). Post-resection intestinal 
adaptation involves alteration of other gut hormones, including GLP-1 and 
peptide YY, which have strong inhibitory effects on gastrointestinal motility 
and secretion. Combination treatments might provide synergistic benefit. 
An 8 week, phase 2, placebo controlled clinical trial in 100 patients with 
moderate to severe Crohn's disease suggests a dose dependent benefit of 
teduglutide treatment; although the placebo response was high (55.6% of 
patients in the highest dose group vs. 33.3% of the placebo group went into 
remission) (Buchman et al. 2006). Further research must determine whether 
these results relate to symptomatic disease control or reflect decreases in 
inflammatory activity and improved mucosal healing. 
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The benefit of GLP-2 related reduction of bone resorption has been studied 
in SBS, because metabolic bone disease is highly prevalent in patients on 
long term PN. Initial results were promising. In a small group of SBS patients 
with jejunostomy, 35 day GLP-2-treatment led to an increase in bone mass 
and bone mineral density (BMD) (Haderslev et al. 2002). However, two 
recent studies could not replicate these findings. A single injection of GLP-2 
reduced s-CTX in 15 healthy control subjects but not in 25 colectomy patients 
(13 ileostomy, 12 jejunostomy); whereas the postprandial decrease in s-CTX 
was preserved in all groups (Gottschalck et al. 2008). 14 day GLP-2 
treatment decreased s-CTX in 13 ileostomy patients, but not in 8 jejunostomy 
patients. 56 day treatment did not change the BMD in the jejunostomy 
patients (Gottschalck et al. 2008). These findings make a direct effect of 
GLP-2 on bone cells less likely; instead it appears that the effect of GLP-2 on 
bone turnover requires an intact small bowel and might be mediated through 
other intestinal downstream effectors. Nonetheless GLP-2 might provide a 
new treatment modality for treatment of osteoporosis in patients with an 
intact intestine.  
GLP-2 has positive effects in animals with chemotherapy- (Boushey et al. 
2001), radiotherapy- (Torres et al. 2007) and ischaemia-reperfusion- (Zhang 
et al. 2008) induced mucosal injury. Improved outcome is thought to reflect 
reductions in apoptosis, stimulatory effects on splanchnic perfusion and 
enhancement of intestinal barrier function with subsequent reduction in 
bacterial sepsis. Preclinical trials of Teduglutide for the treatment of 
chemotherapy induced mucositis and necrotising enterocolitis are 
currently underway (NPS Pharmaceuticals press release). 
 
The question, whether measurement of endogenous GLP-2 plasma 
concentration in SBS can be a useful prognostic tool, has so far only been 
addressed in one study of premature infants (Sigalet et al. 2004). Here, 
postprandial GLP-2 levels were shown to be significantly correlated with 
residual small intestinal length and macronutrient absorption. A significant 
difference in average GLP-2 level of infants, able to achieve TPN 
independence (45.3pmol/l) versus infants unable to achieve TPN 
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independence (2.25pmol/l) at 1 year follow up was demonstrated. 
Interestingly, and in contrast to findings by Jeppesen et al. (Jeppesen et al. 
2000), some infants with severe short bowel but a residual colon had very 
low plasma GLP-2. Out of 4 patients with a GLP-2 level of less than 
15pmol/l, 3 died, but none with a level above this threshold.  
 
It is unlikely that results from an infant patient population can be directly 
applied to the adults in whom short bowel syndrome is caused by a 
completely different spectrum of diseases. However, defining a realistic 
prognosis in this patient group is crucial. Intestinal failure is a chronic 
condition that will require intensive treatment over many years. Accurate 
prognostication allows better management of patient expectations and 
allocation of resources. 
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1.1.9 GLP-2 - tolerability and safety of treatment 
 
Human studies so far report good drug compliance, tolerance and safety of 
native GLP-2 and teduglutide with no significant increase of serious adverse 
events. Most commonly reported adverse events are abdominal pain, 
bloating, constipation, nausea, injection site erythema, lower limb oedema, 
stoma swelling, headache and nasopharyngitis.  
 
The therapeutic use of GLP-2 may require lifelong administration. Because of 
concerns that permanent stimulation of epithelial proliferation might initiate or 
accelerate malignant growth, research into the role of GLP-2 in 
carcinogenesis is ongoing. GLP-2R expression has been demonstrated in 
cancer cell lines and human tumours including colonic adenocarcinoma 
(Koehler et al. 2005; Koehler et al. 2008). GLP-2 also exerts a direct 
proliferative effect on transformed cell lines despite apparent lack of a 
specific receptor (Rocha et al. 2004). Recently however, no GLP-2 
dependent proliferation of GLP-2R transfected colon cancer cell lines could 
be demonstrated (Koehler et al. 2008). In vivo, GLP-2 treatment of tumour-
bearing Apc Min/+ mice showed no increase of tumour burden (Koehler et al. 
2008). However, in another mouse model, GLP-2 promoted the growth of 
chemically induced colonic neoplasms (Thulesen et al. 2004). Until a clear 
safety profile for GLP-2 is established, special vigilance is required. This 
should include screening of prospective patients for pre-malignant lesions 
(particularly colonic adenomas) as well as surveillance during treatment. 
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1.2 Hypotheses 
 
 
The aim of my research was to establish and optimize a method for GLP-2 
measurement and to contribute to the current understanding of GLP-2 
physiology. 
 
The hypotheses to be tested in this thesis are as follows: 
 
 A departmentally generated GLP-2 antiserum (FT-17) can be utilized to 
develop a sensitive and specific radioimmunoassay. 
 
 Measurement of GLP-2 and related L-cell secretions provides insights 
into the regulation of intestinal adaptation to intestinal failure secondary to 
short bowel syndrome. 
 
 Alterations of GLP-2 and related L-cell secretions occur in the obese and 
changes of L-cell secretion are related to the adaptive response following 
obesity surgery. 
 
 Endogenous GLP-2 secretion might be enhanced by bile acid or 
glutamine supplementation.  
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Chapter 2 
 
 
 
 
Description and optimization 
of a glucagon-like peptide-2 
radioimmunoassay 
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2.1 Introduction 
 
2.1.1 Measurement of GLP-2 
 
The importance of GLP-2 as a regulatory gut hormone is increasingly 
understood. Information about GLP-2 secretion in a variety of physiological 
or pathological states is therefore of great scientific interest and may also 
have clinical applications. The concentration of GLP-2 in tissue samples or 
bodily fluids can be determined in a radioimmunoassay (RIA). RIA is a 
highly sensitive technique, able to measure minute amounts of circulating 
peptide, which has revolutionized the field of endocrinology (Buchanan et al. 
1981). The method is described in detail in chapter 2.1.2. Up until now, the 
RIA technique has been utilized in the majority of published GLP-2 research. 
An alternative method of GLP-2 measurement, the enzyme-linked 
immunosorbent assay (ELISA) technique, is described in chapter 2.1.3. 
The substitution of radioisotope by an enzyme label offers certain 
advantages over the RIA: like the lack of radioactive decay, which limits the 
shelf-life of RIA reagents, and the avoidance of the hazards associated with 
radioactive isotopes. The method requires less operator time and can be 
readily automated. However, sensitivity can be lower compared to the RIA 
technique. The greater precision of the RIA has ensured its survival where 
critical quantitative measurement is required (Zola et al. 1996). This might 
explain why so far only a few publications (Martin et al. 2004; Martin et al. 
2005) have documented the use of ELISA techniques for the measurement 
of GLP-2. A Japanese research group has used a biological GLP-2 assay 
which comprises the measurement of serum-induced cAMP production in a 
COS-7 cell line, transfected with a recombinant GLP-2 receptor. This 
approach, that utilizes the fact that GLP-2 receptor stimulation leads to rapid 
cAMP accumulation (Munroe et al. 1999), detects full length, bioactive GLP-
2 and has virtually no cross-reactivity with other glucagon-related peptides 
(Watanabe et al. 2005). 
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When measuring GLP-2, with either RIA or ELISA, the specificity of the 
antiserum used is of great importance. No cross-reactivity should occur with 
related gut hormones (e.g. glucagon, GLP-1, secretin and others). 
Additionally it has to be considered that biologically active GLP-2 (1-33), its 
largely inactive metabolite GLP-2 (3-33) and the pancreatic proglucagon 
product MPGF contain identical amino acid sequences. Therefore, only 
antibodies that specifically recognize the free N-terminus of GLP-2 are 
specific for the measurement of active GLP-2 (1-33). So called “side viewing” 
antibodies, raised against mid-sections of the GLP-2 peptide, will cross-react 
with N- and C- terminally modified forms of this peptide and therefore not 
only recognize active GLP-2 (1-33) but also its metabolites and precursors 
like proglucagon, GLP-2 (3-33) and MPGF. The resulting level is commonly 
referred to as total GLP-2 immunoreactivity.  
 
It is possible to separate GLP-2 (1-33) and GLP-2 (3-33) with 
chromatographic techniques like reverse phase HPLC. However, this is 
technically difficult and laborious, requiring a relatively shallow gradient and 
very rapid fraction collection rate (Brubaker et al. 1997). For the 
measurement of active GLP-2 (1-33) a specific antiserum therefore seems 
preferable. 
 
The main body of published research describes the use of two antisera.  
Antiserum UTTH-7 was developed by the group of Prof Daniel J. Drucker at 
the University of Toronto, Canada (Brubaker et al. 1997). It was raised in 
rabbits against synthetic rat GLP-2 (1-33). The antigenic site recognized by 
UTTH-7 is localized to amino acids 25-30 of GLP-2. This means that this is a 
side viewing antibody with the limitations mentioned above. An N-terminal 
specific GLP-2 radioimmunoassay was developed by the group of Prof Jens 
J. Holst at the University of Copenhagen, Denmark (Hartmann et al. 2000). 
Antiserum 92160 was raised in rabbits against synthetic GLP-2 (1-11). It is 
specific for active GLP-2 (1-33); only a minor cross-reaction of 5.6% + 1.8% 
is reported with synthetic human GLP-2 (3-33). Neither of these antiserums 
is commercially available. Antiserum FT-17 has been developed by Prof. 
Mohammed Ghatei at Imperial College London, UK. FT-17 is a polyclonal 
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antibody, raised in rabbits against synthetic human GLP-2 (1-33), (Bachem 
UK Ltd.) conjugated to BSA by glutaraldehyde. The antiserum cross-reacts 
100% with human and rat GLP-2, less than 0.1% with GLP-1 and does not 
cross-react with any other known gastrointestinal or pancreatic hormone 
(see appendix 1). The antiserum is used at a final dilution of 1:500.000. This 
work aimed to characterise this antiserum further and to determine whether it 
may be suitable for determination of GLP-2 concentration in humans and 
specifically in patients with short bowel syndrome and related disorders. 
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2.1.2 Radioimmunoassay 
 
The radioimmunoassay (RIA) of a peptide (or any other antigen) depends on 
the competition between radioactively-labelled and -unlabelled substrate for 
the specific binding site of an antibody. The amounts of antibody and 
labelled peptide are fixed. The only variable is the unlabelled peptide 
concentration. The higher the concentration of unlabelled peptide, the less 
radioactively labelled peptide will be bound to antibody. This can be 
measured after separating antibody-bound from free label (for example with 
charcoal or with a secondary antibody) and counting the radioactivity of 
either the bound fraction, the free fraction or both (Adrian 1982). By using a 
series of pure peptide standards, covering the full range of expected values, 
a standard curve is calculated from which the quantity of peptide in unknown 
samples can be deducted (Figure 2-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1:  Principle of RIA (charcoal separation) and RIA standard curve.  
Radioactively labelled and unlabelled antigen competes for the specific antibody 
binding sites. Centrifugation separates the unbound antigen (adsorbed to charcoal) 
from the bound antigen (in supernatant). 
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2.1.3 Enzyme-Linked Immuno-Sorbent Assay (ELISA) 
 
An enzyme-linked immuno-sorbent assay (ELISA) is an immunological 
method that can detect and/or quantify the presence of an antibody or an 
antigen in a sample. In this work, the competitive ELISA technique was 
utilized to measure antigen (peptide GLP-2). A commercially available GLP-2 
ELISA kit (Phoenix Pharmaceuticals, Inc.) was used. It contains a 96 well 
immuno-plate which is pre-coated with secondary antibody that binds to the 
Fc fragment of the primary (GLP-2) antibody, whose Fab fragment is 
competitively bound by either biotinylated GLP-2 and GLP-2 standard or 
GLP-2 in samples. The biotinylated peptide interacts with enzyme 
(streptavidin-horseradish peroxidise; SA-HRP) which catalyzes the TMB 
(tetramethylbenzidine) substrate solution and produces a measureable blue 
colour change. The reaction is terminated by addition of HCl solution which 
changes the solution colour from blue to yellow. The intensity of colour 
reaction is directly proportional to the amount of bound biotinylated peptide-
SA-HRP complex and inversely proportional to the amount in standard 
solution and samples. A standard curve of known concentrations is 
established and concentration of peptide in samples extrapolated. 
 
                                  
 
Figure 2-2:  Principle of competitive ELISA.  
Peptide and biotinylated peptide compete for binding sites on the primary (GLP-2) 
antibody. 
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2.1.4 Chromatography 
 
The concentration of gut hormones in plasma is generally very low. The 
sensitivity of any measurement method might be enhanced if the peptide of 
interest is extracted and thereby concentrated. This will also limit non-
specific interference from other plasma components and therefore improve 
accuracy and reproducibility of the measurements. Because minor variations 
in peptide length can have a profound effect on peptide function, as is the 
case with GLP-2, it may also be necessary to distinguish between various 
molecular forms of these hormones such as precursors, active peptide and 
degraded peptide.  
 
These objectives can be achieved by using chromatography. This technique 
comprises a large group of analytical methods for the separation of mixtures. 
In principle, a mixture, containing various components (“solutes”), is carried 
in liquid or gas ("mobile phase"), through a solid or liquid column ("stationary 
phase"). Passage of the solutes through the stationary phase is modified 
through their specific interactions with the stationary phase, which leads to 
their separation. Different solutes may pass through the system at different 
rates and therefore become separated in time (e.g. size exclusion 
chromatography). Alternatively certain solutes may be retained in the solid 
phase and can then be selectively desorbed by washing with an appropriate 
solvent (e.g. solid phase extraction). 
 
a) Solid phase extraction (SPE)  
 
Solid phase extraction is a technique based on selective partitioning of one 
or more components between two phases one of which is a solid sorbent. 
The second phase typically is a liquid, but it may also be an emulsion, a gas, 
or a supercritical fluid. The components of interest may either preferentially 
adsorb to the solid phase, or they may remain in the second, non-solid 
phase. Once equilibrium has been reached, the two phases are physically 
separated by decanting, filtration, centrifugation or a similar process. If the 
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desired analytes are adsorbed on the solid phase they can be selectively 
desorbed by washing with an appropriate solvent. If the components of 
interest remain in the liquid phase they can be recovered via concentration 
or evaporation (McDonald 2001). 
 
In this work, solid phase extraction was utilised to assess whether peptide 
concentration enhances the accuracy and diagnostic value of GLP-2 
measurement. For this purpose, SepPak C18™ (Sample Enrichment & 
Purification) packed bed column cartridges were used. The solid phase 
packed into these cartridges consists of an 18-carbon hydrocarbon chain 
that is bound to silicate. The separation method is based on the interaction 
between this hydrophobic support and the hydrophobic areas located on the 
surface of proteins. The retained peptides can then be desorbed by washing 
with solvent (e.g. methanol) and analysed. 
 
b) Gel permeation chromatography 
 
Gel permeation chromatography, also known as size exclusion 
chromatography, separates molecules on basis of size. Columns are packed 
with porous beads, e.g. Sephadex (Pharmacia), with a specific pore size. 
Sample is loaded onto the column and a constant flow of buffer solution 
moves it through. Larger molecules that are excluded from the pores 
continue following the solvent flow, eluting quickly in what is designated the 
void volume, Vo. This can be determined experimentally by the use of a 
high-molecular weight component, such as dextran blue (MW 2x106), which 
is easily visible. Smaller molecules however enter the porous media and thus 
attain a much larger volume of distribution. They are therefore retained 
longer and pass more slowly through the column. The elution volume for 
material included in the pores is designated the total volume, Vt. This 
represents the total liquid volume of the column and is often determined by 
small molecules, such as 125I-Na which can be detected with a gamma 
counter.  
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The elution volume Ve for a given protein lies between Vo and Vt and can be 
determined with RIA. A partition coefficient can be determined for each 
protein as Kav (Laurent et al. 1964): 
 
Kav = (Ve-Vo)/(Vt-Vo) 
 
Kav = partition coefficient 
Vo = Void volume       
Vt = Total volume         
Ve = Elution volume of the analyte.  
 
In size exclusion chromatography, the macromolecules are not physically 
retained, unlike adsorption techniques; therefore, the protein will elute in a 
defined volume between Vo and Vt. Elution of protein before the void volume 
(Ve<Vo) suggests channelling through the column; for example due to 
improper packing or operation of the column. If the protein elutes after the 
total volume (Ve>Vt), then some interaction must have occurred between the 
matrix and the protein of interest. 
 
 
 
 
 
 
 
 
 
  46 
2.2 Aims and Methods 
 
2.2.1 Specificity of antiserum FT-17 
 
GLP-2 antiserum “FT-17” was raised by Prof Mohammed Ghatei 
(Department of Investigative science, Hammersmith hospital). His work has 
previously established that antiserum FT-17 has a high specificity for the 
detection of GLP-2. Apart from a weak (0.1%) cross-reactivity with GLP-1, no 
reaction occurs with other related gut hormones (laboratory data Prof. M. 
Ghatei, 1997; see Appendix 1). The Antiserum was used in a dilution of 
1:500.000. 
 
It was the purpose of this work to characterize and optimize a RIA utilizing 
FT-17 and to determine, whether this antiserum is specific for the detection 
of active GLP-2 (1-33); or whether cross-reaction occurs with other 
proglucagon derived peptides that contain the GLP-2 sequence. 
 
a) Source of synthetic peptides 
Synthetic human GLP-2 was used as peptide standard. Human carboxy-
terminal GLP-2 (1-33) and GLP-2 (3-33) were obtained from the Wolfson 
Institute for biomedical research, University College London. Peptides had 
greater than 95% purity as determined by HPLC. 
 
b) Preparation of standards 
Standards were prepared gravimetrically (using an electronic microbalance). 
To maintain stability and solubility of the aliquotted peptides, standard vials 
were prepared in freeze-drying solution (appendix), lyophilised and stored in 
vacuo at -20°C. 
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c) Preparation of radioactive label 
The synthesis of a radioactive peptide label is commonly performed through 
iodination of a tyrosine residue with 125Iodine. Neither rat nor human GLP-2 
contains a tyrosine residue for iodination; however a tyrosine extended 
analogue (Tyr-0 GLP-2) can be used for iodination without significant change 
in antigenicity. 125I (Tyr0)-GLP-2 was prepared using iodogen method (Bolton 
1989) and purified by HPLC. Due to departmental safety regulations, 
radioactive labelling was performed by Prof Ghatei. Test-assays to 
determine and monitor label quality were performed by me.  
 
d) Peptide extraction from tissue biopsies 
Terminal ileal and pancreatic tissue from a healthy adult Wistar rat was 
immediately placed in liquid nitrogen following resection. A tissue sample of 
0.2 g was immersed in 0.5 ml of 0.5-molar acetic acid and boiled in a water 
bath for 15 minutes. The substrate was immediately put on ice and buffer 
solution added to a total volume of 1ml. To estimate peptide concentration, 
the extract was analysed with RIA in different dilutions (1:100; 1:10; 1:1) prior 
to chromatography. 
 
e) GLP-2 RIA 
Sample tubes were arranged in Perspex racks. Phosphate buffer solution 
(see Appendix 2), peptide standard, sample, labelled peptide and antibody 
were added with micropipettes according to protocol (Figure 2-3). Tubes for 
quality monitoring were included in every assay (Figure 2-4). Samples were 
set up in duplicates to increase precision and detect random error. For 
incubation of the reagents, the racks were covered in foil and placed in the 
cool room for 72 hours at 4°C. The cool temperature serves to minimize 
proteolytic degradation and evaporation. Following incubation, dextran 
coated charcoal solution was added with a repeating dispenser to adsorb the 
free hormone. The coating of dextran is thought to block the large pores in 
the charcoal and thus prevent adsorption of the antibody complex. Tubes 
were immediately centrifuged at 1600g for 20 min at 4°C. The liquid 
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supernatant was instantly separated from the solid phase (charcoal pellet) 
through aspiration using a Pasteur pipette and dispensed into a 
corresponding empty tube, which was subsequently sealed with heated 
paraffin wax. Radioactivity was counted for 180 sec in both the charcoal 
pellet (containing adsorbed free label) and supernatant (containing antibody 
bound label) in 4 multiple well counters (model NE1600, NE Technology, 
enabling simultaneous counting of 128 tubes). Peptide concentrations in the 
samples were calculated using a non-linear plot (RIA Software, NE 
Technology) and results calculated in terms of the GLP-2 standard 
preparations.  
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Tubes  Type            Buffer AB     Label Final   
         Volume  
      (µl)  (µl)  (µl)  (µl) 
 
1-2  Blank    600 0 100 700 
3-4  1/2    550 100 50 700 
5-6  2x    400 100 200 700 
7-10  Zero    500 100 100 700 
11-12  Standard 1µl    = 2fmol 500 100 100 700 
13-14  Standard 2µl    = 4fmol 500 100 100 700 
15-16  Standard 3µl    = 6fmol 500 100 100 700 
17-18  Standard 5µl    = 10fmol 500 100 100 700 
19-20  Standard 10µl    = 20fmol 490 100 100 700 
21-22  Standard 15µl    = 30fmol 490 100 100 700 
23-24  Standard 20µl    = 40fmol 480 100 100 700 
25-26  Standard 30µl    = 60fmol 470 100 100 700 
27-28  Standard 50µl    = 100fmol 450 100 100 700 
29-30  Standard 100µl   = 200fmol 400 100 100 700 
31-32  Zero    500 100 100 700 
33- x  Samples 100 µl  400 100 100 700 
y1-y2  XS     600 100 700 
  
Figure 2-3:  Typical set up of a RIA rack for determination of GLP-2 concentration in plasma 
samples 
 
 
• Blank:  
o Contains all assay reagents except antibody 
o Evaluates non-specific binding of labelled hormone to plasma proteins 
• 1/2:   
o Half concentration of labelled hormone 
o Addresses whether greater sensitivity could have been achieved by adding a smaller 
amount of label 
• 2x:  
o Double concentration of labelled hormone 
o Addresses whether greater sensitivity could have been achieved by adding a greater 
amount of label 
• Zero: 
o Contains no unlabelled hormone 
o Included at regular intervals (approximately every 100 tubes) 
o Detects any drift, e.g., due to reagent deterioration or syringe fatigue 
• XS:   
o Excess antibody  
o Should bind the entire labelled hormone 
o Measure of the immunological integrity of the labelled hormone 
o Can be used to assess the quality of the label (once the label becomes older and 
starts to break down, the percentage of bound radioactivity in the “Blank” tube rises 
and in the “XS” tube falls) 
 
 
Figure 2-4:  Tubes for quality monitoring adapted from (Adrian 1982) 
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f) Gel permeation chromatography 
 
A 0.9x60 cm column was prepared using pre-swollen Sephadex G-50 
superfine (Pharmacia, Uppsala Sweden) and equilibrated overnight with 
column buffer (0.06 M phosphate buffer containing 0.2 M NaCl and 0.3% 
BSA). Caution was taken, not to disturb the gel once the column had set, as 
small surface disruptions are known to disturb flow speeds and may lead to 
complete disintegration of the column. To determine the partition coefficient 
Kav, dextran blue (50 µl, MW 2x106 daltons) and 125I-NA (30Bq) and horse 
heart cytochrome C (50 µl, MW 12 384 daltons) were added to each sample. 
All samples (as detailed below) were loaded onto the top of the column with 
a syringe at a total volume of 0.7ml. The remaining sample was saved to 
determine peptide recovery. Once the sample had completely entered the 
gel, the column was filled with buffer solution. Then the system was closed 
and connected to a pump, allowing constant flow of column buffer through 
the gel at 3.2 ml/hr. The eluent was collected in a rotating rack. Collection 
time was 15 minutes per fraction. Fractions of 0.8 ml were collected and RIA 
used to determine the elution profile of GLP-2-IR. Dextran Blue and 125I-Na 
were used to mark the void volume and total column volume respectively. 
Elutes of synthetic peptide standard were analysed at a volume of 100µl. All 
other sample elutes were analysed at a volume of 300µl. Samples were 
analysed in groups, each containing a run of GLP-2 (1-33) standard. All 
samples within one group were analysed in a single RIA. 
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Samples analysed with gel permeation chromatography:  
 
Synthetic human GLP-2 (1-33)   1.5 pmol in 1ml buffer  
 
Synthetic human GLP-2 (1-33)  1.5 pmol in 1ml plasma 
 
Synthetic human GLP-2 (3-33)  37.5 pmol in 1 ml buffer 
 
Human plasma (fasting)    1.1ml 
 
Human plasma (postprandial)  1.1ml 
 
Human plasma postprandial (SepPak) Extract of 2ml, freeze-dried 
      (Reconstituted in 1.2 ml buffer) 
 
Rat pancreas extract    500µl in 300µl buffer    
      (Estimated GLP-2 conc. 1.5 pmol) 
 
 
Rat terminal ileum extract   375µl in 425µl buffer    
      (Estimated GLP-2 conc. 1.5 pmol)
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2.2.2 Optimization of assay conditions 
 
a) Albumin concentration  
 
Antibody-antigen interaction may be influenced by the presence of proteins 
and other constituents of plasma. Antiserums vary in their susceptibility to 
these non-specific effects (Adrian 1982). Ideally, the standard curve of a 
plasma assay should always be set up with an equal volume of hormone-
free plasma in place of the sample to minimize any residual error; but this is 
not always available. Other measures known to reduce non-specific plasma 
effects include reducing the proportion of plasma in the assay tube and 
hormone extraction. Bovine serum albumin (BSA) can be added to the buffer 
solution as a simple measure to adjust for this confounding factor and in 
order to prevent “non-specific sticking” of the peptide to the test tube.  
 
To investigate the impact of varying BSA concentration in the assay buffer, 
three series of standards (0-100fmol) were prepared in phosphate buffer 
containing 0.3%; 1% and 3% BSA and analysed according to protocol. 
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b) Separation method 
 
The ability to separate antibody-antigen complexes from free antigen 
reliably, consistently and rapidly is essential for any good radioimmunoassay 
(Bretheron-Watt 1991). Separation can be achieved in various ways such as 
through immuno-precipitation with a secondary antibody, chemical 
precipitation (alcohol, polyethylene glycol or ammonium sulphate) or 
adsorption (with cellulose, talc or charcoal) (Adrian 1982). Charcoal 
separation is a relatively uncomplicated and commonly used method. To 
examine whether immuno-precipitation with a secondary antibody enhances 
assay sensitivity, two series of standards (0 -100fmol) were prepared. After a 
4 day incubation period samples were separated by means of: 
 
 
1. Charcoal adsorption:  Phosphate buffer 100 ml 
Charcoal 2.4 g,  
Dextran   0.24 g 
(250 µl of solution added to sample immediately 
prior centrifugation.) 
   
2. Immunoprecipitation: Anti-rabbit antibody (sheep) (100µl),   
    Triton X (500µl) 
(Samples are incubated with the antibody for 
1hour at room temperature. Triton X is added and 
samples immediately centrifuged) 
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2.2.3 Optimization of sampling conditions 
 
a) Protease inhibitor  
 
In view of the rapid degradation of GLP-2 through the serine protease 
DPPIV, enzyme inhibitors are commonly added to the collection system to 
prevent peptide loss. The protocols differ amongst laboratories, most likely 
due to local experience and availability of the reagents. The most commonly 
inhibitors used are Trasylol, a non-specific protease inhibitor, phenyl-methyl-
sulphonyl fluoride (PMSF), a serine protease inhibitor and Diprotin A, a 
specific inhibitor of DPPIV. These inhibitors are used either alone or in 
combination. In this laboratory, Trasylol is used routinely when collecting 
blood samples for gut hormone analysis. To assess whether, through 
addition of a specific serine protease inhibitor, peptide loss can be reduced 
when measuring GLP-2, PMSF was added to selected plasma samples. 
 
Pre- and postprandial (60, 120, 180 and 240 minutes) samples of 6 healthy 
volunteers were obtained. 10ml venous blood was drawn from a peripheral 
vein and transferred into Lithium Heparin tubes, containing either Trasylol 
(0.2ml) alone or a combination of Trasylol and PMSF (200 mM, 40µl). 
Subsequently blood samples were processed in the usual manner and GLP-
2 IR measured in an RIA. 
 
GLP-2 immunoreactivity in the samples collected at different time points, with 
and without addition of PMSF was compared, using the paired t-test and 
ANOVA. A p-value of less than 0.05 was regarded as statistically significant. 
 
b) Peptide extraction 
 
Assay sensitivity may be enhanced by removing interference from other 
plasma components through extraction of peptides. To assess whether result 
interpretation could be aided by extracting GLP-2 prior analysis, solid phase 
extraction with SepPak C18 ™ cartridges was performed for selected 
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samples. Peptide recovery was assessed by extracting peptides in plasma 
samples with known quantity of synthetic GLP-2 standard (100fmol, n=8 and 
300fmol, n=8). Fasting and post-prandial blood samples of 8 healthy subjects 
were obtained and GLP-2-IR in unextracted samples was compared with 
results in corresponding extracted plasma samples.  
 
For the extraction process, SepPak C18 cartridges were pre-conditioned with 
10 ml of methanol, followed by 20 ml of water. The prepared cartridges were 
then stored in 4% acetic acid to prevent drying out. 1ml of plasma sample 
was mixed with 1ml of 0.1M hydrochloric acid (HCl) and drawn up into 2ml 
syringes. The mixture was then “loaded” by gently pushing through the 
cartridge into an empty syringe at constant speed. This process was 
repeated ten times to ensure maximum adsorption of the peptide. The 
remnant plasma was discarded. The cartridges were washed with 10ml of 
4% acetic acid, to flush out any interfering compounds. The cartridge was 
placed on top of an eluting tube. 1.5ml methanol was filled into an empty 
syringe without plunger and the solvent was left to slowly filter through the 
cartridge. The eluent was collected and freeze dried and stored. Prior to 
analysis it was dissolved in 100µl of water, left for 60 min at room 
temperature and then re-suspended with 400µl of buffer.  
 
For the comparison of the fasting values with different postprandial time 
points as well as for comparison of neat versus concentrated samples the 
paired student t-test was used. For the evaluation whether the percentage 
change from baseline to a number of subsequent times varied between 
measurements of non-extracted vs. extracted plasma, analysis of 2-factor 
ANOVA was performed. A p-value of less than 0.05 was regarded as 
statistically significant. 
 
c) Freeze-thaw cycle 
 
The stability of peptides is dependent on amino acid composition and 
sequence. Peptide degradation can occur through hydrolysis, deamidation, 
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oxidation and racemization (loss of chiral integrity) of the amino acid or 
peptide. Lyophilized peptides are generally more stable than peptides in 
solution. If the peptide is in solution, freeze-thaw cycles should be avoided 
but this is not always achievable in practice.  
 
To determine whether repeat thawing and re-freezing influences the 
measurement of GLP-2-IR, a post-prandial plasma sample was frozen in 2ml 
aliquots. Aliquots were defrosted 1x, 2x, 3x, 4x, 5x and 10x and GLP-2-IR 
analysed in a single assay (n=12 for each aliquot to determine intra-assay 
variability). Statistical differences between the mean GLP-2-IR 
concentrations in the groups were examined with single factor analysis of 
variance. A p-value of less than 0.05 was regarded as statistically significant. 
 
 
d) Haemolysis 
 
Haemolysis is understood as the release of haemoglobin and other 
intracellular components from erythrocytes to the surrounding plasma, 
following damage or disruption of the cell membrane. It may occur either in 
vivo (due to pathological conditions, such as autoimmune haemolytic 
anaemia or transfusion reaction) or in vitro (due to improper specimen 
collection, processing, or transport). Haemolysis may interfere with 
laboratory testing due to leakage of haemoglobin and other intracellular 
components into the surrounding fluid, which induces false elevations of 
some analytes or reductions through dilution effects (Lippi et al. 2006). 
Serum does not look haemolysed until the concentration of haemoglobin 
reaches 0.2 g/L (Kroll et al. 1994). Products of haemolysis may interfere with 
immunoassays. However not all peptides appear to be affected to the same 
extend and the severity of haemolysis might also be of relevance (O'Rahilly 
et al. 1987).  
 
To determine the influence of haemolyses on the measurement of GLP-2-IR, 
20ml of venous blood was separated into 10ml aliquots. 10ml were 
immediately spun down at 1600g at 4°C and 10ml were first frozen at -20°C, 
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then defrosted and spun down, causing severe haemolysis of the sample. 
Defined amounts of haemolytic plasma were added to the non-haemolytic 
sample and GLP-2 immunoreactivity measured. Differences between the 
groups were determined by single factor analysis of variance and Student-
Newman-Keuls test (post hoc ANOVA analysis for pair-wise comparisons). A 
p-value of less than 0.05 was regarded as statistically significant. 
 
In a separate experiment, synthetic GLP-2 (1-33) peptide standard was 
added and standard curves obtained for different concentrations of 
haemolysed plasma. Difference between the standard curve values was 
determined by student T-test and two factor analysis of variance. A p-value 
of less than 0.05 was regarded as statistically significant. 
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2.2.4 Quality control 
 
a) Sensitivity 
 
Assay sensitivity is the lowest hormone concentration that can be reliably 
detected. It is determined by the steepness of the dose-response curve 
(which depends on the antibody-antigen affinity) and the error of a given 
value on the standard curve. The main causes of error of a 
radioimmunoassay occur through counting error and pipetting error (mostly 
during separation) (Sarson 1982). The maximum sensitivity of each assay 
was calculated as the smallest standard curve value, 2 standard deviations 
from the zero standard (95% confidence interval).  
 
b) Reproducibility  
 
Many factors cause variation in assay performance including deterioration of 
the radioactive label, low antiserum affinity, errors of technique and 
inefficient equipment (Sarson 1982). Comparative data are needed to 
evaluate the quality of a single assay as well as assay performance over 
time. Quality control tubes were included in every assay to determine the 
non-specific binding of the labelled antigen and the quality of the label 
(Figure 2-4). Zero hormone standard tubes were included at various points 
within each assay to allow detection of any drift in measurement. 
Reproducibility controls were prepared by adding synthetic GLP-2 (1-33) to 
pooled human plasma such that 100 µl of plasma would read off the GLP-2 
standard curve in the range of “high”, “medium” or “low”. Plasma was 
aliquoted, lyophilised and stored in vacuo at -20°C. Inter-assay variation was 
determined by adding quality controls to consecutive assays (n=5); intra-
assay variation was determined by inclusion of replicates in a single assay 
(n=8). In addition, aliquoted fresh plasma from a single subject was also 
frozen and stored at -20°C and inter-assay variation (n= 5) and intra-assay 
variation (n=10) determined. 
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To determine reproducibility of GLP-2-IR in physiological samples, pre-and 
postprandial GLP-2-IR concentration of 8 subjects was analysed at 10 time 
points over 270 minutes in 2 sequential RIAs (see also 2.2.5). Pearson 
coefficient of correlation was determined between the duplicate samples 
within in each assay and between the means of the duplicates for the two 
RIA-runs.  
 
c) Sample carryover 
 
Separation of bound and unbound fractions following centrifugation is 
performed with a single pipette. Carryover of analyte from one sample into 
one or more following samples can falsely increase the measured analyte 
concentration. To determine whether this carryover effect is a relevant 
source of error, 100 µl of plasma was analysed as per protocol (“low 
concentration” sample). Synthetic GLP-2 standard (30fmol) was added to 
selected tubes (“high concentration” sample). Sample position within the 
assay was chosen, so that separation would occur in the order of:  low-high-
high-low concentration sample. Samples were analysed in duplicates. 
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2.2.5 Postprandial GLP-2-IR profile in healthy humans 
 
Nutrients are the main stimulants of GLP-2 secretion. A valid assay should 
therefore be able to demonstrate a postprandial secretory response. It has 
been demonstrated that the postprandial GLP-2 secretion depends on 
nutrient composition and calorie content of an ingested meal (Xiao et al. 
1999). It is well documented that in particular lipids and carbohydrates lead 
to a substantial rise in GLP-2 plasma levels (Xiao et al. 1999; Hartmann et 
al. 2000). Reports of response to protein-rich meals vary (Xiao et al. 1999; 
Henriksen et al. 2003; Feltrin et al. 2006). A test-meal, evoking a reliable 
GLP-2 response, should therefore be energy-dense and have high lipid- 
and/or carbohydrate content. Other aspects to consider are consistent and 
reproducible nutrient composition, ease of preparation and, last but not least, 
palatability. Commercial ice-cream fulfils most of these criteria and was 
therefore used as a test-meal in healthy volunteers (Table 2-1). It was 
postulated that the available assay will be able to demonstrate a significant 
postprandial rise of plasma GLP-2. 
 
 
 
Test meal:  Ice cream (chocolate flavour, Sainsbury’s Finest) 
 
Test meal composition:  Volume    500 ml 
    Energy content  920 kcal 
    Total fat   50g 
    Saturated fat   30.8g 
    Total carbohydrates  127.5g 
    Sugar    101.1g 
    Protein    14g 
    Fibre    6g 
 
 
Table 2-1: Test meal composition 
Nutrient and energy content as per product label 
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Ethical approval for this procedure was obtained from the local research 
ethics committee (REC 04/Q0405/83).  
 
8 healthy volunteers (6 male, 2 female; median age 43.4 years; range 32-66 
years) were asked to consume 500ml of ice cream, served in semi-liquid 
form at 4°C, over a time period of 15-20 minutes. Venous sampling was 
undertaken at 2 time-points prior and at half hourly intervals (up to 240 min) 
after the meal. Blood was collected in 10ml lithium-heparin tubes containing 
0.2ml Trasylol. Samples were immediately spun down in a refrigerated 
centrifuge at 4°C for 10 min at 1600g. Plasma was collected and stored at -
70°C until analysis. All samples were analysed in a single RIA. For the 
comparison of the fasting values with different postprandial time points the 
paired t-test was used. A p-value of less than 0.05 is regarded as statistically 
significant.  
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2.2.6 Correlation to antiserum 92160 
 
An N-terminal-specific GLP-2 radioimmunoassay (92160) was developed by 
the group of Jens J. Holst. 92160 is the only antiserum in published literature 
that is specific for the measurement of biologically active GLP-2 (1-33) and 
RIAs using this antiserum could therefore be considered as the “gold 
standard” of GLP-2 measurement. Antibody 92160 was raised in Danish 
white rabbits against synthetic PG 126–136 coupled to bovine serum 
albumin with carbodiimide. It shows no cross-reaction with GLP-1 (1-
36NH2), GLP-1 (7-36NH2), glicentin, oxyntomodulin, glucagon, pituitary 
adenyl cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide 
(VIP), growth hormone-releasing factor (GHRF), gastric polypeptide (GIP), 
secretin and peptide histidine isoleucine amide (PHI) in concentrations up to 
5 nmol/l. Experimental detection limit is 5pmol/l, intra-assay coefficient of 
variation has been quoted as 2.3% at 40pmol/l (Wojdemann et al. 1998). 
 
Venous blood samples from 14 healthy volunteers were collected in the 
fasted state and 60 and 120 minutes following a standard meal as described 
in section 3.3.2. Plasma samples were frozen in 1 ml aliquots and both 
analysed with RIA using antiserum FT-17 and also sent to the University of 
Copenhagen and analysed by Dr. Jens J. Holst using antiserum 92160. 
None of the samples had been defrosted prior to measurement. GLP-2 
concentrations in plasma were measured after extraction of plasma with 70 
% ethanol.  
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2.2.7 Correlation to ELISA 
 
The measurement of GLP-2 with radioimmunoassay is labour- and time 
intensive, depends on the availability of a specific laboratory and involves the 
use of radioactive substances. Measurement of GLP-2 using ELISA 
technique might be a useful alternative which could be applied in wider 
laboratory settings. GLP-2 RIA (FT-17) measurements were therefore 
compared with results from a commercially available ELISA kit (Phoenix 
Pharmaceuticals, Inc). Usual assay performance (as per company 
information) indicates a sensitivity of 0.1ng/ml, intra-assay variation <5%, 
inter-assay variation: <14%, detectable range: 0-100ng/ml and linear Range: 
0.1-1.72 ng/ml. Cross-reactivity is reported as 100% with human and rat 
proglucagon (126-159) which corresponds to GLP-2 (1-33)-Arg). There is 6% 
cross-reactivity with human GLP-1 (7-36), 5% with human GLP-1 (7-37) and 
no cross-reactivity with Glucagon, GIP, VIP or Insulin. 
 
Venous blood samples from 14 healthy volunteers were collected in the 
fasted state and 60 and 120 minutes following a standard meal as described 
in section 3.3.2. Plasma samples were frozen in 1 ml aliquots and analysed 
with RIA using antiserum FT-17 and also processed with the commercial 
ELISA kit as described below. None of the samples had been defrosted prior 
to measurement. Samples were analysed in duplicate. 
 
The GLP-2 ELISA was performed as per manufacturers’ instruction. Peptide 
standard solutions were prepared. 50µl of standard or sample, 25µl primary 
antiserum and 25µl biotinylated peptide was added to the wells. The 
immunoplate was sealed and incubated at room temperature for 2 hours on 
an orbital plate shaker at 400rpm. The immunoplate was washed 5 times 
with 350µl/well of buffer. 100µl/well of SA-HRP solution was added. The 
immunoplate was incubated as above for 1 hour. The immunoplate was 
washed 5 times with 350µl/well of buffer. 100µl/well of substrate solution was 
added. The immuno-plate was incubated as above for 1 hour. 100µl/well of 
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2N HCl was added to terminate the reaction. Absorbance (O.D.) was read at 
450nm and concentrations extrapolated from the standard curve. 
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2.3 Results 
 
2.3.1 Specificity of antiserum FT-17 
 
 
Interlocked RIA of GLP-2 (1-33) and (3-33) standard (Figure 2-5): Within 
normal standard curve concentrations (2-200fmol/tube) there was minimal 
antibody displacement by GLP-2 (3-33) at 200fmol. Analysis of 1, 10 and 
100 pmol GLP-2 (3-33) quantified 4% cross reactivity with antiserum FT-17 
(1pmol GLP-2 (3-33) resulted in 28% binding of GLP-2 (1-33) standard 
(equals 40 fmol). 
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Figure 2-5:  Cross reactivity of FT-17 with GLP-2 metabolite (3-33) 
Displacement of antiserum FT-17 with standard concentrations of synthetic GLP-2 
(1-33) and synthetic GLP-2 (3-33) 
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GLP-2-IR elution profile of synthetic GLP-2 standards (Figure 2-6):  
The elution profile of synthetic GLP-2 (1-33) standard identified GLP-2-IR in 
5 adjacent collection fractions with a maximum peak at Kav of 0.52. Recovery 
of peptide standard was 60%. The elution profile of truncated GLP-2 (3-33) 
shows an identical peak to GLP-2 (1-33) at Kav 0.52. When GLP-2 (1-33) 
standard was diluted in plasma instead of column buffer, GLP-2-IR appeared 
to elute earlier (peak Kav 0.44). As in some of the chromatography runs, 
plasma or tissue samples were compared with GLP-2 standard diluted in 
buffer, this finding had to be taken into consideration for the result analysis. 
 
GLP-2-IR elution profile in rodent tissue extracts (Figure 2-7):  
The elution profile of rat terminal ileal extract shows a single peak 
corresponding to elution of GLP-2 (1-33) standard. Rat pancreatic tissue 
extract shows 2 large peaks of GLP-2-IR material with maximum Kav at 0.15 
and at 0.56-0.63. There is no obvious peak corresponding to the elution point 
of GLP-2 standard (Kav 0.48).  
 
GLP-2-IR elution profile in unextracted plasma samples (Figure 2-8):  
Elution profiles of pre- and post-prandial human plasma samples were 
obtained and representative profiles are shown (Figure 2-8 B and C). In the 
fasting sample, GLP-2-IR mainly consists of larger molecular weight material 
(max Kav peaks at 0.24 and 0.29). There is only a very small peak 
corresponding to the elution of GLP-2 (1-33) standard, which is outside of 
the sensitivity limitations of the FT-17 assay. In the postprandial plasma, 
overall GLP-2-IR is increased. There is a discernable peak, corresponding to 
the elution point of GLP-2 standard (25% of total GLP-2-IR).   
 
GLP-2-IR elution profile in extracted plasma samples (Figure 2-9): 
The GLP-2-IR elution profile of plasma following peptide extraction with a 
SepPak cartridge shows a reduction in overall GLP-2-IR compared to 
unextracted plasma. However it appears that, following the removal of most 
large molecular weight material in the extracted plasma, a small peak 
corresponding to the elution point of GLP-2 (1-33) standard can be shown 
(43% of total GLP-2 IR). 
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Figure 2-6:  GLP-2-IR elution profiles with Sephadex G50 chromatography.              
A) GLP-2 (1-33) standard in column buffer.                      
B) GLP-2 (3-33) standard in column buffer.                     
C) GLP-2 (1-33) in plasma.  
Std indicates the elution of GLP-2 (1-33) standard in buffer, cc indicates elution of 
cytochrome C (MW 12384). Dextran Blue (MW >2,000 000) elutes at Kav = 0 and 
Na 125 I at Kav = 1. 
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Figure 2-7:  Elution profile of GLP-2-IR using Sephadex G50 chromatography.             
A) GLP-2 standard in buffer.                 
B) Rat intestinal extract                  
C) Rat pancreatic extract 
Std indicates the elution of synthetic GLP-2 (3-33) in buffer, cc indicates elution of 
cytochrome C (MW12 384). Dextran Blue (MW >2,000 000) elutes at Kav = 0 and 
Na 125 I at Kav = 1. 
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Figure 2-8: Elution profile of GLP-2-IR using Sephadex gel G50 chromatography.            
A) Synthetic GLP-2 (1-33) in column buffer.                      
B) Non-extracted human plasma (fasting).                      
C) Non-extracted human plasma (postprandial).  
The arrow indicates the elution of GLP-2 (1-33) standard in buffer.          
Dextran Blue (MW >2,000 000) elutes at Kav = 0 and Na 125 I at Kav = 1. 
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Figure 2-9:  Elution profile of GLP-2-IR using Sephadex G50 chromatography.             
A) Synthetic GLP-2 (1-33) standard in plasma.               
B) Unextracted postprandial plasma sample.               
C) Postprandial plasma sample following peptide extraction (SepPak).  
Std indicates the elution of synthetic GLP-2 (1-33) in buffer, cc indicates elution of 
cytochrome C (MW12 384). Dextran Blue (MW >2,000 000) elutes at Kav = 0 and 
Na 125 I at Kav = 1. 
  71 
2.3.2  Optimisation of assay condition 
 
a) Albumin concentration 
 
Variation of bovine serum albumin (BSA) concentration in the assay buffer 
caused no difference in antibody displacement by peptide standard, resulting 
in overlapping standard curves. 
 
 
 
0
10
20
30
40
50
60
0 50 100 150 200
GLP-2 (1-33) (fmol)
%
 b
in
di
ng
0.30%
1%
3%
 
 
 
Figure 2-10:  Variation of the BSA concentration (0.3%, 1%, 3%) in the buffer solution had no 
apparent impact on the binding characteristics of the GLP-2 assay, resulting in 
overlapping standard curves.  
 
 
 
 
 
 
  72 
b) Separation method 
 
Both, charcoal separation and immunoprecipitation with secondary antibody 
produced acceptable standard curves (Figure 2-11). There was a small 
difference in assay sensitivity (2fmol/tube in charcoal vs. 4fmol/tube in 
secondary antibody separation). This would result in a detection limit of 20 
and 40pmol/l (on the basis of a 100µl sample). 
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Figure 2-11:  Variation of separation method (adsorption to charcoal versus immuno-
precipitation with secondary antibody). Both methods achieve acceptable standard 
curves and assay sensitivity. 
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2.3.3 Optimization of sampling conditions 
a) Protease inhibitor 
 
Addition of PMSF to the collection tubes does not increase the 
measurements of GLP-2 IR in plasma samples. For most time points, no 
significant difference between measurements using Trasylol alone or in 
combination with PMSF was demonstrated. At 240 min, mean tGLP-2-IR 
was unexpectedly reduced in the Trasylol + PMSF samples (Table 2-2; 
Figure 2-12). This reduction was not significant in analysis of variance 
(ANOVA 0.31). 
 
 
Timepoint Trasylol Trasylol + PMSF p
(min) GLP-2 IR (pmol/l) GLP-2 IR (pmol/l)
mean (SEM) mean (SEM)
0 135 (18) 134 (14) 0.93
60 209 (37) 184 (33) 0.11
120 218 (43) 221 (42) 0.78
180 216 (34) 186 (26) 0.12
240 205 (29) 154 (25) 0.001  
Table 2-2:  Mean tGLP-2 IR at selected time-points. Lithium heparin tubes were prepared with 
Trasylol alone or Trasylol + PMSF. (n = 5 per time point),        
p (paired student T-test) 
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Figure 2-12:  Mean tGLP-2-IR at selected pre- and post-prandial time-points. Lithium heparin 
tubes pre-prepared with Trasylol (broken line) or Trasylol + PMSF (cont. line). (n=5 
per time point); * p = 0.001 (paired, student t-test); ANOVA: p=0.3. 
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b) Peptide extraction 
 
Peptide recovery following SepPak extraction in plasma samples, spiked 
with synthetic GLP-2 standard, was 44% (on addition of 100fmol GLP-2, 
n=8) and 58% (on addition of 300fmol GLP-2, n=8) (Figure 2-13).  
 
A significant increase of GLP-2-IR versus the fasting level could be 
demonstrated (t-test; p ≤ 0.05) at all postprandial time points, equally in both 
non-extracted and SepPak concentrated samples (Figure 2-14). When 
values for concentrated samples were adjusted for approximately 50% 
reduced recovery, no significant difference could be shown between the 
samples (t-test; p>0.05 for all time points). Notably however, there was a 
substantial reduction in the GLP-2-IR SEM following solid-phase extraction; 
27 vs. 13pmol/l; average SEM for all time points measured (paired t-test, 
p<0.001). 
 
There was a trend towards a greater relative GLP-2-IR increase in SepPak 
extracted samples compared to unextracted samples (Figure 2-15), although 
this difference did not reach statistical significance for any time point 
(ANOVA; p = 0.13).  
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Figure 2-13:  Peptide recovery of after solid phase extraction with SepPak C18 cartridges, after 
spiking plasma with  
A: 100fmol of synthetic GLP-21-33 standard; n=8.              
B: 300fmol of synthetic GLP-21-33 standard; n=8.  
Values are mean +/- SD  
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Figure 2-14:  Pre- and postprandial level of GLP-2 IR.       
A: Plasma samples were analysed unprepared and following peptide concentration 
in SepPak cartridges. (Mean+/-SEM) * p<0.05; # p<0.01 versus baseline (student T 
test)                  
B: Equivalent to diagram A, values for SepPak concentrated samples now adjusted 
for a 50% peptide loss of recovery (mean, error bars not included). No significant 
difference between the samples can be shown by paired student T test. 
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Figure 2-15:  Relative postprandial increase of tGLP-2-IR from baseline (%)  
measured at selected postprandial time points, following peptide concentration in 
SepPak cartridges (hatched bars) or in non-extracted plasma (empty bars). MEAN 
+/- SEM. There is a trend towards a greater increase in extracted samples; however 
the difference is not significant for any time-point. ANOVA p=0.13 
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c) Freeze-thaw cycle 
 
Up to 10 repeat cycles of defrosting and refreezing did not lead to significant 
alterations of the measured GLP-2-IR concentration in a random post-
prandial plasma sample (single factor ANOVA p=0.68). The variation in the 
mean GLP-2-IR between all cycles was within the sample intra-assay 
variability. 
 
Freeze-thaw Samples GLP-2IR
cycles n Mean SD SEM CV
(pmol/l)
1-10 72 167.8 4.2 1.7 2.5
1 12 162.5 20.5 5.9 12.6
2 12 170.7 22.7 6.6 13.3
3 12 169.3 16.5 4.8 9.7
4 12 164.1 10.7 3.1 6.5
5 12 173.5 24.1 7.0 13.9
10 12 166.6 9.4 2.7 5.6
 
 
Table 2-3:  GLP-2-IR after cycles of plasma freezing and defrosting  
12 tubes were analysed for each freeze thaw cycle to determine intra-assay 
variability. 
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Figure 2-16:  GLP-2-IR after cycles of plasma freezing and defrosting 
12 tubes were analysed for each freeze-thaw cycle to determine intra-assay 
variability. Single factor Anova: p= 0.68 
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d) Haemolysis 
 
The stepwise addition of haemolysed plasma to a random plasma sample 
led to a significant, dose dependent, increase of GLP-2-IR (p<0.001; Figure 
2-17). Severe haemolysis lead to GLP-2-IR concentrations outside the steep 
part of the binding curve, resulting in increased variability of results (Table 2-
3). Resultant GLP-2-IR concentrations fall outside the physiological range.  
 
Binding curves, obtained by adding standard amounts of synthetic GLP-2 (1-
33) to different concentrations of haemolysed plasma show that haemolysis 
significantly alters antibody binding to the peptide standard (p<0.05). A small 
degree of haemolysis (5% of total plasma volume) does not alter the 
standard curve. There is however considerable change with stronger 
haemolysis. This especially affects the steep part of the binding curve, 
resulting in a flat binding curve when 60% of the total plasma volume is 
haemolysed and thus causing overestimation of the GLP-2 concentration 
(Figure 2-18) 
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Factor Heamolysis n Mean SD CV p vs. 
(%) (pmol/l) factor
1 0 10 151.7 26.9 17.7 <0.05 2, 3, 4
2 10 10 372.7 63.6 17.1 <0.05 1, 3, 4
3 50 10 1318.2 296.7 22.5 <0.05 1, 2
4 100 9 1142.7 288.5 25.3 <0.05 1, 2
 
 
 
Table 2-4:  GLP-2-IR (mean+/-SD) in a random plasma sample is significantly altered with the 
stepwise increase of haemolysed plasma content. 
In grossly haemolysed samples the coefficient of variation (CV) is increased.           
(p = Student-Newman-Keuls test (post hoc ANOVA analysis for pair-wise 
comparisons). 
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Figure 2-17:  GLP-2-IR (mean +/-SD) of random plasma sample with stepwise addition of 
haemolysed plasma 
 
* P<0.001 (vs. non-haemolysed plasma, student t-test), ANOVA p< 0.001 
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Figure 2-18: A) FT-17 binding curves of GLP-2 (1-33) standard, obtained in different 
concentrations of haemolysed plasma.  
Plasma haemolysis needs to significant variation between the standard curves 
(ANOVA: p<0.05). Low level haemolysis (5% of total plasma volume) causes no 
significant change.  
B) Estimation of GLP-2-IR.               
The legend indicates the percentage of haemolysed plasma in the total plasma 
volume. 
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2.3.4 Quality control 
 
a) Sensitivity 
 
Assay sensitivity was determined as the smallest standard value, 2 SD 
below the mean of all zero standard values (95% CI). Assay sensitivity of 10 
sequential RIAs is shown in Table 2-5. The mean sensitivity in these assays 
was 2.6 ± 0.9 fmol/tube, which equates to 26 ± 9 pmol/l for a 100 mcl 
sample. 
 
 
 
Assay Zero binding  n SD Sensitivity
mean (%) % fmol/tube
1 54.2 45 2.3 2
2 54.3 29 1.2 2
3 59.8 26 2.1 2
4 56.7 20 1.3 2
5 60.4 18 2.0 2
6 51.5 50 2.6 2
7 57.2 16 2.0 2
8 53.4 38 2.4 4
9 52.6 22 2.1 4
10 55.6 18 1.9 4
Mean 0.9 2.6  
 
 
Table 2-5:  Assay sensitivity (fmol/tube) 
Assay sensitivity was determined as the smallest standard value, 2 SD below the 
mean of all zero binding values (95% CI) shown for 10 sequential assays.  
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b) Reproducibility  
 
The intra- and inter-assay coefficients of variation as calculated from repeat 
estimations of quality control samples are shown in Table 2-6. This was 
assessed in a random sample of fresh frozen plasma as well as in pooled, 
lyophilized plasma which had been spiked with GLP-2 (1-33) standard (such 
that 100 µl of plasma would read off the GLP-2 standard curve in the range 
of “high”, “medium” or “low”). The maximum intra-assay variation was 17.8%. 
The maximum inter-assay variation was 22%. 
 
 
Intra-assay variation Inter-assay variation
Plasma Frozen Lyophilized Frozen Lyophilized 
Zero Low Medium High Zero Low Medium High
Mean (fmol/tube) 11.3 13.9 16.4 34.4 72.9 13.1 11.6 14.5 28.9 62.6
SD 1 1.5 2.9 4.6 12.8 2.5 2.6 2.5 4.4 12.0
n 10 8 8 8 8 5 5 5 5 5
*CV (%) 8.8 11.1 17.8 13.5 17.6 19.1 22.0 17.3 15.4 19.1
 
 
 
Table 2-6:  Reproducibility of RIA FT-17  
Intra- and inter-assay coefficients of variation were calculated from repeat 
estimations of quality control samples.  
*CV= SD/mean*100 
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The pre-and postprandial GLP-2-IR concentration of 8 healthy subjects was 
analysed at 10 time points over 270 minutes. Two RIAs (No 944 and No 950) 
were performed on all samples (n=80 samples per assay, analysed in 
duplicates). 
 
Figure 2-19 shows a high correlation between the two RIA series (r = 0.91, 
r2= 0.82; p<0.001). Sub-analysis of different time points in Table 2-7 
demonstrated a highly significant positive correlation between the two sets of 
measurements at all time points. This result is comparable with the intra-
assay correlation between the duplicates in each assay: r=0.91 (RIA 944) 
and r=0.94 (RIA 950). 
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Figure 2-19:  Correlation of 2 consecutive RIAs 
Pre-and –postprandial GLP-2-IR concentration in 8 subjects over 270minutes, 
estimated in two sequential RIAs (“950” and “944”) (n=80 per assay).  
A significant correlation can be demonstrated          
(Pearson coefficient r=0.91, r 2 = 0.82, p<0.001).       
Regression line and 95 % CI (dotted lines) 
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-30 0.91 0.002
0 0.97 <0.001
30 0.97 <0.001
60 0.98 <0.001
90 0.95 <0.001
120 0.93 <0.001
150 0.99 <0.001
180 0.98 <0.001
210 0.96 <0.001
240 0.98 <0.001
time r p
 
 
 
Table 2-7:  Correlation analysis of 2 consecutive RIAs  
Pre-and –postprandial GLP-2-IR concentration in 8 subjects over 270minutes, 
estimated in two sequential RIAs (“950” and “944”).  
r = Pearson coefficient of variation. 
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c) Sample carryover 
 
The average change of GLP-2-IR in low concentration plasma samples, 
analysed before and after high concentration plasma samples (spiked with 
30fmol GLP-2 (1-33) standard), was <4%. This is well within the limits of 
intra-assay variation; indicating that there is no appreciable carryover effect 
when analysing adjacent high and low concentration samples.  
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Figure 2-20: Sample carryover 
Estimation of GLP-2-IR (mean ± SD) in low concentration plasma      
(2 fasting samples in duplicates; empty columns) before and after high concentration 
plasma (4 samples spiked with 30fmol GLP-2(1-33) standard; filled columns). 3 runs 
performed. 
 
 
pre post pre/post pre/post
Run 1 11.2 12.2 2/2 1.0/0.9 8.82
Run 2 11.2 11.1 2/2 0.4/0.7 0.36
Run 3 11.6 11.6 2/2 0.2/0.3 0.41
Mean Change 3.19%
GLP-2 (fmol/tube) n SD Change %
 
 
Table 2-8: Sample carryover 
% change of GLP-2-IR in low concentration plasma (2 fasting samples in duplicates) 
before and after high concentration plasma (4 samples spiked with 30fmol GLP-2 (1-
33) standard). 3 runs performed. 
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2.3.5 Postprandial GLP-2-IR profile in healthy humans 
 
 
Figure 2-22 depicts the concentration of GLP-2-IR in 8 healthy volunteers in 
the fasted state (-30 min; 0 min) and following (30-240 min) ingestion of a 
920 kcal standardized meal. 
 
Analysis of the two fasting time points, at -30 and 0, shows a small 
difference between the two times that was not statistically significant 
(p=0.80). As a result of this finding, the average value of the two fasting time 
points was taken for each subject (termed fasting or baseline value), and 
used in the subsequent analysis. 
 
The mean fasting GLP-2-IR levels in 8 healthy individuals was 122.2pmol/l. 
There was considerable variation among subjects (Figure 2-21). It appeared 
that one individual had a particularly high fasting level (shown as an outlier). 
However, this subject had an appropriate postprandial increase of GLP-2-IR 
(65% increase from baseline at 90 minutes) and was therefore included in 
the analysis. 
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Figure 2-21:  Fasting GLP-2 IR (average of time points -30 and 0), 8 healthy subjects.  
Central box: 25 to 75 percentile; middle line: median; vertical line extends from the 
minimum to the maximum value, excluding an outlier (upper quartile plus 1.5 times 
the interquartile range). 
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A significant rise in mean postprandial GLP-2-IR was recorded at 30 
minutes and levels remained significantly elevated at all postprandial time 
points until the end of the study period at 240 minutes (Figure 2-22, Table 2-
9). The largest differences from the fasting times were observed from time 
60 to time 180. When examining individual postprandial profiles, postprandial 
peaks were reached at different time-points: 90min (n=2); 120min (n=1); 
150min (n=1); 180min (n=2); 240min (n=2).  
 
Even though an increase from baseline was recorded in every subject, there 
were considerable differences in relative and absolute postprandial increase 
of GLP-2-IR between individual subjects. The area under the curve (AUC) 
was calculated for each subject and the increase of AUC from baseline 
determined.  
 
Figure 2-23 shows the wide distribution of results. There was no correlation 
between the baseline GLP-2-IR and the magnitude postprandial AUC 
increase; Pearson correlation coefficient r=0.27, p=0.51 (Figure 2-23). 
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Figure 2-22:  Meal related GLP-2 IR (MEAN +/- SEM) 
8 healthy subjects were investigated before and after a 920cal standard meal. There 
is a significant increase in all post prandial time points versus the baseline GLP-2-IR 
concentration (average of time -30 and 0) * p <0.05   # p <0.01 
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Time  GLP-2-IR  (pmol/l) 95% CI P-value
30 32 4-60 0.03
60 53 11-93 0.02
90 58 16-100 0.01
120 60 20-101 0.01
150 54 17-91 0.01
180 56 21-90 0.007
210 46 8-84 0.02
240 38 6-76 0.03
Inrease from baseline 
 
 
Table 2-9: Mean postprandial increase of GLP-2-IR over time.  
Difference between the average fasting values and each subsequent time point is 
calculated. Statistical analysis is performed using the paired t-test.  
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Figure 2-23: A) Box-and-whisker plot of increase in area under the curve (AUC) from baseline 
AUC (-30 to 0) in 8 healthy subjects. (Central box: 25 to 75 percentile; middle line: 
median; vertical line: minimum to maximum value, excluding an outlier (upper 
quartile plus 1.5 times the interquartile range). It is shown that there is considerable 
variation between the subjects.  
B) There is no significant correlation between the baseline level of GLP-2-IR and 
postprandial increase of the area under the curve (r=0.27, p=0.51). Shown are the 
linear regression line and the 95% confidence interval for the regression line (dotted 
lines).   
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2.3.6 Correlation to antiserum 92160 
 
 
Plasma samples from 14 healthy subjects were collected in the fasted state 
and 60 and 120 minutes following a standard meal containing 866 calories. 
GLP-2-IR was determined in separate (first thaw) aliquots with RIA using 
antiserum FT-17 at our laboratory and antiserum 92160 at the University of 
Copenhagen.  
(One subject was excluded from analysis as samples were incomplete). 
 
Significant correlation could be shown between the two assays for all time 
points combined (r=0.77; p<0.0001; Figure 2-24 ).  
 
On separate analysis of the time points however it became apparent that 
there is no correlation between the RIAs in the fasting levels (r=0.18; p=0.5). 
Correlation was high however between the postprandial GLP-2-IR readings 
(r was >0.8 for time points 60 and 120 as well as for the absolute increase of 
GLP-2 IR from fasting at 60 and 120 minutes (p<0.001) (Figure 2-25). The 
Pearson correlation coefficient (r) and coefficient of determination (r2) for all 
time points are detailed in Table 2-10.  
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Figure 2-24: Correlation of GLP-2 IR using antiserum FT-17 and 92160 
Scatter diagram of GLP-2-IR concentration measured during meal stimulation in 13 
subjects with RIA using antiserum FT-17 and RIA using antiserum 92160 at time 
points 0, 60 and 120 (n=39).  
There is significant correlation between the measurement methods; r2=0.6.  
Shown are the linear regression line and the 95% confidence interval for the 
regression line (dotted lines).  
 
 
Timepoints n r r2 p
0 13 0.30 0.09 0.55
60 13 0.82 0.68 <0.001
120 13 0.81 0.66 <0.001
PP 60+120 26 0.74 0.54 <0.0001
All (0+60+120) 39 0.77 0.6 <0.0001
Increase n r r2 p
60-0 13 0.87 0.75 <0.001
120-0 13 0.85 0.72 <0.001
All (60-0)+(120-0) 26 0.80 0.63 <0.0001
Correlation RIA 92160 / RIA FT-17
 
 
Table 2-10: Correlation of GLP-2 IR using antiserum FT-17 and 92160 
Correlation of GLP-2-IR concentrations measured during meal stimulation in 13 
subjects with RIA using antiserum FT-17 and 92160.  
(PP=postprandial; significances given for correlation coefficient r) 
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Figure 2-25:  Correlation of GLP-2 IR using antiserum FT-17 and 92160 
Scatter diagram of GLP-2-IR concentration measured during meal stimulation in 13 
subjects with RIA using antiserum FT-17 and RIA using antiserum 92160.  
      
A) Fasting levels (0min; n=13; r= 0.3; P=0.55).  
B) Postprandial levels (60min+120min; n=26; r=0.74; p<0.0001). 
C) Increase of GLP-2-IR vs. baseline (60min+120min; n=26; r=0.8; p<0.0001). 
Shown are the linear regression lines and the 95% confidence interval for the 
regression line (dotted lines). 
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2.3.7 Correlation to ELISA 
 
A satisfactory GLP-2 standard curve was obtained with the commercial 
ELISA kit (Figure 2-26).  
 
GLP-2 concentration was determined in plasma samples from 14 healthy 
subjects, collected in the fasted state and 60 and 120 minutes following a 
standard meal. All samples were analysed in duplicate. The coefficient of 
variation between duplicates was 9.2 ± 6.6%; (mean ± SD). Results were 
correlated with those obtained from the RIA FT-17 and RIA 92160.  
 
Overall, there was significant correlation between postprandial GLP-2 
immuno-reactivity measured with radioimmunoassay using antiserum FT-17 
and ELISA. (r=0.8, p<0.001) (Figure 2-27). There was no positive correlation 
between the fasting levels (r=0.41, p=0.17). Correlation was significant 
between the postprandial GLP-2-IR readings as well as for the absolute 
increase of GLP-2 IR from fasting at 60 and 120 minutes (Table 2-11, Figure 
2-28). 
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Figure 2-26:  GLP-2 ELISA standard curve 
  cpm=count per minute 
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Figure 2-27:  Correlation of GLP-2 IR using antiserum FT-17 and ELISA 
Scatter diagram of GLP-2-IR concentration measured during meal stimulation in 13 
subjects with RIA using antiserum FT-17 and ELISA at all time points (0, 60 and 
120; n=39).  
There is significant correlation between the measurement methods; r=0.8, r2=0.6 
(p<0.001).  
Shown are the linear regression line and the 95% confidence interval for the 
regression line (dotted lines). 
 
 
 
Timepoints n r r2 p
0 13 0.41 0.16 0.17
60 13 0.76 0.58 0.002
120 13 0.85 0.72 0.0002
PP 60+120 26 0.80 0.64 <0.0001
All (0+60+120) 39 0.80 0.64 <0.0001
Increase n r r2 p
60-0 13 0.63 0.40 0.02
120-0 13 0.72 0.52 0.006
All (60-0)+(120-0) 26 0.66 0.44 0.0003
Correlation  RIA FT-17 / ELISA
 
 
Table 2-11:  Correlation of GLP-2 IR using antiserum FT-17 and ELISA 
Correlation coefficient r and coefficient of determination r2 of GLP-2 IR 
concentrations at separate time points.  
(PP=postprandial; significances given for correlation coefficient r) 
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Figure 2-28: Correlation of GLP-2 IR using antiserum FT-17 and ELISA 
A) Fasting levels (0min; n=13; r= 0.41; P=0.17).        
B) Postprandial levels (60+120min; n=26; r=0.80; p<0.0001).       
C) Increase of GLP-2-IR vs. baseline (60+120min; n=26; r=0.66; p=0.0003) 
Shown are the linear regression lines and the 95% confidence interval for the 
regression line (dotted lines). 
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Correlation of the commercial ELISA with RIA (92160) was weak when all 
time points were combined (r=0.44; p=0.005). No significant correlation could 
be shown when analysing the fasting and postprandial levels alone or the 
postprandial increase of GLP-2 concentration (Table 2-12). 
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Figure 2-29:  Correlation of GLP-2 IR using antiserum 92160 and ELISA 
GLP-2-IR concentration measured during meal stimulation in 13 subjects with RIA 
using antiserum 92160 and ELISA at all time points 0, 60 and 120 (n=39). There is a 
weak correlation between the measurement methods; r2=0.19. Shown are the linear 
regression line and the 95% confidence interval for the regression line (dotted lines). 
 
 
 
Timepoints n r r2 p
0 13 0.06 0.004 0.84
60 13 0.49 0.24 0.09
120 13 0.48 0.23 0.09
PP 60+120 26 0.34 0.12 0.08
All (0+60+120) 39 0.44 0.19 0.005
Increase n r r2 p
60-0 13 0.48 0.23 0.09
120-0 13 0.48 0.23 0.09
All (60-0)+(120-0) 26 0.36 0.13 0.007
Correlation  RIA 92160 / ELISA
 
 
Table 2-12: Correlation of GLP-2 IR using antiserum 92160 and ELISA 
Correlation coefficient r and coefficient of determination r2 of GLP-2 IR 
concentrations at separate time points.  
(PP=postprandial; significances given for correlation coefficient r) 
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2.4 Discussion  
 
GLP-2 secretion from intestinal L-cells has been acknowledged as a key 
process in the regulation of intestinal growth and adaptation. The ability to 
determine GLP-2 concentration accurately has not only furthered the 
understanding of intestinal physiology but has also paved the way towards 
exploration of therapeutic GLP-2 supplementation in a variety of intestinal 
conditions. 
 
As detailed in section 1.1, intestinal GLP-2 is characterised by low plasma 
concentrations, a short half life and sequence homologies with its 
precursors, degradation products as well as other gut hormones. 
Measurement of this peptide therefore requires a method with a high degree 
of sensitivity and specificity. The radioimmunoassay, a standard technique in 
the quantification of gut hormones, can deliver these qualities. Availability of 
a specific GLP-2 antiserum is limited. In addition, commercially available 
RIA- and ELISA kits often do not provide sufficient information about the 
specificity of the antiserum used.  
 
FT-17 is a polyclonal antiserum, raised in rabbits against synthetic human 
GLP-2 (1-33) coupled with BSA by carbodiiamide. It had been previously 
established that the antiserum has a high specificity for the detection of GLP-
2 and does not cross-react with most related gut hormones. A negligible 
cross-reactivity with GLP-1 has been documented (Appendix 1). It was the 
aim of this study to characterise antiserum FT-17 specificity further and to 
optimise sampling and assay conditions and thus ensure maximal sensitivity 
before utilizing the assay for research into intestinal adaptation. 
 
Cross-reactivity with the main GLP-2 degradation product, GLP-2 (3-33), has 
not been established previously. The chromatographic elution profile of 
synthetic GLP-2 (3-33) revealed GLP-2-IR at the point of GLP-2 (1-33) 
standard elution, confirming cross-reactivity. Quantitative RIA estimated 4% 
cross-reactivity with GLP-2 (3-33). It was postulated that FT-17 might also 
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cross-react with major proglucagon fragment (MPGF), a large proglucagon 
derived peptide (PG 72-158). MPGF is secreted as a by-product of glucagon 
synthesis in the pancreas and contains the entire GLP-2 (and GLP-1) 
sequence. Direct demonstration of cross-reactivity with MPGF is hampered 
by the fact that, due to its large size, a synthetic standard of this peptide is 
difficult to generate. As a surrogate marker, pancreatic and intestinal tissue 
extracts were examined. Pancreatic extract is known to contain large 
amounts of MPGF but only minimal GLP-2, whereas intestinal extracts 
predominantly contain GLP-2 (Orskov et al. 1987; Hartmann et al. 2000). In 
agreement with these studies, GLP-2-IR elution profile of rodent intestinal 
tissue extract, shown in this work, document an isolated peak at the elution 
point of GLP-2 (1-33) standard. The GLP-2-IR elution profile of pancreatic 
extract on the other hand, suggests cross-reaction of the antiserum with 
other substances of larger and smaller molecular weight. There were two 
major peaks (at Kav 0.15 and at 0.56-0.63) with no obvious peak at the 
elution point of GLP-2 (Kav 0.48). This indicates that FT-17 cross-reacts with 
other pancreatic proglucagon-derived peptides. It is possible that the elution 
fractions around Kav 0.15 contain MPGF. It is of note however that 
cytochrome C (MW 12 384 daltons) elutes at a later Kav (0.26). The 
estimated molecular weight of MPGF has been reported as 10 000 daltons 
(Patzelt et al. 1984). MPGF should therefore elute after cytochrome C, 
unless earlier elution is caused by reduced size due to protein folding. It is 
feasible that the antiserum cross-reacts with other large molecular weight 
constituents of the pancreatic extract. To elucidate this matter further, either 
synthetic MPGF would need to be tested on the column or the eluent of 
pancreatic extract should be analysed with a specific MPGF antiserum. The 
nature of the molecules eluting at Kav 0.56-63 also requires further 
exploration. Pancreatic extract contains glucagon which has been shown to 
elute after GLP-2 (Hartmann et al. 2000). Previous data (Appendix 1, Prof. 
Ghatei) however have shown no cross-reactivity of FT-17 with glucagon at 
concentrations between 1-100 pmol/tube. If cross-reactivity with glucagon 
exists at higher concentrations it is unlikely to be relevant when measuring 
GLP-2 concentration in plasma under physiological conditions.  
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Plasma profiles obtained by gel chromatography were investigated by 
Orskov et al. (Orskov et al. 1987). They concluded that: “the predominating 
glucagon-like peptide in the fasting state is a large peptide which is at least 
GLP-1 immuno-reactive”. After a meal however, a large proportion of GLP-1-
immuno-reactivity eluted at the position of synthetic GLP-1, suggesting that 
the peptide released in response to a mixed meal corresponds to the 
intestinal GLP-1. Due to lack of a sensitive assay at the time of publication, 
this was not replicated for GLP-2. However it is now known that GLP-1 and 
GLP-2 are co-secreted in response to an appropriate nutritional stimulus 
(section 1.1.4). Chromatographic elution profiles of fasting and postprandial 
plasma (Figure 2-8), obtained for this study, are in agreement with Orskov’s 
findings. In the fasting sample, the GLP-2-IR mainly consisted of larger 
molecular weight material with only a very small peak corresponding to the 
elution of GLP-2 (1-33) standard. The peak of larger molecular weight 
material elutes after cytochrome C and is likely to contain MPGF. In the 
postprandial plasma, overall GLP-2-IR was increased. There was now a 
discernable peak, corresponding to the elution point of GLP-2 standard, 
comprising 25% of total GLP-2-IR.  
 
Documentation of a clear response to a physiological stimulus is an 
important sign of a valid RIA assay. Measurement of plasma samples with 
antiserum FT-17 demonstrated a significant increase in GLP-2-IR in 
response to a high caloric, lipid rich, semi-liquid test-meal in healthy 
volunteers.  
 
In the literature, fasting GLP-2 (1-33) levels in adults, measured using N-
terminal specific antibody 92160, are reported in the region of 10-30 pmol/l 
(Hartmann et al. 2000; Jeppesen et al. 2000; Sorensen et al. 2003; Schmidt 
et al. 2005). In comparison, fasting levels of total GLP-2 immunoreactivity, 
measured with side viewing antibodies, are reported between 100 - 230 
pmol/l (Brubaker et al. 1997; Xiao et al. 1999). This is in keeping with fasting 
GLP-2-IR concentrations measured here and supports the conclusion that 
the utilized GLP-2 antibody is a “side viewing antibody”, measuring total 
GLP-2-IR.  
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There was considerable variation in the amount of fasting GLP-2-IR levels 
between the subjects and the fasting GLP-2-IR was not correlated to the 
individual post-prandial GLP-2 response. One subject showed a particularly 
high fasting level, but still had an appropriate postprandial GLP-2 increase. 
All subjects were asked to undergo a minimum 9 hour fasting period. It is 
possible that there were differences in the timing of meals prior to the fasting 
period and/or differences in gastric emptying and small bowel transit. 
However, given the fact that GLP-2 (1-33) only accounts for minimal 
proportion of total GLP-2-IR in fasting plasma, it is more likely that the 
variation in fasting total GP-2IR levels is caused by variation in other 
circulating proglucagon derived peptides. This conclusion is also 
strengthened by the finding of a poor correlation between measurement of 
fasting total GLP-2-IR with antiserum FT-17 and fasting GLP-2 (1-33) with 
antiserum 92160. It implies that a comparison of fasting GLP-2-IR levels 
between subjects, measured with antiserum FT-17, can’t reliably detect 
differences in GLP-2 (1-33). It is theoretically possible to separate the fasting 
samples with Sephadex Chromatography and quantify changes in the GLP-
2-IR peak that elutes at the point of GLP-2 standard. This approach is very 
laborious and unlikely to be utilized in routine analysis. In addition, given the 
small concentration of GLP-2 (1-33) in fasting plasma and the peptide loss 
due to the procedure, a large amount of sample would be required.  
 
The utilized test meal had high lipid content and caused significant 
postprandial increase of GLP-2-IR at all measured time points (30-240 min 
post meal). A rise of GLP-2 IR following a lipid meal (35% whipping cream) 
has been demonstrated by (Hartmann et al. 2000). In their study, fat induced 
a biphasic tGLP-2-IR release with peaks at 45 and 90 minutes. In the study 
presented here, the greatest increase occurred between 60 and 180 
minutes. The maximum postprandial tGLP-2-IR increase of 69.7% is 
comparable with results published by Hartman et al., who report a 69% and 
96% increase at 45 and 90 minutes respectively. 
 
We have shown a strong correlation between the measurements of 
postprandial total GLP-2-IR, (measured with antiserum FT-17) and GLP-2 (1-
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33) (measured with antiserum 92160). A strong correlation could also be 
shown for the estimation of tGLP-2-IR/GLP-2(1-33) increase from baseline. 
This indicates that the post-prandial increase of tGLP-2-IR is a good 
measure of GLP-2 (1-33) secretion. 
 
Total GLP-2-IR might also be altered by non-specific interaction of the GLP-2 
antibody with other plasma components. It is shown in section 2.3.1 that 
peptide extraction of postprandial plasma through Sep Pak cartridges can 
lead to a reduction of large molecular weight material and therefore to a 
relative increase of GLP-2 (1-33) within the total GLP-2-IR. This method of 
peptide extraction however is very time and labour-intensive and may 
introduce additional sources of error. Even though extraction was performed 
according to protocol, peptide recovery was lower (44% and 58%) compared 
to other reports: 84 ±17%. (Xiao et al. 2000). Different reagents were used to 
acidify the sample prior to passage trough the cartridge (trifluoroacetic acid 
vs. hydrochloric acid) and for peptide elution (isopropanolol vs. methanol), 
which might account for some of the difference. Other, methods of GLP-2 
extraction have been described, e.g. the use of 96% ethanol (Hartmann et al. 
2000) which is not as labour intensive. However reported peptide recovery 
was only 68%. 
 
When examining the GLP-2-IR response to nutrient stimulation, the expected 
post-prandial rise of GLP-2-IR could be demonstrated in unextracted plasma 
as well as after peptide extraction. There was a trend towards a greater 
relative increase of GLP-2-IR in extracted plasma samples, although no 
significant difference could be shown. A greater postprandial increase could 
indicate that the specificity of the assay to detect postprandial increase of 
GLP-2 is enhanced through removal of interferences that are not nutrient 
dependent and that therefore any changes in tGLP-2-IR are a more accurate 
reflection of postprandial increase in active GLP-2(1-33). A confounding 
factor however is the finding that in control samples (using different 
concentrations of synthetic GLP-2 standard) higher GLP-2 levels before 
extraction have led to a higher peptide yield.  
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The mean sensitivity of the GLP-2-RIAs performed was 2.6 ± 0.9 fmol/tube. 
This is equal to published results of side viewing antiserum UTTH7 where 
sensitivity was quoted as 10pg/tube which equates to 2.6 fmol/tube (Xiao et 
al. 1999). The intra-assay variation of freshly frozen quality control plasma 
samples was 8.8 %, the inter-assay variation 19.2%. It is generally 
recognized that the inter-assay variation between RIAs can be very high and 
comparison between assays is therefore not usually undertaken. An intra-
assay variation of <10% appears acceptable, although better performance of 
other assays has been reported (3.2% (Xiao et al. 1999)). It is unclear why 
the lyophilized control samples showed more inconsistency with a maximum 
intra-assay variation of 17.8%. It is possible that the generation of these 
samples (dilution of standard, separation into aliquots, freeze-drying and 
reconstitution) has introduced additional error. A high level of correlation was 
found (r=0.91) when 2 consecutive complete assays of the same samples 
were compared.  
 
Assay conditions depend upon the characteristics of a given antibody and 
antigen. Antibody-antigen interactions might be influenced by a variety of 
factors like type and pH of the buffer solution, incubation time and 
temperature. It has previously been established that for antibody FT-17, the 
use of phosphate buffer (pH 7.4) and an incubation time of 3 days achieve 
optimum binding conditions. Two additional factors that might alter assay 
sensitivity, buffer albumin content and separation method were investigated. 
The present results indicate that variation of albumin in the buffer solution 
(ranging from 0.3-3%) had very little impact on assay performance. In 
subsequent assays, buffer BSA content was therefore maintained at 0.3%, 
as previously used. Similar analytical sensitivity was achieved when 
separation of antibody-antigen complexes from free antigen through 
adsorption to charcoal was compared to immuno-precipitation with a 
secondary antibody. As charcoal separation is readily available, rapid, and 
inexpensive, it was utilized for all subsequent assays. 
 
Usage of a specific serine protease inhibitor (PMSF) in addition to Trasylol, 
used in the described manner, did not increase the diagnostic yield when 
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measuring GLP-2-IR. Assuming that a certain amount of GLP-2 undergoes 
degradation during sample processing and measurement, the most likely 
explanation for an apparent lack of protection through PMSF would be that 
both full length peptide as well as peptide degradation products are equally 
detected by the antibody used. It is unclear why measurements of tGLP-2-IR 
are lower at 240 minutes but overall it would seem that this finding is likely to 
be random. In the current experimental set up, enzyme activity should be 
minimal. A non-specific enzyme inhibitor (Trasylol) continued to be used 
routinely in all collection tubes. Samples are transported on ice and spun 
down immediately in a refrigerated centrifuge, stored at -70 °C and, after 
thawing, processed on cold trays or in the cold room at 4°C. It is likely that 
these precautions alone are adequate measures of minimizing peptide 
degradation. 
 
The impact of haemolysis on the binding characteristics of FT-17 was 
examined by diluting severely haemolysed plasma with non haemolysed 
plasma obtained at the same venepuncture. Mild haemolysis (5% of total 
volume) had no significant impact on the binding curve of GLP-2 standard. 
Severe haemolysis however, leads to over-estimation of GLP-2 
concentration and increased variability of results. Visibly haemolysed 
samples should probably be excluded from analysis. 
 
In order to protect samples from multiple freeze-thaw cycles and thus 
enhance their longevity, it is usual practice to separate plasma into several 
aliquots prior to storage. However, if the total sample volume is limited, 
samples may undergo repeat freeze-thawing. It is shown here that repeat 
freeze-thawing of a postprandial plasma sample does not lead to significant 
changes of GLP-2-IR. As detailed above, GLP-2 (1-33) only accounts for a 
certain proportion of total GLP-2-IR. To gain more specific insight into the 
effect of repeat freeze-thawing on GLP-2 (1-33), assessment of the increase 
of GLP-2-IR from fasting levels might be a more sensitive marker of GLP-2 
(1-33) in the samples. In the meantime, the safest policy is to continue 
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freezing samples in small aliquots and to use first defrost samples if 
possible. 
 
Carry over was assessed, because during the GLP-2 RIA, a single glass 
pipette is used for the entire assay to separate the bound and unbound 
fractions. This practice does not appear to lead to significant error if high and 
low concentration samples are measured in succession.  
 
GLP-2-ELISA has been shown in the literature to be a very suitable 
alternative to RIA in the measurement of GLP-2. Previous published results 
by (Martin et al. 2005), using an ELISA kit that is not commercially available 
(anti-ALE-0303 antiserum, raised against the first 18 residues of native 
human GLP-2, NPS pharmaceuticals) have shown a strong correlation to 
RIA using antiserum 92160 (r2 = 0.95%; confidence interval of 0.944 to 
0.985; n = 36). The results of a different ELISA kit (Phoenix Pharmaceuticals, 
Inc) presented here appear less favourable with no correlation to RIA 
(92160). Due to financial constraints, only a single ELISA kit could be tested. 
Samples were analysed in duplicate with an acceptable level of variation 
(9.2%). However a repeat correlation with antiserum 91260 should be 
attempted before reaching final conclusions about the utility of this ELISA kit. 
Only limited information was available with regards to antibody specificity 
with no data indicating cross-reactivity with GLP-2 (3-33) or MPGF. This 
emphasises the need to validate any analytical method against the current 
gold standard in order to interpret results accurately. 
 
Summary: It has been shown that a radioimmunoassay using antiserum FT-
17 provides a sensitive and specific method for the measurement of total 
GLP-2 immuno-reactivity in plasma samples and tissue extracts. FT-17 is not 
specific for the detection of biologically active GLP-2 (1-33), but belongs to 
the category of “side viewing antibodies” that cross-react with GLP-2 
precursors and degradation products. It has to be taken into consideration 
that the concentration of active GLP-2 (1-33) in the fasted state is low in 
relation to the total GLP-2 immuno-reactivity. The concentration of fasting 
total GLP-2 immuno-reactivity is subject to considerable variation and 
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correlates only poorly to GLP-2 (1-33) concentration. When using antiserum 
FT-17, estimation of biologically-active GLP-2 (1-33) secretion is therefore 
probably most precise when the dynamic GLP-2 response to a physiological 
stimulus is measured. 
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Chapter 3 
 
 
 
 
GLP-2 secretion 
as part of the L-cell response 
in short bowel syndrome 
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3.1 Introduction and aim 
 
Enteroendocrine L-cells are part of the diffuse endocrine system of the gut, 
originating from endodermal stem cells (Hocker et al. 1998). The majority of 
L-cells are located in the distal small bowel, colon and rectum, where they 
are scattered amongst endothelial cells in the crypts of Lieberkühn (Eissele 
et al. 1992). Recently it was established that L-cells are also present in the 
human duodenum (Theodorakis et al. 2006).  
 
Peptide tyrosine tyrosine (PYY) and proglucagon derived peptides (PGDP) 
are the main products of L-cell secretion. Proglucagon undergoes 
posttranslational processing into glucagon-like peptides-1 and -2 (GLP-1 and 
GLP-2) as well as Glicentin and Oxyntomodulin. The latter two both contain 
the entire pancreatic glucagon sequence and were previously identified as 
enteroglucagon.  
 
Over the last two decades much progress has been made towards 
delineating the diverse biological activity of these peptides and it has 
become evident that they possess therapeutic potential for a variety of 
clinical conditions. As an incretin hormone, GLP-1 enhances insulin 
secretion, whilst inhibiting glucagon release and has been shown to improve 
glycaemic control in animal models of type-2 diabetes as well as in human 
clinical studies (Todd et al. 2007). Reduction in food intake has been 
demonstrated following systemic administration of PYY (Batterham et al. 
2003), GLP-1 (Verdich et al. 2001) and Oxyntomodulin (Wynne et al. 2005) 
making these peptides possible targets for the treatment of obesity. 
Enhancement of L-cell secretion also appears advantageous in a variety of 
intestinal conditions. PYY and GLP-1 are potent inhibitors of gastro-intestinal 
motility and secretion (Savage et al. 1987; Wettergren et al. 1993) and thus 
might be developed into novel anti-diarrhoeal drugs. GLP-2 has received 
much attention for its specific effects on intestinal mucosal proliferation and 
repair (Drucker et al. 1996; Bulut et al. 2004). Early clinical trials have 
suggested positive treatment effects in patients with short bowel syndrome 
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(Jeppesen et al. 2001; Jeppesen et al. 2005) and Crohn’s disease (Buchman 
et al. 2006).  
 
The morphology of L-cells as open type cells with long projections toward the 
intestinal lumen suggests that these cells are sensing luminal contents 
(Theodorakis et al. 2006). In keeping with this, ingestion of nutrients, 
particularly of carbohydrates and lipids, constitutes a strong, secretory 
stimulus for PYY and PGDPs. It remains largely unexplored how the release 
of these peptides is coordinated, to what extend their production and 
secretion is mediated by the same stimuli or can be driven by separate 
signals and how changes of intestinal anatomy or biochemical environment 
impact on this balance.  
 
In animals subjected to massive small bowel resection, the remnant intestine 
undergoes a patterned response known as intestinal adaptation. Well-
documented indices of this adaptive response include structural (increases in 
intestinal crypt depth and villus height) and functional (increases in digestive 
and absorptive capacity per unit intestinal length) changes. The significance 
of intestinal adaptation is that its net effect is to increase the absorptive 
efficiency and capacity of the remnant intestine in animals subjected to 
intestinal resection. However, there is a paucity of evidence documenting the 
significance of this phenomenon in humans (Tavakkolizadeh et al. 2002).  
 
Animal models of massive small intestinal resection have demonstrated an 
adaptive increase of both PGDPs and PYY if the L-cell reservoir in the distal 
bowel is preserved (Fuller et al. 1993; Bilchik et al. 1995; Adrian et al. 1996). 
Fuller and colleagues have shown a parallel increase of PYY and 
proglucagon mRNA in the ileal mucosa following massive small bowel 
resection in rats, suggesting that the increased synthetic activity is an L-cell 
specific response (Fuller et al. 1993). In a similar model however, Bilchik and 
colleagues demonstrated differences between concentrations of PYY and 
proglucagon mRNA in different parts of the intestine and came to the 
conclusion that the response to intestinal resection might be gene specific 
(Bilchik et al. 1995).  
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In clinical practice, patients with short bowel syndrome following extensive or 
repeated intestinal resections, divide into two common groups: those with a 
jejunostomy and those with jejunum in continuity with the colon. The two 
patient groups greatly differ in their requirements of nutritional support. 
Whereas both groups have problems with nutrient absorption, jejunostomy 
patients have additional problems of maintaining their fluid and electrolyte 
balance. It is thought that differences in gut hormone secretion may 
contribute to variations in gastric emptying rate and gastrointestinal 
secretions between short bowel patients with and without a colon 
(Nightingale et al. 1996). 
 
Different aspects of L-cell secretion in this patient population have previously 
been studied. Nightingale and colleagues have shown low fasting and 
postprandial PYY values in short bowel patients without a colon and high 
values in short bowel patients with a retained colon (Nightingale et al. 1996). 
Jeppesen and colleagues have found impaired postprandial GLP-2 secretion 
in patients without a colon (Jeppesen et al. 1999) and elevated fasting and 
postprandial plasma levels of GLP-1 and GLP-2 in patients with a retained 
colon (Jeppesen et al. 2000). Although these results suggest parallel 
changes of PYY and PGDP secretion, it needs to be considered that these 
results were derived from different patient populations. If the mucosal 
response to injury leads to a general reduction or enhancement of L-cell 
mass or function, a positive correlation between PYY and PGDP secretion 
could be assumed. If however, as suggested by Bilchik’s study, the response 
to intestinal resection is gene specific, the secretory response between 
PGDPs and PYY might deviate.  
 
In order to investigate changes in L-cell secretory response following 
extensive intestinal resection in humans, we measured fasting and 
postprandial plasma levels of PYY, GLP-1 and GLP-2 in patients with short 
bowel syndrome and healthy controls. 
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3.2 Methods 
 
3.2.1 Subjects 
 
The study was performed according to the principles of the Declaration of 
Helsinki and approved by the Harrow research ethics committee (REC 
reference 04/Q0405/83). All participants gave written consent to take part in 
the study after receiving oral and written information. All samples were 
collected at St Mark’s hospital between 2005 and 2006. All of the work, 
including experimental design, subject recruitment, sample collection, 
sample analysis and data interpretation was carried out by the author. Three 
subject groups were investigated.  
 
HC: Healthy controls. These subjects, mainly hospital staff, had no previous 
history of intestinal surgery or other significant co-morbidity. This group 
included 14 subjects (8 male, 6 female) with a median age of 40 years 
(range 31-54 years) and a median BMI of 26 (range 24-29). 
 
SBS-1: Short bowel patients with no terminal ileum or colon in continuity. 
This group included 16 subjects (4 male, 12 female) with a median age of 52 
years (45-58) and a median BMI of 22 (19-25). Underlying diagnosis leading 
development of SBS was: Crohn’s disease (n=8); mesenteric infarct (n=5); 
volvulus (n=2); colorectal cancer (n=1). Five patients had a jejunostomy and 
no remaining colon. Three patients had a jejunostomy and an unconnected 
rectal stump. A further 8 patients had either the whole or part or their colon 
preserved but this was not in continuity. The median small bowel length was 
100 cm (68-100). Eight patients (subgroup SBS-1-adapted) were clinically 
stable patients who had undergone their last small bowel resection more 
than two years prior to participation in the study. It can be assumed that 
maximum intestinal adaptation has taken place in this group (Goodlad et al. 
2001). The other 8 patients (SBS-1-non-adapted) were acutely hospitalized 
patients who had undergone their last small bowel resection less than one 
year prior to the study (usually at the same admission). All but one patient 
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(subject 05) was in need of parenteral nutritional support. Patient details are 
listed in Table 3-1. 
 
SBS-2: Short bowel patients with terminal ileum and/or colon in 
continuity. This group included 11 patients (4 male, 7 female) with a median 
age of 50 years (44-62) and a median BMI of 21 (21-23). Underlying 
diagnosis leading development of SBS was: mesenteric infarct (n=10); 
volvulus (n=1). These patients had either all (n=4) or part of the colon (n=7) 
preserved and this was in continuity with the small bowel. Median small 
bowel length was 40 (18-60) cm with 80 % (65-100) of colon in continuity. 
This group consisted of 5 stable (SBS-2-adapted) and 6 acute (SBS-2-non-
adapted) patients as described above. Patient details are listed in Table 3-1. 
 
The small bowel length was measured at the time of the last surgical 
resection in 21 cases and assessed radiologically with a barium follow 
through in 5 patients. The small bowel length could not be quantified in one 
subject (SBS-1-11). The operation notes stated that “proximal jejunum was 
brought out as jejunostomy”. Colonic length was estimated as sum of: 
caecum + ascending colon = 25%; transverse colon = 25%; descending 
colon = 20%, sigmoid colon = 20% and rectum = 10%. Subjects were 
continued on their regular medications which included standard treatment for 
SBS: antidiarrhoeal medications (loperamide and codeine), antisecretory 
drugs (proton pump inhibitors). Only one patient (SBS-1-10) received twice 
daily octreotide injections. The morning dose was withheld until after the 
collection of blood. One subject was included in both groups, before and 
after restoration of continuity between jejunum and colon (SBS-1-10 = SBS-
2-27). 
 
The basic metabolic rate (BMR) of all subjects was calculated using the 
Harris Benedict equation (Harris et al. 1918): BMR (Men) = 66.4730 + 
(13.7516 × Weight) + (5.0033 × Height) − (6.7550 × A ge); BMR (Women) = 
655.0955 + (9.5634 × Weight) + (1.8496 × Height) − (4.6756 × Age) 
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 SBS-1: no colon in continuity
ID Age/Sex BMI D Small Colon Stoma Out of stream Last PN 
bowel resection
(cm) (%) (months)
01 36M 23.2 CD 100 0 jejunostomy        180 yes
02 47F 21.5 CD 60 0 jejunostomy        180 yes
03 54F 18.6 CD 40 0 jejunostomy        48 yes
04 54F 21.8 CD 80 0 jejunostomy        156 yes
05 58M 26.0 CD 100 10 jejunostomy rectal stump 72 no
06 58F 18.7 CD 110 10 jejunostomy rectal stump 36 yes
07 59F 19.8 CD 80 10 jejunostomy rectal stump 216 yes
08 59F 26.4 MI 75 75 jejunostomy colon 60 yes
09 52F 18.2 Ca 100 0 jejunostomy        3 yes
10* 24M 19.6 V 110 95 jejunostomy colon 2 yes
11 42F 37.6 MI 100 jejunostomy jejunum, ileum, colon 2 yes
12 33F 24.6 MI 25 65 jejunostomy colon 3 yes
13 52F 30.0 MI 100 75 jejunostomy colon 3 yes
14 52F 18.1 CD 0 75 duodenostomy colon 1 yes
15 46M 24.4 V 120 100 jejunostomy ileum, colon 9 yes
16 70F 19.1 MI 100 80 jejunostomy ileum, colon 2 yes
 
SBS-2: colon in continuity
ID Age/Sex BMI D Small Colon Stoma Anastomosis Last PN 
bowel resection
(cm) (%) (months)
17 59F 22.2 MI 0 55 none duodeno-colonic 72 yes
18 40F 23.5 MI 29 35 colostomy jejuno-colonic 48 yes
19 62F 21.2 MI 0 100 none duodeno-caecal 276 yes
20 47F 23.4 MI 20 100 none duodeno-ileal 72 yes
21 62F 20.9 MI 50 80 none jejuno-colonic 144 yes
22 68F 17.9 MI 45 100 none jejuno-caecal 2 yes
23 63M 21.0 MI 120 65 none jejuno-colonic 6 yes
24 48M 27.9 MI 70 100 none gastro-ileal 4 yes
25 41M 22.9 MI 15 75 colostomy jejuno-colonic 8 yes
26 50F 21.2 MI 40 65 colostomy jejuno-colonic 1 yes
27* 24M 18.3 V 110 95 none jejuno-caecal 1 yes
 
Table 3-1: Patient details 
D: Diagnosis, CD: Crohn’s disease, MI: Mesenteric infarct, V: Volvulus 
PN: Parenteral nutrition 
 
* subject SBS-1-10 = SBS-2-27 (before and after restoration of bowel continuity) 
 
(Small bowel length of 0cm indicates: duodenum only) 
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3.2.2 Test meal  
 
A calorie-dense, lipid-rich, standardized test meal was chosen in order to 
induce adequate and reproducible postprandial GLP-2 secretion. Palatability 
and ease of consumption were other important considerations. These criteria 
were met by using a combination of liquid nutritional supplements. One 
serving of Calshake® (a gift from Fresenius Kabi), made up with 250ml 
whole milk, was enriched with 60ml of the long chain triglyceride emulsion 
Calogen® (a gift from Nutricia Clinical). To enhance palatability, the drink 
was served in a choice of flavours and mixed with ice. Table 3-2 details the 
macronutrient composition of the meal. Subjects were asked to consume the 
meal completely within 20 minutes. 10 (out of 16) patients from the SBS-1 
and 9 (out of 11) patients from the SBS-2 group completed the test meal. 
Reasons for not taking or finishing the standard meal included lactose 
intolerance, nausea, fullness and concerns over fluid restriction. In patients 
who had not completed the full meal, only fasting blood samples were 
analysed. 
 
 
Standard meal Per serving 
Energy (kcal) 866 
Protein (g) 11.6 
Carbohydrate (g)  68.4 
Fat (g) 60.8 
Fibre (g) 0 
 
Table 3-2:  Macronutrient composition of standard meal  
(as per manufacturers’ information). 
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3.2.3 Sampling 
 
Venous blood was collected after an overnight fast. Patients received their 
normal parenteral nutrition over night. In hospitalized patients blood was 
collected in the morning (between 8 and 10am). As most stable outpatients 
have a long journey time to the hospital, sample collection occurred during 
the nutrition clinic in the afternoon (between 1 and 3pm). These patients 
were allowed unsweetened tea or coffee without milk in the morning and 
then water until the test. Samples were collected in 10ml lithium-heparin 
tubes containing 0.2ml Trasylol and immediately spun down in a refrigerated 
centrifuge at 4°C for 10 min at 1600g. Plasma was collected and stored at -
70°C until analysis. In patients who consumed the standard meal two further 
blood samples were drawn 60 min and 120 minutes after the meal was 
ingested.  
 
3.2.4 Radioimmunoassay 
 
Total GLP-2-IR was measured using antiserum FT-17 and GLP-2 (1-33) 
concentration was determined by Prof. Jens Holst, using antiserum 92160. 
Both assays are described in chapter 2.  
 
Plasma glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) were 
measured in duplicate by established specific and sensitive in-house assays 
(Adrian et al. 1985; Kreymann et al. 1987).  
 
GLP-1 (7-36) was measured using an antibody, produced in rabbits against 
GLP-1 coupled by carbodi-imide to BSA. The antibody cross reacted 100% 
with all amidated forms of GLP-1 but did not cross react with glycine 
extended forms [GLP-1 (1-37) and GLP-1 (7-37)] or any other known 
pancreatic or gastrointestinal peptide. 125I-GLP-1 (7-37 amide) was 
prepared by the iodogen method (Wood et al., 1981) and purified by HPLC. 
The specific activity of the 125I GLP-1 label was 48 Bq/fmol. The assay was 
performed in a total volume of 0.7 ml of 0.06 M sodium barbitone buffer (pH 
  113 
8.0) containing 0.3 % BSA. The assay was incubated for three days at 4ºC 
before separation of the free and antibody bound label by charcoal 
absorption. The limit of detection was 7.5p mol/l, with an intra-assay variation 
of 5.4%. All samples were assayed in duplicate and in one assay to avoid 
inter-assay variation.  
 
PYY-like immunoreactivity measured the biologically active components, 
both the full length (PYY1-36) and the fragment (PYY3-36). The antiserum 
(Y21) was produced in a rabbit against synthetic porcine PYY (Bachem, UK) 
coupled to bovine serum albumin with glutaraldehyde and used at a final 
dilution of 1:50 000. This antibody cross-reacts fully with the biologically 
active circulating forms of human PYY, but not with pancreatic polypeptide, 
neuropeptide Y, or any other known gastrointestinal hormone. 125I-labeled 
PYY was prepared by the iodogen method and purified by high pressure 
liquid chromatography. The specific activity of the 125I-labelled PYY was 54 
Bq per fmol. The assay was performed in a total volume of 700 µL of 0.06 M 
phosphate buffer, pH 7.26, containing 0.3 % bovine serum albumin. The 
samples were incubated for 3 days at 4 ºC before separation of free and 
antibody-bound label by sheep anti-rabbit antibody. 200 µL of unextracted 
plasma was assayed. The assay has been reported to detect changes of 
2pmol/L, with an intra-assay coefficient of variation (CV) of 5.8 % and an 
inter-assay CV of 9.8 %.  
 
3.2.5 Statistics 
 
Calculations were performed using Excel and MedCalc statistical 
programmes. Non-parametric statistical tests were applied in view of the 
sample size and the inequality of sample numbers between groups. Results 
are expressed as median (range). Wilcoxon test for paired samples was 
applied to assess the postprandial response (time point 0 vs. 60 and 120) 
within each group. Kruskal-Wallis test was used for comparison between all 
subject groups. Mann-Whitney-U test for independent samples was used for 
post hoc analysis. Spearman’s coefficient of rank correlation was applied to 
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assess the correlation between intestinal length and hormone 
concentrations. A value of p<0.05 was considered significant. 
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3.3 Results 
 
3.3.1 Demographic characteristics 
 
The study groups included 14 healthy control subjects (8 male, 6 female), 16 
SBS-1 subjects: short bowel patients with no colon in continuity (4 male, 12 
female) and 11 SBS-2 subjects short bowel patients with all or part of the 
colon preserved and in continuity with the small bowel (4 male, 7 female). 
Full patient details are described in the methods section (3.3). 
 
There were no significant differences in age or height between the study 
groups. Body weight, body mass index (BMI) and basic metabolic rate 
(BMR) were lower in both SBS groups compared with the healthy controls. 
The residual small bowel was shorter in the SBS-2 subjects who had part of 
their colon in continuity. There was no difference in the overall time from 
surgery between the SBS-1 and SBS-2 group (Table 3-3). 
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HC SBS-1 SBS-2 p
Number all 14 16 11
a NA 8 6
n-a NA 8 5
Sex   all 8/6 4/12 4/7 0.19
(F/M) a NA 2/6 4/2
n-a NA 2/6 0/5
Age  all 40 (31-47) 52 (45-58) 50 (44-62) 0.2
(years) a NA 49 (40-52 49 (43-60)
n-a NA 56 (52-58) 59 (47-62)
p (a vs. n-a) 0.08 0.9
Weight all 81 (69-89) 57 * (51-74) 61 * (55-66) 0.01
 (kg) a NA 63 (50-78) 66 (62-71)
n-a NA 55 (52-72) 56 (54-59)
p (a vs. n-a) 0.7 0.08
Height all 173 (168-180) 164 (161-174) 165 (157-177) 0.2
(cm) a NA 166 (162-176) 177 (172-180)
n-a NA 163 (160-169) 158 (156-163)
p (a vs. n-a) 0.6 0.03
BMI all 26 (24-29) 22 * (19-25) 22 *  (21-23) 0.02
(kg/m2) a NA 22 (19-26) 21 (18-23)
n-a NA 22 (20-24) 22 (21-23)
p (a vs. n-a) 0.9 0.5
BMR  all 1627 (1548-1870) 1291* (1193-1631) 1322* (1191-1570) 0.01
(cal/day) a NA 1415 (1191-1716) 1577 (1361-1709)
n-a NA 1128 (1200-1424) 1197 (1184-1287)
p (a vs. n-a) 0.6 0.08
Time since surgery all NA 23 (3-93) 8 (3-72) 0.9
(months) a NA 3 (2-3) 3 (1-6) 0.9
n-a NA 114 (57-180) 72 (72-276) 0.9
p (a vs. n-a) <0.0001 0.004
Small bowel all NA 100 (68-100) 40 (18-60) 0.05
(cm) a NA 100 (63-105) 58 (41-100) 0.7
n-a NA 80 (71-100) 10 (0-29) 0.005
p (a vs. n-a) 0.3 0.05
Colon in continuity all NA NA 80 (65-100) NA
(%) a NA NA 85 (68-99)
n-a NA NA 80 (55-100)
p (a vs. n-a) 0.7
Group characteristics
 
Table 3-3:  Demographic characteristics of subjects.  
Results are given as median (interquartile range).  
The study groups were compared using the Kruskal-Wallis test (Chi-square test for 
sex of subjects). A p-value < 0.05 was considered significant.  
Mann Whitney U test was applied for post hoc analysis * = p<0.05 and for 
comparison of adapted (a) vs. non-adapted (n-a) subjects within the groups. 
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3.3.2 Hormone concentration 
 
 
Measurement of fasting hormone concentration in SBS-1 patients (without 
terminal ileum and/or colon in continuity) revealed reduced plasma 
concentrations of GLP-1 (p<0.001), and PYY (p<0.001) compared with 
healthy controls. There was a trend towards reduction for GLP-2 (1-33) 
(p=0.07). This could not be demonstrated for tGLP-2-IR measured with 
antiserum FT-17. 
 
In SBS-2 patients (with preserved terminal ileum and/or colon), the median 
fasting concentrations of GLP-1 and GLP-2 (1-33) were also reduced 
compared with controls but this difference was not significant. In contrast, the 
median fasting plasma PYY concentration was 3-fold higher in this patient 
group (p< 0.001) (Table 3-4 and Figure 3-1). 
 
 
 
 
 
 
 
 
  118 
Fasting
HC SBS-1 SBS-2
n 14 16 11
GLP-1 (pmol/l) 51 (43-56) 22 (17-30) 25 (23-56)
p vs. HC 0.0003 0.1
GLP-2 (1-33) (pmol/l) 9 (7-10) 5 (1-9) 6 (5-14)
p vs. HC 0.07 0.4
tGLP-2 IR (pmol/l) 118 (85-143) 111 (79-148) 147 (90-185)
p vs. HC 0.9 0.2
PYY (pmol/l) 20 (12-30) 6 (5-12) 69 (49-95)
p vs. HC 0.0004 0.0001
 
Table 3-4: Fasting hormone concentrations; median (range).  
p vs. HC (Mann-Whitney-U test) 
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Figure 3-1: Fasting hormone concentrations; change versus HC (set as 100%) 
**p<0.001 vs. HC; # p<0.00001 vs. SBS-1 (Mann-Whitney-U test) 
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Comparison between non-adapted (last resection <12 months) and adapted 
(last resection > 24 months) patients in the SBS-1 group shows a significant 
reduction in fasting GLP-1 and PYY in both subgroups. Fasting GLP-2 was 
only reduced in the acute subgroup.  
 
In the SBS-2 group GLP-1 is significantly reduced in the non-adapted 
subgroup. There is no change in fasting GLP-2 in either subgroup. Fasting 
PYY values are elevated in non-adapted and adapted SBS-2 patients 
(Figure 3-2). 
 
 
HC
Fasting non-adapted adapted non-adapted adapted
n 14 8 8 6 5
Last resection (months) NA 3 (2-3) 114 (57-180) 3 (1-6) 72 (72-276)
Jejunum (cm) NA 100 (63-105) 80 (71-100) 58 (41-100) 10 (0-29)
p (non-adapted vs. adapted) 0.3 0.05
Colon in continuity (%) NA NA NA 85 (68-99) 80 (55-100)
p (non-adapted vs. adapted) 0.7
GLP-1 (pmol/l) 51  (43-56) 22  (19-29) 20  (15-30) 25  (24-37) 46  (22-65)
p (vs HC) 0.0008 0.001 0.03 0.7
p (non-adapted vs. adapted) 0.8 0.7
GLP-2 (pmol/l) 9  (7-10) 2  (1-4)  9  (7-12) 7  (5-13) 6  (5-13)
p (vs HC) 0.0007 0.7 0.5 0.6
p (non-adapted vs. adapted) 0.007 0.9
PYY (pmol/l) 20  (13-30) 6  (5-13) 7  (5-10) 69  (55-69) 59  (48-103)
p (vs HC) 0.006 0.002 0.0005 0.006
p (non-adapted vs. adapted) 0.8 0.5
SBS-1 SBS-2
 
Table 3-5:  Fasting hormone concentration in adapted and non-adapted subgroups.      
p (Mann-Whitney-U test) 
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Figure 3-2:  Fasting hormone concentration in non-adapted (NA) and adapted (A) 
subgroups:       
A) GLP-1 B) GLP-2 (1-33)  C) PYY 
(Values shown: median, 25 to 75 percentile, minimum to maximum, outliers) 
SBS-1 NA  = No colon in continuity,  resection < 12 months ago  (n=8)              
SBS-1 A  = No colon in continuity,  resection > 24 months ago  (n=8)                   
SBS-2 NA = Colon in continuity,  resection < 12 months ago  (n=6)              
SBS-2 A  = Colon in continuity,  resection > 24 months ago  (n=5)                                       
HC  =    Healthy controls    (n=14)   
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Postprandial hormone concentrations were determined 60 and 120 
minutes following a standardized nutrient challenge. The highest hormone 
level of the two time-points (Max) was compared with the fasting 
concentration. A significant postprandial rise of GLP-1, GLP-2 ((1-33) and 
tGLP-2-IR) and PYY concentration from baseline was demonstrated in all 
subject groups (Table 3-6 and Figure 3-3).   
 
 
SBS-1 SBS-2
n 14 10 9
GLP-1 (pmol/l) Fasting 50.56 (43.3-56.1) 28.1 (23.4-33.5) 41.4 (23.5-65.2)
Max 69.7 (66.3-89.2) 42.4 (33.3-64.5) 97 (70.7-126.4)
p 0.0001 0.01 0.012
GLP-2 (1-33) (pmol/l) Fasting 8.5 (7.3-9.8) 3.5 (1.0-7.5) 6 (5.0 -13)
Max 30.5 (23.7-44.0) 11.5 (9.3-14.5) 35 (23-52)
p 0.0002 0.008 0.004
tGLP-2 IR (pmol/l) Fasting 117.5 (85-143) 93.4 (71-166.1) 146.6 (101.8-193.9)
Max 203 (156.7-260.5) 169.9 (117-232.4) 371.6 (237.4-376.1)
p 0.0006 0.002 0.004
PYY (pmol/l) Fasting 19.5 (12.8-29.9) 10.1 (7.4-14.2) 70.2 (58.5-239.5)
Max 39.6 (29-57.7) 23.8 (14.8-36.1) 200.9 (159.2-396.6)
p 0.0001 0.002 0.004
HC
 
Table 3-6: Hormone concentration in fasted state versus maximum postprandial level  
(Max = concentration at 60 or 120 minutes post meal) 
Values given are: median (interquartile range). (p: Wilcoxon test for paired samples) 
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Figure 3-3: Hormone concentration in fasted state versus maximum postprandial level  
(Max = concentration at 60 or 120 minutes post meal) 
Values given are: median (interquartile range).  
The difference between fasting and maximum hormone concentration was 
significant for all groups and hormones analysed (see Table 3-5). 
  HC  = Healthy controls       
  SBS-1 = No colon in continuity      
  SBS-2 = Colon in continuity      
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The magnitude of the postprandial secretory response for each hormone 
was assessed by calculating the maximum increase of hormone 
concentration from baseline (at 60 or 120 minutes).   
 
SBS-1 patients showed a reduced response of GLP-2 (1-33) compared to 
HC. No statistically significant changes could be demonstrated for tGLP-2-
IR, GLP-1 or PYY. 
 
In SBS-2 patients, there was no significant difference in postprandial GLP-1 
or GLP-2 secretory response. However, postprandial PYY secretion in SBS-
2 patients showed a very strong increase (8.5-fold higher compared to HC) 
(Table 3-7; Figure 3-4). 
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HC SBS -1 SBS-2
n 14 10 9
GLP-1 (pmol/l) 21 (12-36) 12 (6-31) 30 (22-43)
p vs. HC 0.2 0.6
GLP-2 (1-33) (pmol/l) 23 (12-36) 10 (3-12) 27 (15-38)
p vs. HC 0.02 0.2
tGLP-2 IR (pmol/l) 70 (32-144) 31 (26-106) 168 (91-225)
p vs. HC 0.3 0.1
PYY (pmol/l) 18 (13-24) 12 (8-24) 150 (91-163)
p vs. HC 0.5 0.0001
Maximal postprandial increase from fasting
 
Table 3-7: Maximum postprandial increase in hormone concentrations (at 60 or 120 min)
         
Values: median (range);            
p vs. HC:  (Mann-Whitney-U test) 
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Figure 3-4: Maximum increase in hormone concentrations (at 60 or 120min)               
Change versus healthy controls: HC (set as 100%)  
*p<0.05 vs. HC; **p<0.001 vs. HC, # p<0.0002 vs. SBS-1 (Mann-Whitney-U test) 
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Comparison between non-adapted (last resection <12 months) and adapted 
(last resection > 24 months) patients in the SBS-1 group shows a reduction 
of the postprandial GLP-1 and GLP-2 response vs. healthy controls in the 
non-adapted group but no difference in the adapted group. The postprandial 
PYY increase is similar to that of healthy controls in both subgroups.  
 
In the SBS-2 group the GLP-1 and GLP-2 response is similar to the controls 
in non-adapted and adapted patients. The strongly increased postprandial 
PYY response can be shown in both subgroups. (Table 3.8 and Figure 3-5). 
 
 
HC
Max increase non-adapted adapted non-adapted adapted
n 14 5 5 5 4
Last resection (months) NA 3 (2-3) 72 (60-156) 4 (2-6) 108 (66-177)
Jejunum (cm) NA 100 (25-100) 80 (80-100) 45 (40-70) 25 (15-34)
p (non-adapted vs. adapted) 1 0.1
Colon in cont. (%) NA 0 0 75 (65-100) 90 (69-100)
p (non-adapted vs. adapted) 0.6
GLP-1 (pmol/l) 21  (12-36) 11  (2-12) 35  (22-36) 26  (22-30) 40  (29-46)
p (vs HC) 0.02 0.4 1 0.4
p (non-adapted vs. adapted) 0.03 0.4
GLP-2 (pmol/l) 23  (12-36) 4  (3-9) 11  (10-14) 19  (15-38) 31  (24-39)
p (vs HC) 0.02 0.19 0.7 0.4
p (non-adapted vs. adapted) 0.22 0.9
PYY (pmol/l) 18  (13-24) 9  (6-16) 19  (9-28) 150  (91-157) 152  (115-167)
p (vs HC) 0.9 0.3 0.006 0.001
p (non-adapted vs. adapted) 0.2 0.9
SBS-1 SBS-2
 
 
Table 3-8: Maximum increase in hormone concentrations (at 60 or 120min) in non-adapted 
and adapted subgroups. 
p ( Mann Whitney U test). 
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Figure 3-5: Maximum postprandial secretory response (at 60 or 120 minutes) in non-adapted  
(NA) and adapted (A) subgroups:  
 A) GLP-1 B) GLP-2 (1-33)  C) PYY 
(Values shown: median, 25 to 75 percentile, minimum to maximum, outliers) 
SBS-1 NA  = No colon in continuity,  resection < 12 months ago  (n=5)              
SBS-1 A  = No colon in continuity,  resection > 24 months ago  (n=5)                   
SBS-2 NA = Colon in continuity,  resection < 12 months ago  (n=5)              
SBS-2 A  = Colon in continuity,  resection > 24 months ago  (n=4)                                       
HC  =    Healthy controls    (n=14)    
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Analysis of fasting L-cell hormone concentration in a single subject with 
SBS secondary to mesenteric volvulus demonstrates reduced GLP-1, GLP-2 
and PYY levels (compared to median concentrations in HC) 2 months 
following resection and formation of jejunostomy (110 cm small bowel). One 
month after restoration of colonic continuity (95% colon preserved), fasting 
GLP-1 and GLP-2 concentration remain low but a strong increase in fasting 
PYY concentration can be seen (Figure 3-6). 
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Figure 3-6: Fasting hormone concentrations in a single subject with SBS 
2 months after jejunostomy formation (110cm small bowel) (dotted bar) 
1 month following restoration of colonic continuity (striped bar) 
Compared to median hormone levels in healthy controls (HC; empty column) 
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The correlation between remaining intestinal lengths and hormone 
plasma concentrations (fasting and maximum increase) was calculated 
using the Spearman’s coefficient of rank correlation (rho). There was a 
suggestion of a positive correlation between length of remaining small bowel 
and maximum postprandial PYY increase (rho=0.69, p=0.03) in the SBS-1 
group. No other significant correlations could be demonstrated. 
 
 
 
n GLP-1 GLP-2 PYY
rho p rho p rho p
SBS-1
Fasting SB length 15 0.25 0.4 -0.11 0.6 0.02 0.9
Max Increase SB length 10 0.12 0.7 0.48 0.1 0.69 0.03
SBS-2
Fasting SB length 11 0.47 0.1 -0.04 0.9 0.37 0.2
Colon length 11 -0.07 0.8 -0.06 0.8 0.07 0.8
Max Increase SB length 9 -0.3 0.3 0.48 0.2 0.23 0.5
Colon length 9 0.5 0.1 0.46 0.2 0.19 0.6
Correlation to intestinal length
 
 
Table 3-9: Correlation between hormone concentration and intestinal length.  
The remaining intestinal lengths (SB=small bowel and Colon) was correlated with 
GLP-1, GLP-2 and PYY plasma concentration (fasting and maximum postprandial 
increase).  
Spearman’s correlation coefficient (rho); n= number of subjects.  
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3.4 Discussion 
 
The enteroendocrine L-cell is the source of intestinal PYY and proglucagon 
derived peptide (PGDP) production. These hormones have important 
regulatory functions within the gastrointestinal tract as well as exert a range 
of extra-intestinal effects. Changes in PYY and PGDP secretion from L-cells 
following massive intestinal resection have been demonstrated in animal 
models and humans (Fuller et al. 1993; Bilchik et al. 1995; Adrian et al. 
1996; Nightingale et al. 1996; Jeppesen et al. 1999; Jeppesen et al. 2000). 
The question, whether this adaptive response is L-cell specific or whether 
the secretion of different L-cell products may be regulated independently has 
not yet been answered.  
 
Patients with short bowel syndrome (SBS) due to extensive intestinal 
resection appear to achieve better functional adaptation if their colon has 
been retained. It has been suggested that this might partly be caused by 
differences in gut hormone secretion (Nightingale et al. 1996). 
 
The results of this study demonstrate that SBS patients, who have no 
terminal ileum or colon in continuity (SBS-1 group), have deficient 
secretion of PYY as well as GLP-1 and GLP-2. The fasting plasma 
concentration of GLP-1 and PYY was significantly reduced compared to 
healthy controls and there was a trend towards reduction for GLP-2 (1-33). 
No difference was shown for tGLP-2-IR. The latter finding is not unexpected, 
given that the amount of glucagon-like peptides in fasting samples is thought 
to be very small (Orskov et al. 1987) and we have found no correlation 
between fasting levels of GLP-2 (1-33) and tGLP-2-IR (section 2.3.6). 
Reductions in fasting GLP-1 and PYY were shown in non-adapted and 
adapted SBS-1 patients.  
 
The SBS-1 patients in this study showed a preserved postprandial secretory 
response with significant increases of GLP-1, GLP-2 and PYY. However, the 
maximum postprandial increase of GLP-2 (1-33) was attenuated when 
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compared with healthy controls. Reductions in median postprandial response 
for GLP-1 and PYY did not reach statistical significance.  
 
Nightingale and colleagues showed that jejunostomy patients (median 
jejunal length 90 cm (55-125)) had low fasting PYY values and a reduced 
secretory response following a mixed 640 kcal meal (Nightingale et al. 1996). 
A study from Morgan et al. describes a preserved but attenuated GLP-1 
response following a 625 kcal meal in 6 jejunostomy patients (residual 
jejunal length 50-160 cm) (Morgan et al. 1993). Jeppesen and colleagues 
also describe impaired postprandial GLP-2 secretion in jejunostomy patients 
but in contrast to our findings showed no significant difference in fasting 
GLP-2 levels between jejunostomy patients and healthy controls (Jeppesen 
et al. 1999). It is conceivable that this is due to the fact that their patient 
population (n=7) had slightly longer jejunal remnants (111 cm (range 30-
150cm) vs. 100 (68-100). The majority of L-cells are located in the distal 
ileum and colon. However, smaller quantities can also be found in the 
proximal jejunum and duodenum (Eissele et al. 1992; Theodorakis et al. 
2006). Thus, a positive correlation between remaining jejunal length and L-
cell secretions could be postulated. However, we were unable to 
demonstrate a correlation between fasting peptide levels and length of 
jejunal remnant in jejunostomy patients. It is very possible that the subject 
number and the variations of residual intestinal length were insufficient to 
demonstrate such correlation. 
 
In Jeppesen’s study, the jejunostomy patients had only a small postprandial 
GLP-2 response following a liquid 450 kcal and a separate mixed 936 kcal 
meal (meal A and B respectively) with no significant increase from baseline 
at any time point (10-180min). The test meal used in our study contained 866 
kcal, which is comparable to meal B, however was of different consistency 
(liquid) and nutrient composition. This might cause differences in gut 
distension and speed of gastric empting and nutrient delivery to sensor cells, 
thus resulting in a different L-cell response. 
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Intestinal adaptation occurs over a period of time. Initial changes to mucosal 
DNA synthesis and cell production can occur rapidly. In animal models, 
increase in PYY and proglucagon mRNA has been demonstrated within 
hours from resection (Bilchik et al. 1995). The majority of intestinal 
adaptation takes place within the first 12-24 months (Goodlad et al. 2001). 
Certain intestinal functions, for example the intestinal calcium absorption, 
may continue to increase for more than 2 years after resection (Gouttebel et 
al. 1989). It is of note that the subgroup of non-adapted jejunostomy patients 
in our study had a significantly reduced postprandial GLP-1 and GLP-2 
response compared to healthy controls (in keeping with Jeppesen’s 
findings); whereas no difference was demonstrated in the adapted subgroup 
(both groups had comparable amounts of jejunal remnant). This could 
suggest that GLP secretion from L-cells may continue to adapt beyond 12 
months. However this hypothesis would need to be tested by monitoring 
subjects longitudinally over several years. 
 
Overall, the data from this work and the available literature suggests that L-
cell secretion of PYY as well as PGDP is impaired in SBS patients with a 
jejunostomy. The length of jejunal remnant might be related to fasting PGDP 
levels, although a positive correlation could not be shown here. Prolonged 
time for adaptation (>12 months) might increase the level of postprandial 
PGDP secretion.  
 
It is generally acknowledged that the preservation of colon during extensive 
intestinal resection is beneficial in the functional adaptation of the intestinal 
remnant and reduces the need for parenteral nutrition (Nightingale et al. 
1992). The colon itself has a large capacity for electrolyte and water 
absorption. In addition, colonic fermentation of carbohydrates to short chain 
fatty acids that can be easily absorbed from the colon, contributes towards 
salvage of energy (Nordgaard et al. 1996; Jeppesen et al. 1999). Lastly, 
activation of the colonic brake mechanism in SBS patients with a preserved 
colon is thought to prohibit the increased rate of gastric emptying, found in 
jejunostomy patients (Nightingale et al. 1993). The colonic bake is thought to 
be mediated through L-cell hormone secretion, in particular PYY, which is 
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known to slow gastric emptying (Savage et al. 1987). Increased fasting and 
postprandial levels of PYY in SBS patients with a preserved colon have been 
demonstrated (Nightingale et al. 1996). Jeppesen and colleagues found a 
two-fold increase of GLP-1 and a more than threefold increase of GLP-2 
level in short bowel patients with a preserved colon, suggesting that 
increased secretion of these PGDPs might also contribute to the positive 
effect of a preserved colon in short bowel syndrome (Jeppesen et al. 2000). 
 
In our study, SBS patients with preserved colon in continuity (SBS-2 
group) also demonstrated a marked increase in fasting and postprandial 
PYY concentration. Surprisingly, and in contrast to Jeppesen’s findings 
however, fasting GLP-1 and GLP-2 levels were not increased. In the non-
adapted subgroup, the fasting concentration of GLP-1 was even reduced. 
Equally, the maximum postprandial PGDP response did not differ 
significantly from that of healthy subjects. The patient cohort in Jeppesen’s 
study consisted of 7 subjects with an average small bowel length of 89cm 
(range 45-140). The mean colonic remnant was 84% (57-100). Only 2 
patients received parenteral support. In our cohort the median remnant small 
bowel was shorter (average 41cm, median 40cm; range 18-60 cm). All 
patients were dependent on parenteral nutritional support indicating a lower 
level of functional adaptation.  
 
In contrast to Jeppesen’s hypothesis that L-cells in the human colon are 
capable of significant GLP-1 and GLP-2 secretion when the ileum has been 
removed, our results suggest that a preserved colon alone might not suffice 
for an adaptive increase of PGDP secretion. It is interesting to speculate 
that, whereas the increase of PYY secretion occurs in the colon, the residual 
jejunum is primarily responsible for the adaptive hyperenteroglucagonemia 
as has been proposed previously (Bilchik et al. 1995). However, given the 
deficient peptide secretion in subjects after colectomy, the colon appears to 
play a pivotal role in signalling mechanisms for PGDP increase. 
 
The finding of differential L-cell secretion appears to be corroborated by the 
observation of fasting L-cell hormone concentrations in a single jejunostomy 
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patient. One month after restoration of colonic continuity, there is only a 
small increase of fasting GLP-1 and GLP-2 concentration and a 
disproportionally strong elevation in fasting PYY (Figure 3-6). Low plasma 
glucagon-like peptide -2 levels despite the presence of residual colon are 
also described in a study of premature infants with severe short bowel 
syndrome (Sigalet et al. 2004). 
 
The differential secretory response of L-cells surprises, as PYY and PGDPs 
are co-localized in these cells. In rabbit colon, where L-cells constitute 33% 
of enteroendocrine cell mass, PYY and enteroglucagon co-localization was 
documented in all L-cells examined (Nilsson et al. 1991). The labelling 
density was generally higher for PYY but there appeared to be variations in 
the PYY/enteroglucagon labelling ratio between cells. Co-localization was 
seen in 83% of secretory granules, 15% contained PYY and 2% 
enteroglucagon only. It is therefore not surprising that parallel stimulation of 
PYY and PGDP production release can usually be seen postprandially 
(Feltrin et al. 2006). Nonetheless a differential response to certain nutrients 
and stimuli has also been described. In isolated perfused rabbit colon, 
selective release of either PYY or enteroglucagon occurs upon stimulation 
with bile salts or fatty acids respectively. In rats, a differential secretory 
response was seen following intra-colonic oleic acid, short chain fatty acids 
and L-Name. Similar results have been reported in humans, where infusions 
of oleic acid into the ileal pouch of patients with total colectomy did not 
modify enteroglucagon levels but induced a dose-dependent increase of 
PYY (Pironi et al. 1993). 
 
It is also noteworthy that other hormones appear to be co-localised in L-cells. 
Hoersch et al. describe complex, zone related coexistence patterns of 
peptides and other transmitters found in individual cell populations in the 
mucosa of the human anal canal. In the colonic mucosa they not only 
describe co-existence of GLP-1 and PYY but also GLP-1 and serotonin (5-
HT) (Horsch et al. 1994). In human duodenal L-cells, Theodorakis et al. have 
identified co-localisation of GLP-1 and gastric inhibitory polypeptide (GIP). 
They reach the conclusion that the concept of distinct cell populations 
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dedicated to the synthesis and release of separate peptides should be 
reviewed under the perspective of a multipotent cell population, producing 
peptides according to stimuli in the metabolic or biochemical milieu 
(Theodorakis et al. 2006). 
 
Cell turnover in the intestinal mucosa is very high. The life span of 
enteroendocrine cells is estimated at 3-4 days in mice (Schonhoff et al. 
2004). It has been shown that normal enteroendocrine cells are a terminally 
differentiated, non-proliferating population and that therefore population 
expansion precedes differentiation (Barrett et al. 1995). Endocrine-
committed, intermediate cells are possibly the proliferating elements 
responsive to tissue-specific physiological stimuli (Rindi et al. 2004). In 
response to intestinal resection, L-cells show an increase of rough 
endoplasmic reticulum indicating a hyper-functional state (Buchan et al. 
1985). Whether different populations of L-cells respond to varying 
physiological stimuli, whether adaptation of L-cells occurs early on during 
entero-endocrine differentiation resulting in a changing L-cell-phenotype or 
whether the profile of secretory granules in a mature L-cell can adapt to a 
changing biochemical environment requires further research.  
 
In addition to its anti-motility and anti-secretory properties, PYY is known to 
have inhibitory effects on appetite and food intake (Vincent et al. 2008). 
Adaptive hyperphagia is a known phenomenon in adult short bowel patients. 
Given the marked increase in fasting and postprandial PYY concentration in 
SBS patients with colonic continuity, it is interesting to note that in a study of 
90 SBS patients, the presence or absence of the colon did not appear to be 
related to oral energy intake (Crenn et al. 2004). 
 
Both, PYY and PGDPs have therapeutic potential in SBS. PYY, as inhibitor 
of gastro-intestinal motility and secretion (Savage et al. 1987), might lead to 
a more favourable fluid balance, especially in jejunostomy patients. This has 
not yet been assessed in clinical trials. The long acting GLP-2 analogue 
teduglutide has been highly effective in improving fluid absorption in SBS 
patients with and without preserved colon (Jeppesen et al. 2001; Jeppesen 
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et al. 2005). A subsequent larger multicentre double blinded placebo 
controlled trial has recently shown that this can lead to meaningful reductions 
in parenteral nutrition requirements for patients with short bowel syndrome 
(O'Keefe et al. 2008).  
 
Our findings could have implications for the development of therapeutic 
strategies in short bowel syndrome. Jeppesen et al. have demonstrated 
elevated endogenous GLP-2 levels in most (but not all) of their SBS patients 
with a retained colon. They have shown that this patient group still derived 
significant benefit from exogenous teduglutide administration (Jeppesen et 
al. 2005). As a possible mechanism they speculate that supraphysiological 
doses of teduglutide produce high concentrations locally, which suppress 
gastric acid secretion and induce small bowel growth. Our work suggests 
that in addition, a subgroup of SBS patients who have a retained colon but 
only a very short remaining small bowel remnant might be GLP-2 deficient 
and therefore benefit from replacement therapy. 
 
As an alternative to exogenous hormone administration, stimulation of 
endogenous peptide secretion might constitute a worthwhile therapeutic 
concept. Our results suggest that blind/non-specific stimulation of L-cells 
might not lead to a uniform secretory response. Instead secretions might 
vary in different individuals depending on their intestinal anatomy. It is 
conceivable that other factors like underlying pathology and mucosal health 
might also be relevant. Further research into the mechanisms of L-cell 
differentiation and stimulation is needed.  
 
The results of this study in context with the other cited publications illustrate 
that SBS patients are a very heterogeneous subject group. All studies, 
published so far describe a relatively small number of subjects. This is also a 
weakness of the presented study. We have postulated that differences in gut 
hormone secretion might be related to the length of remaining small 
intestine, although a correlation could not be shown in this patient 
population. It would be useful in future studies to achieve a sufficient subject 
number in order to allow a subgroup analysis of different small bowel length. 
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Other potential confounding factors are time of surgery and underlying 
pathology. Recruitment of SBS patients can be problematic as SBS is a rare 
condition and patients are usually followed up in specialist hospitals. This 
means long journeys to the study centre and therefore potential subjects 
may not be able to commit sufficient time for meal stimulated test. Admission 
of subjects might be necessary but is often inconvenient for the patient and 
very costly.  
 
The small bowel length of most, but not all patients was determined from 
surgical notes. Although it is now considered good surgical practice to record 
the remaining intestinal lengths following resection, this has not always been 
the case in the past when often the length of resected intestine alone was 
documented. Although in these patients the small bowel length was 
estimated radiologically there might have been room for error. Given the 
important implications of the intestinal anatomy on functional adaptation and 
post resection recovery, accurate documentation of postsurgical anatomy is 
of great importance. 
 
SBS patients in this study were not malnourished and had a body mass 
index within the normal range. However, there was a miss-match with the 
healthy control group, which contained a higher proportion of overweight and 
obese subjects. It is of note that attenuated secretion of PYY has been 
shown in morbidly obese subjects (mean BMI 40.3) (Le Roux et al. 2006). 
However the magnitude of PYY increase in SBS-2 patients compared to 
controls, shown in this study and others, is unlikely to be explained through 
the difference in weight alone. Nonetheless, body weight might need to be 
considered as a confounding factor when assessing PYY secretion. 
Secretion of GLP-1 and GLP-2 does not appear to differ between normal 
weight and obese subjects (see Chapter 4). 
 
The choice of test meal was determined by various factors. In order to elicit a 
good postprandial response it needed to provide a sufficient caloric load. 
Other important considerations were the ease of preparation, standardization 
and reproducibility, ease of consumption and palatability. A liquid meal of 
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nutritional supplements was therefore chosen. Gastric emptying of liquids 
can be rapid in SBS patients. In 2 patients with very short jejunal remnant 
the test meal rapidly emptied into the stoma bag. To allow better 
comparability with other studies, it might be useful to investigate the 
response to a mixed solid meal. However some SBS patients have problems 
consuming such meal (Nightingale et al. 1996).  
 
Summary: In keeping with previous studies, we have shown deficient L-cell 
secretion of PYY and PGDP (GLP-1 and GLP-2) in SBS patients with 
jejunostomy. Patients with retained colon had an increase of PYY- but not of 
PGDP plasma concentration. This finding contrasts previously published 
results which describe elevated PGDP fasting levels in this patient group. 
We propose that despite their co-localisation in enteroendocrine L-cells, the 
secretion of PYY and PGDP is regulated differentially and may vary 
depending on the intestinal anatomy.  
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Chapter 4 
 
 
 
 
Meal stimulated 
glucagon-like peptide secretion 
in normal weight and obese subjects 
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4.1 Introduction and aim 
 
The burden of obesity related illnesses threatens to overwhelm healthcare 
systems worldwide. It is hoped that unveiling the physiological pathways of 
appetite control may lead to new strategies for fighting this epidemic. A 
variety of gut hormones have been shown to influence appetite, nutrient 
intake and satiety. It is now thought that changes in hormonal release pattern 
may contribute towards the pathophysiology of obesity.  
 
The proglucagon derived peptides, glucagon-like peptide-1 (GLP-1) and 
glucagon-like peptide-2 (GLP-2) are gut hormones, co-secreted from 
mucosal enteroendocrine L- cells. They are partly co-localized with glucose-
dependent insulinotropic polypeptide (GIP) in the proximal small bowel and 
with peptide tyrosine tyrosine (PYY) in the distal small bowel and colon 
(Mortensen et al. 2003). Nutrients, in particular fats and carbohydrates, are 
the primary physiologic stimulus for glucagon-like peptide (GLP) and PYY 
secretion (Adrian et al. 1985; Hartmann et al. 2000).  
 
PYY is a major mediator of the ileal and colonic brake which slows gastro-
intestinal transit and secretion, allowing for increased nutrient absorption. 
Identification of its role in appetite regulation has been a key advance in 
obesity research. PYY shows a blunted postprandial secretion profile in the 
obese, indicating that the release of PYY from the intestinal tract may be 
inhibited. Moreover, exogenous PYY administration reduces food intake in 
rodents and humans (Batterham et al. 2003; Le Roux et al. 2006). 
 
As an incretin hormone, GLP-1 enhances insulin secretion, whilst inhibiting 
glucagon release. GLP-1 is also part of the ileal brake mechanism. 
Intravenous infusions of GLP-1 reduces energy intake in lean and 
overweight subjects in a dose dependent manner. It is thought that the 
reduced gastric emptying rate may contribute to increased satiety (Verdich et 
al. 2001). An attenuation of the postprandial GLP-1 response in obese 
humans has been reported (Verdich et al. 2001). Other studies have 
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however shown an increased GLP-1 response to oral nutrients in the obese 
(Fukase et al. 1993) or no difference of GLP-1 secretion between normal 
weight and obese subjects (Feinle et al. 2002).  
 
GLP-2 has recently received much attention for its specific effects on 
intestinal mucosal proliferation, perfusion and nutrient absorption. GLP-2 has 
also been shown to delay gastric emptying but is less potent than GLP-1 
(Nagell et al. 2004). Although intracranial injection of GLP-2 appears to 
confer anorexic effects in rodents (Lovshin et al. 2001), peripheral 
administration of GLP-2 in humans has shown no impact on hunger 
sensation (Nagell et al. 2004). There is a paucity of literature investigating 
GLP-2 release in the obese. One study detected no difference between lean 
and obese subjects in the fasted state (Mersebach et al. 2003).  
 
The aim of this study was to determine the GLP-1 and GLP-2 response to a 
series of standard meals in normal weight and obese subjects. We 
specifically wanted to determine whether, given the reduced postprandial 
PYY response in obese subjects, a corresponding reduction of glucagon-like 
peptide secretion would be found, suggesting global reduction of L-cell 
response in this patient group. 
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4.2 Methods 
 
The study was performed according to the principles of the Declaration of 
Helsinki and approved by the Local Research and Ethics Committee at 
Hammersmith Hospital (REC number 03/6499). All participants gave written 
consent to take part in the study after receiving oral and written information. 
This study was performed in collaboration with Dr. Carel Le-Roux who 
developed the experiment and coordinated subject recruitment and sample 
collection. Sample analysis with radioimmunoassay and data interpretation 
was performed by the author. 
 
4.2.1 Subjects 
 
Nineteen normal weight (N) and 19 obese (O) subjects were studied. The 
obese subjects were recruited from the Lifestyle or Diabetes clinics at 
Hammersmith Hospital and the lean subjects from internal advertising on the 
hospital site. The body weight of all subjects had been stable for 3 months. 
Mean body mass index was 21.7 ± 0.4 kg/m2 in the normal weight group and 
40.3 ± 1.1 kg/m2 in the obese group. Both groups consisted of 13 females 
and 6 males. Mean age was 28.6 ± 1.6 years in the normal-weight group and 
29.0 ± 2.0 years in the obese group. Insulin resistance was determined using 
the homeostasis model assessment insulin resistance index [HOMA-IR 
index; calculated as: fasting glucose (mM) × fasting insulin (mU/L) / 22.5; 
values > 3.8 were considered diagnostic of insulin resistance (Ascaso et al. 
2001)]. Nine out of 19 obese subjects were insulin resistant (HOMA-IR > 
3.8). None of the normal weight subjects was insulin resistant. 
 
The following exclusion criteria applied: chronic medical or psychiatric 
illness, substance abuse, pregnancy, more than two alcoholic drinks per day, 
and aerobic exercise for more than 30 minutes three times per week. 
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4.2.2 Study protocol 
 
The trial was performed in a double blind, randomized manner. All subjects 
fasted from 21:00 on the evening prior each study day. For twenty-four hours 
prior to each meal subjects refrained from taking strenuous exercise or 
drinking alcohol. All subjects were asked to attend hospital on three separate 
occasions. Lean and obese subjects were randomly allocated to two groups 
(Group-1: 10 lean and 10 obese subjects; Group-2: 9 lean and 9 obese 
subjects). Depending on their study group, subjects received (in random 
order) either a 500 ml (Group 1: 250, 500 and 1000 kcal) or a 900 ml (Group 
2: 1000, 2000 and 3000 kcal) liquid standard meal. Venous blood was 
collected through an indwelling forearm cannula in the fasted state followed 
by sampling in 30 min intervals for 3-h after every meal. Blood samples were 
collected into lithium heparin bottles containing aprotinin (50000 units), 
centrifuged and plasma immediately stored at -20oC until analysis. The 
subjects were sedentary during the entire study. Conditions for each subject 
remained constant on each occasion as the temperature was controlled and 
the subjects were allocated the same chair or bed. The subjects were 
encouraged to relax and allowed to read or watch videos. 
 
4.2.3 Test meal 
 
The postprandial secretion of glucagon-like peptides is related to the 
macronutrient composition and calorie content of a meal (Chapter 1.1.4). 
Palatability and ease of consumption are other important considerations 
when choosing a standardized test meal. In this experiment, ice cream with 
variable lipid content was utilized. This allowed investigation of the secretory 
response to different caloric challenges, whilst maintaining comparable meal 
composition. The macronutrient content of each meal is detailed in Table 
4.1. The ice cream was prepared to the highest food safety standards and 
consumed at 4 °C in a semi liquid state. All subjects were required to drink 
the entire volume. Each different calorie meal looked and tasted similar and 
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the subjects were blinded to the calorie content. On each occasion the meal 
was given in the same containers, and at the same temperature.  
 
 
 
Carbohydrate 
(g) 
Fat 
(g) 
Protein 
(g) 
Calories 
(kcal) 
500mL meal     
250 calories 32.3 10.2 16 258 
500 calories 52 26.5 18 518 
1000 calories 63.3 75.3 17.1 1000 
     
900mL meal     
1000 calories 99 52.9 32.6 1002 
2000 calories 107.5 161.7 29.5 2004 
3000 calories 94.5 274.95 24.75 2952 
 
 
Table 4-1: Macronutrient content of the standard meals 
  Meals consisted of liquid drinks with similar consistency.  
CHD: Carbohydrate. 
 
 
 
4.2.4 Radioimmunoassay 
 
Total GLP-2-IR was measured using antiserum FT-17 as described in 
chapter 2. Detection limit was 25pmol/l; intra-assay CV 8.3%. Antibody FT-
17 was validated by correlating it with the current gold-standard, antibody 
92160 (Hartmann et al. 2000). The coefficient of determination R2 was 0.77 
(p<0.01) for the detection of postprandial increase of GLP-2. 
 
GLP-1 (7-36) was measured using an established specific and sensitive in-
house assay (Kreymann et al. 1987). The GLP-1 antibody was raised in 
rabbits against GLP-1 coupled by carbodi-imide to BSA. It cross reacts 100% 
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with all amidated forms of GLP-1 but does not cross react with glycine 
extended forms [GLP-1 (1-37) and GLP-1 (7-37)] or any other known 
pancreatic or gastrointestinal peptide. 125I-GLP-1 (7-37 amide) was 
prepared by the iodogen method (Wood et al., 1981) and purified by HPLC. 
The specific activity of the 125I GLP-1 label was 48 Bq/fmol. The assay was 
performed in a total volume of 0.7 ml of 0.06 M sodium barbitone buffer (pH 
8) containing 0.3 % BSA. The assay was incubated for three days at 4ºC 
before separation of the free and antibody bound label by charcoal 
absorption. The limit of detection was 7.5p mol/l, with an intra-assay variation 
of 5.4%. All samples were assayed in duplicate and in a single assay. 
 
4.2.5 Statistics 
 
Data analysis of the data was performed in Excel and MedCalc ® software. 
Normality of data distribution was tested by using the Kolmogorov-Smirnov 
test. Data are expressed as mean values ± SEM. For comparison of the 
postprandial secretory response to the 3 meals within a subject group, we 
used one way ANOVA and the Student-Newman-Keuls test for post hoc pair 
wise comparisons. Differences in postprandial response between lean and 
obese were compared with the use of two tailed Student’s t tests. The values 
for the area under the curve (AUC) were calculated using the trapezoid rule.  
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4.3 Results 
 
There was no difference in the fasting hormone concentration levels 
between normal weight controls (NWC) and obese subjects for either GLP-1 
or tGLP-2-IR (Table 4-2, Figure 4-1).  
 
The meal stimulation curves for all groups are shown in Figures 4-2 to 4-4. 
The 500ml-250kcal meal did not elicit a significant increase of GLP-1 or 
tGLP-2-IR from baseline at any time point. 
 
To investigate the postprandial secretory response, the increase of 
postprandial plasma concentration from baseline for each postprandial time-
point as well as the change of area under the curve from baseline (∆ AUC 
30-180 minutes) was determined.  
 
It was firstly evaluated, how the subject groups responded to the increasing 
calorie load (Table 4-3). In the 500ml groups, ∆ AUC (GLP-1 and tGLP-2-IR) 
was significantly greater following the 1000kcal meal compared to the 250 
and 500kcal meal in NWC subjects.  There was a similar trend in the obese 
subjects but this difference was not significant.  In the 900ml groups, there 
was no difference in the GLP-1 response between the 1000, 2000 and 3000 
kcal meal in the NWC group, whereas in the obese subjects the greatest 
response was achieved at 3000kcal. ∆ AUC tGLP-2-IR was greatest in the 
2000kcal group in NWC subjects, whereas there was no significant 
difference between the 3 meals in the obese subject group.  
 
Meal response curves, comparing the postprandial increase of GLP-1 and 
tGLP-2-IR plasma concentration from baseline between NWC and obese for 
each time-point, are illustrated in Figure 4-6 (500ml groups) and 4-7 (900ml 
groups). In the 500ml meal groups a significant difference between NWC 
and the obese is only shown in a single time-point (GLP-1, 90min, 250 kcal). 
This is unlikely to have physiological relevance. In the 900ml meal groups, 
GLP-1 concentration appears higher in the NWC group at 2000kcal (120min 
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and 150min); whereas the GLP-1 concentration at these time points appears 
lower at 3000kcal.  
 
Accordingly the only significant differences of ∆ AUC (Figure 4-8A) are 
shown in these 2 groups: ∆ AUC (GLP-1, 30-180 minutes) in the 2000 kcal 
meal, showed a higher level in the NWC, whereas in the 3000 calorie meal, 
∆ AUC (GLP-1) was significantly higher in the obese. This was not 
accompanied by corresponding differences in tGLP-2-IR concentration. 
Investigating the early postprandial response only (∆ AUC, 30-60 minutes), 
no difference between NWC and obese groups was shown in any meal 
(Figure 4-8B). 
 
Le Roux et al. have shown a consistent reduction of PYY 90min-peak 
secretory response in the same subject group (Le Roux et al. 2006). This 
time point was therefore analysed separately and comparative peak 
hormone concentrations for all meals are illustrated in Figure 4-9. It is 
apparent that the trend of reduced L-cell hormone secretion in the obese, 
shown for PYY, can’t be demonstrated for GLP-1 or tGLP-2-IR. There were 
also no significant differences in the 90min peak hormone concentrations of 
any meal if only obese subjects with insulin resistance (HOMA-IR > 3.8; n=5 
in 500ml group and n=4 in 900ml group) were compared with NWC. 
 
The correlation between GLP-1 and tGLP-2-IR was calculated for all 
samples and is detailed in Figure 4-10. There was no correlation between 
the fasting samples. This is due to the fact that, as detailed in chapter 2, 
tGLP-2-IR correlates only poorly to the concentration of active glucagon-like 
peptide secretion. A significant positive correlation was demonstrated for all 
postprandial time points as well as for the maximum increase from baseline. 
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Fasting Levels of GLP-1 and tGLP-2-IR 
 
Time NWC Obese p
GLP-1 (pmol/l) -30 21.4 20.6 0.5
0 20.8 18.9 0.1
tGLP-2IR (pmol/l) -30 195.9 217 0.1
0 185.1 209 0.07
 
Table 4-2: Fasting hormone concentrations (mean) 
p (unpaired student t-test, normal weight controls (NWC) vs. obese subjects) 
 
 
GLP-1 (pmol/l) Fasting (-30)
50
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0
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GLP-1 (pmol/l) Fasting (0)
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A      B 
tGLP-2IR (pmol/l) Fasting (-30)
500
400
300
200
100
0
NWC Obese
 
tGLP-2IR (pmol/l) Fasting (0)
500
400
300
200
100
0
NWC Obese
 
C      D 
Figure 4-1:  Fasting hormone concentrations at time -30 and 0 
Median values, 25 to 75th percentile, minimum to the maximum value and outside 
values are shown. 
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Meal stimulated plasma concentration of GLP-1: 
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Figure 4-2: GLP-1 meal response curves (500ml) 
Fasting (time -30-0) and postprandial (time 30-180) plasma concentration of GLP-1 in 
obese subjects (n=9) and normal weight controls (NWC, N=10) consuming a 500ml test-
meal with increasing caloric content (circle: 250kcal, square 500kcal, triangle 1000kcal)  
Values are mean (SED)             
Filled points = t-test, p<0.05 vs. fasting (time 0)    
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Figure 4-3: GLP-1 meal response curves (900ml) 
Fasting (time -30-0) and postprandial (time 30-180) plasma concentration of 
GLP-1 in obese subjects (n=10) and normal weight controls (NWC, n=9) 
consuming a 900ml test-meal with increasing caloric content (circle: 1000kcal, 
square 2000kcal, triangle 3000kcal) 
Values are mean (SED)          
Filled points = t-test, p<0.05 vs. fasting (time 0) 
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Meal stimulated plasma concentration of tGLP-2-IR 
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Figure 4-4: tGLP-2-IR meal response curves (500ml) 
Fasting (time -30-0) and postprandial (time 30-180) plasma concentration of 
tGLP-2-IR in obese subjects (n=9) and normal weight controls (NWC, N=10) 
consuming a 500ml test-meal with increasing caloric content (circle: 250kcal, 
square 500kcal, triangle 1000kcal) 
Values are mean (SED)         
Filled points = t-test, p<0.05 vs. fasting (time 0) 
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Figure 4-5: tGLP-2-IR meal response curves (900ml) 
Fasting (time -30-0) and postprandial (time 30-180) plasma concentration of 
tGLP-2-IR in obese subjects (n=10) and normal weight controls (NWC, n=9) 
consuming a 900ml test-meal with increasing caloric content (circle: 1000kcal, 
square 2000kcal, triangle 3000kcal) 
Values are mean (SED)         
Filled points = t-test, p<0.05 vs. fasting (time 0)  
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Δ AUC (30-180min) in response to increasing caloric load 
within each subject group: 
 
 
 
GLP-1(pmol/l)    tGLP-2-IR (pmol/l) 
  
ml kcal Group n Δ AUC 180
500 250 NWC 9 151 (285)3
500 NWC 9 629 (256)3
1000 NWC 9 1716 (323)1,2
p 0.003
900 1000 NWC 8 1621 (240)
2000 NWC 8 1768 (352)
3000 NWC 8 981 (168)
p 0.1
500 250 Obese 8 314 (268)
500 Obese 8 858 (341)
1000 Obese 8 1275 (200)
p 0.07
900 1000 Obese 8 1264 (276)3
2000 Obese 8 761 (143)3
3000 Obese 8 2049 (251)1,2
p 0.003
 
ml kcal Group n Δ AUC 180
500 250 NWC 9 8100 (4900)3
500 NWC 9 5710 (4020)3
1000 NWC 9 20220 (2440)1,2
p 0.03
900 1000 NWC 7 15590 (4600)2
2000 NWC 7 30230 (3330)1
3000 NWC 7 26670 (4010)
p 0.0048
500 250 Obese 6 4770 (4170)
500 Obese 6 3380 (3990)
1000 Obese 6 14680 (3270)
p 0.1
900 1000 Obese 9 16300 (2840)
2000 Obese 9 24940 (3720)
3000 Obese 9 25290 (3110)
p 0.1
 
 
 
Table 4-3: Δ AUC of postprandial response 
Δ AUC (over 180min) in response to increasing calorie load within each subject group. 
Data are expressed as mean values ± SEM                
p was determined with one way ANOVA.                 
If p<0.05; Student-Newman-Keuls test for post hoc pair wise comparisons was applied. 
Only subjects for whom samples of all three meals were available were included. 
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Increase from baseline in obese subjects and normal weight 
controls (NWC); 500ml meal 
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Figure 4-6: Postprandial increase of plasma GLP-1 and tGLP-2-IR concentration (30-180min)  
 
Obese subjects and normal weight controls (NWC)      
Consuming a 500ml meal of 250, 500 and 1000 kcal  
Data are expressed as mean values ± SEM 
*p<0.05 (Student T-test, obese vs. NWC) 
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Increase from baseline in obese subjects and normal weight 
controls (NWC); 900ml meal 
 
 
GLP-1    tGLP-2-IR 
 
1000 kcal 
-10
0
10
20
30
30 60 90 120 150 180
Time (min)
G
LP
-1
 (p
m
ol
/l)
Obese NWC
  
1000 kcal 
-100
0
100
200
300
30 60 90 120 150 180
Time (min)
tG
LP
-2
-IR
 (p
m
ol
/l)
Obese NWC
 
 
2000 kcal 
-10
0
10
20
30
30 60 90 120 150 180
Time (min)
G
LP
-1
 (p
m
ol
/l)
Obese NWC
* *
  
2000 kcal 
-100
0
100
200
300
30 60 90 120 150 180
Time (min)
tG
LP
-2
-IR
 (p
m
ol
/l)
Obese NWC
 
 
3000 kcal 
-10
0
10
20
30
30 60 90 120 150 180
Time (min)
G
LP
-1
 (p
m
ol
/l)
Obese NWC
**
  
3000 kcal 
-100
0
100
200
300
30 60 90 120 150 180
Time (min)
tG
LP
-2
-IR
 (p
m
ol
/l)
Obese NWC
*
 
 
 
Figure 4-7: Postprandial increase of plasma GLP-1 and tGLP-2-IR concentration (30-180min) 
 
Obese subjects and normal weight controls (NWC)       
Consuming a 900ml meal of 1000, 2000 and 3000 kcal       
Data are expressed as mean values ± SEM 
*p<0.05 (Student T-test, obese vs. NWC) 
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Δ AUC in obese subjects and normal weight controls (NWC) 
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A:  Δ AUC from fasting (time 0) to 180 min 
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B:  Δ AUC of early postprandial response (from fasting (time 0) to 60 min) 
 
Figure 4-8:  Δ AUC (GLP-1 and tGLP-2-IR) 
Obese subjects (dotted bar) and normal weight controls (NWC, empty bar) 
A: over 180 minutes               
B: over 60 minutes (early postprandial response) 
Data are expressed as mean values ± SEM            
*p<0.05, unpaired student-t test 
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Figure 4-9: Peak concentration (pmol/l) at the 90 minute time-point in obese (bullet) and 
normal-weight controls (NWC) (empty circle). 
 
A) Peak PYY level, *p<0.05 (unpaired t-test) (Le Roux et al. 2006).           
B) GLP-1               
C) tGLP-2-IR 
* p=0.048 (unpaired t-test NWC vs. Obese) 
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Correlation between GLP-1 and tGLP-2-IR 
 
 
Time n r r2 p
Fasting -30 100 0.2069 0.04 0.03
0 98 0.1684 0.03 0.1
Postprandial 30 98 0.3306 0.11 0.0009
60 98 0.401 0.16 <0.0001
90 100 0.4154 0.17 <0.0001
120 99 0.3889 0.15 0.0001
150 98 0.3605 0.13 0.0003
180 91 0.4378 0.19 <0.0001
Max 30-180 100 0.4426 0.20 <0.0001
Correlation of GLP-1 and tGLP-2-IR plasma concentration
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Figure 4-10: Correlation between GLP-1 and tGLP-2-IR  
A: All fasting and postprandial time-points             
(Differences in n-numbers due to missing samples) 
B: Fasting (linear regression line and 95% CI) 
C: Point of maximum postprandial increase (linear regression line and 95% CI)  
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4.4 Discussion 
 
Hormones, released from the gastrointestinal tract in response to nutrients, 
have received attention for their possible role in the initiation, termination and 
frequency of meals. It is thought that an imbalance of anorexigenic (e.g.: 
Cholecystokinin, PYY, Oxyntomodulin, GLP-1) and orexigenic (e.g.: ghrelin) 
mediators may result in disorders of feeding behaviour.  
 
Attenuation of PYY, a L-cell product, has been reported in the obese (Le 
Roux et al. 2006). PYY reduces food intake in rodents and humans. It was 
postulated that lower postprandial PYY levels may result in an increase in 
food intake to achieve the same level of satiety as seen in normal-weight 
subjects and thus form part of the pathophysiological mechanism that helps 
to maintain the obese state.  
 
Similar observations have been shown for glucagon-like peptides. Some 
studies have demonstrated attenuation of fasting levels and postprandial 
GLP-1 in the obese (Ranganath et al. 1996; Verdich et al. 2001; Adam et al. 
2005). However, these findings have not been consistent. Importantly, no 
differences were found when nutrients were given intraduodenally, thus 
avoiding the influence of gastric emptying (Fukase et al. 1993; Feinle et al. 
2002). In this study obese subjects and healthy normal weight controls 
(NWC) exhibited similar fasting levels of GLP-1 and tGLP-2-IR. There was 
also no meaningful difference in early and overall postprandial secretory 
response to a large range of caloric challenges.  
 
A variety of factors might account for discrepancies between the studies. In a 
report of decreased GLP-1 secretion in obese diabetic patients, compared 
with matched obese healthy subjects, it was suggested that the presence 
and magnitude of insulin resistance might influence GLP-1 secretion in the 
obese (Vilsboll et al. 2003). Addressing this point, we analysed the data, 
including only insulin resistant obese subjects. No significant attenuation of 
the secretory profile in the obese was found and no trend was apparent. 
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However, the subject numbers were not large enough to exclude small 
changes confidently. It has also been suggested that the obese have slightly 
decreased sensitivity for GLP-1 release that could be overcome by providing 
a stronger nutritional challenge (Adam et al. 2005). This study did not detect 
any differences over a wide range of caloric stimulation. Nutrient composition 
might be another relevant factor. Our study used a meal stimulus with mixed 
nutrient composition. Thus, Ranganath’s suggestion that L-cell 
responsiveness to carbohydrates might be particularly affected in the obese 
could not be tested (Ranganath et al. 1996). We aimed to investigate the 
secretory response to a standard nutritional stimulus. It remains to be 
explored in a future study whether adjusting each test meal for the 
individual’s metabolic rate would provide additional information. Lastly, the 
antibodies used for radioimmunoassay were not specific for active forms of 
GLP-1 or GLP-2 and thus could not detect subtle changes in secretion. 
 
The results of this study, suggesting similar fasting levels and postprandial 
responses of glucagon-like peptide concentrations in lean and obese 
subjects contrast the finding of attenuated PYY release in the obese subjects 
of the same study group (Le Roux et al. 2006). This is particularly interesting 
since glucagon-like peptides and PYY can be found in the same cells and 
are co-localised in secretory granules. However, this co-localization does not 
appear exclusive. It has been shown in rabbits that colonic L-cells can exhibit 
different populations of secretory granules (Nilsson et al. 1991). Moreover, 
differential secretion of PYY and proglucagon derived peptides in response 
to specific nutritional stimuli has been demonstrated in rodents (Anini 1999) 
and also in patients with short bowel syndrome (chapter 3). In this context, a 
possible explanation for our findings could be that the stimulation of proPYY 
and proglucagon synthesis is differentially regulated in the obese and thus 
may lead to altered L-cell peptide content compared to normal weight 
subjects. Alternatively, different secretion patterns following luminal 
stimulation could be caused by a predominant loss of sensitivity for PYY 
secretion in the obese. A previous report of disproportionate postprandial 
secretion of PYY and GLP-2 in pigs has suggested that GIP may have a 
differential effect on L-cell hormone secretion (van Goudoever et al. 2001).  
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The strength of this study lies in the fact that glucagon-like peptide 
concentrations could be compared with PYY measurements from the same 
subject groups. A significant drawback however is the small subject number 
within each group. In view of the high standard deviations for both GLP-1 
and GLP-2 measurements, type II errors can’t be excluded. The statistical 
power to detect a 20% reduction in the 90 minute postprandial GLP-1 peak 
was 56% on average (range 35-96% depending on meal and time-point). It 
would not be practically feasible to repeat the same experimental design with 
a greater subject number. In order to confirm the findings presented here, a 
future study should utilize a single meal with a good post-prandial response 
(e.g. using 1000kcal). Estimating a 90 minute peak of 30 pmol/l in NWC and 
a SD between subjects of 7 pmol/l; at least 17 (68) subjects need to be 
recruited into both study groups (NWC and obese) to allow 80% power of 
detecting a significant (p<0.05) reduction of 20% (10%) in the obese.  
 
Summary: In contrast to an attenuated postprandial PYY response, no 
evidence of a reduction in glucagon-like peptide secretion could be found in 
obese subjects. It may be possible that the balance of glucagon-like peptides 
and PYY in secretory L-cells granules is altered in the obese or that the 
secretion of these peptides is regulated by differential signals. Limitations of 
this study in view of limited subject number must be taken into consideration. 
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Chapter 5 
 
 
 
 
Glucagon-like peptide-2 response  
after Roux-en-Y gastric bypass 
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5.1 Introduction and aim 
 
Bariatric surgery is not only the most effective means of achieving sustained 
weight loss in subjects with morbid obesity; it also consistently alleviates 
obesity-related complications (Sugerman et al. 2003; Buchwald et al. 2009). 
The Roux-en-Y gastric bypass (RYGB), a technique in which a small 
stomach pouch is joined to the proximal jejunum through a narrow gastro-
jejunal anastomosis (Figure 5-1) achieves sustained loss of 35–40% of total 
body weight, and most of this effect is maintained for at least 15 years 
(Cummings et al. 2004). Although initially evolving from procedures designed 
to cause malabsorption, subjects undergoing RYGB report only transient 
gastrointestinal side effects and, despite the loss of intestinal length, 
macronutrient malabsorption is rarely clinically relevant. The degree of 
weight loss appears to be disproportionate to the degree of macronutrient 
malabsorption, suggesting that a change in energy intake is the principal 
mechanism of weight loss after RYGB (Cummings et al. 2004). Recently, the 
postsurgical alteration of gut hormone secretion, in particular changes in 
PYY and GLP-1 concentration, has been implicated in causing decreased 
appetite and calorie intake. The insulinotropic properties of GLP-1 may 
contribute to the early resolution of type 2 diabetes (Borg et al. 2006; le Roux 
et al. 2007).  
 
Morphological adaptation of the intestine might also contribute to reducing 
post-operative malabsorption. An increase in small bowel villus height has 
been described in humans following bilio-pancreatic diversion, a similar 
bariatric procedure to RYGB (Stock-Damge et al. 1986). Intestinal thickening 
and enhanced proliferative activity can be shown in rodents following RYGB 
(le Roux, unpublished results). A change in intestinal growth factor 
concentration has not yet been demonstrated in this context. The 
intestinotrophic gut hormone glucagon-like peptide-2 (GLP-2) is a key 
mediator of post-resection intestinal adaptation (see chapter 1). GLP-2 levels 
correlate with the magnitude of gut resection, the severity of malabsorption, 
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and the degree of crypt cell proliferation (Martin et al. 2005). We aimed to 
determine changes in GLP-2 levels in obese patients after RYGB.  
 
 
 
 
 
 
 
Figure 5-1:    Principle of Roux-en-Y Gastric bypass.  
The technique involves creating a stomach pouch out of a small portion of the stomach 
and attaching it directly to the small intestine through gastro-jejunal anastomosis. Thus, 
storage capacity of the stomach is reduced. Ingested food bypasses approximately 95% 
of the stomach, the entire duodenum, and a small portion of the proximal jejunum. (Figure 
from the Imperial Weight Centre at Imperial College Healthcare NHS Trust, with 
permission.) 
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5.2 Methods 
 
The study was performed according to the principles of the Declaration of 
Helsinki and approved by the Local Research and Ethics Committee at 
King’s College Hospital, London (LREC protocol number: 01-03-020) and 
Musgrove Park Hospital, Taunton (LREC protocol number: 05/Q2202/96). All 
participants gave written consent to take part in the study after receiving oral 
and written information.  
 
This study was performed in collaboration with Dr. Carel Le-Roux who 
developed the experiment and coordinated subject recruitment and sample 
collection. The surgical procedures were performed by Mr Richard Welbourn. 
Sample analysis with radioimmunoassay and data interpretation was 
performed by the author.  
 
5.2.1 Subjects 
 
Obese patients (WHO grade III, body mass index (BMI) > 40 kg/m2) 
attending an obesity clinic, who had elected to undergo RYGB, with stable 
weight for at least 3 months prior to recruitment, were invited to participate. 
 
Laparoscopic Roux-en-Y gastric bypass was performed creating a small 
isolated lesser curve-based gastric pouch excluding the fundus. The length 
of the Roux limb was 100 cm for patients with a body mass index (BMI) 
below 50 kg/m2 and 150 cm for patients with a BMI above 50 kg/m2.  
 
Diabetes was defined according to the World Health Organisation definition 
(– fasting plasma glucose ≥ 7.0mmol/l or 2–h plasma glucose after ingestion 
of 75g oral glucose load ≥ 11.1mmol/l).  
 
Exclusion criteria included pregnancy, substance abuse and more than two 
alcoholic drinks per day.  
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Two subject groups were investigated pre- and postoperatively. Each patient 
acted as their own control in a prospective controlled study design: 
 
In study 1 (short term follow up), 5 male and 11 female subjects; mean 
age 48 (±2.0) years; mean preoperative BMI 49 (±1.3) kg/m2 were recruited. 
Plasma samples were collected according to protocol before and 2, 4, 7 and 
42 days after RYGB.  
 
In study 2 (long term follow up), 6 female obese patients, mean age 47 
(±3.4) years; mean preoperative BMI 48 (±1.4) kg/m2 were recruited. Plasma 
samples were collected according to protocol before and 1, 3, 6, 12 and 24 
month after RYGB. The RYGB procedures were performed laparoscopically 
with a Roux limb of 112 cm. 
 
5.2.2 Study Protocol 
 
Patients attended after a 12-hour fast, an intravenous cannula was sited and 
venous samples were taken at baseline and at 30 min intervals thereafter up 
to 180 min following a standard semi-liquid mixed 420kcal meal. Plasma was 
collected, immediately separated and stored at -70ºC until analysis.  
 
5.2.3 Radioimmunoassay 
 
Total GLP-2-IR was measured using antiserum FT-17 as described in 
chapter 2.  FT-17 cross-reacts 100% with human GLP-2, less than 0.1% with 
GLP-1 and does not cross-react with any other known gastrointestinal or 
pancreatic hormone. FT-17 detects intact GLP-2 (1-33), its primary 
degradation product GLP-2 (3-33) and major proglucagon fragment (MPGF). 
Detection limit was 25pmol/l; intra-assay CV 8.3%. We validated our 
antibody FT-17 by correlating it with the current gold-standard, antibody 
92160 (Hartmann et al. 2000). The coefficient of determination R2 was 0.77 
(p<0.01) for the detection of postprandial increase of GLP-2. 
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5.2.4 Statistics 
 
Data are expressed as mean ± SEM unless stated otherwise. tGLP-2-IR 
concentration is described as peak concentration, increase from fasting and 
by calculation of the area under the curve (AUC) using the trapezoidal rule. 
Fasting concentrations were compared with repeated measure ANOVA. 
Total tGLP-2-IR AUC (0-180 min) was determined for each individual 
response, and responses were analysed by repeated measures analysis of 
variance (ANOVA). Comparisons were made for the increase in AUC against 
the pre-operative response using repeated measures ANOVA, and where 
the F-statistic was significant, using paired student t-test.  
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5.3 Results 
 
5.3.1 Study 1 (short term follow up) 
 
Fasting levels of tGLP-2-IR remained constant during the post-operative 
period to day 42 (p=0.3); Figure 5-2 A.  
 
During the preoperative meal, the 420 kcal nutritional stimulus did not 
cause a significant increase of the post-prandial tGLP-2-IR concentration 
from fasting at any time point (p=0.9, single factor ANOVA). The maximum 
peak occurred at 120minutes (209 ± 25pmol/l). The increase was equal to 
23% of the fasting value. Following RYGB, postprandial tGLP-2-IR 
concentrations were significantly raised compared to fasting levels between 
30 and 120 minutes in every test meal up to 42 days. The maximum post-
prandial peak occurred at 60 minutes (day 2, 4, 7) or 30 minutes (day 42); 
with the highest value of 396±65pmol/l at day 42 (increase equal to 185% of 
the fasting value, Figure 5-2B). Postprandial profiles before and after RYGB 
(for day 2 and 42) are shown in Figure 5-2C. 
 
The area under the curve (AUC 0-180min) was calculated for every meal-
stimulated tGLP-2-IR profile. The tGLP-2-IR AUC in post-RYGB meals was 
significantly increased in every meal up to 42 days post surgery with a 
maximum AUC increase at day 7 (85% from pre-RYGB meal (Table 5-1 and 
Figure 5-3).  
 
There was a significant disparity in the tGLP-2-IR response between diabetic 
(n=8) and non-diabetic subjects (n=8) at day 2 post RYGB. In contrast to the 
increased postprandial response in non-diabetics, diabetic subjects had a flat 
postprandial meal profile, similar to the pre-operative response. This 
difference gradually reduced over the trial period (Figure 5-4, Figure 5-5; 
Table 5-2). 
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Figure 5-2:  Meal related tGLP-2-IR plasma concentration pre- and up to 42 days post 
RYGB (n=16).  
A) Fasting tGLP-2-IR.                  
B) Fasting and maximum tGLP-2-IR. Solid line; pre RYGB (p=0.2 fasting vs. max), 
broken lines post RYGB (p<0.05 fasting vs. max for all meals). 
C) Meal profiles before and after RYGB (shown for day 2 and 42; day 4 and 7 have 
similar appearance to day 2 graph and were omitted for clarity).  
All depicted values represent the mean (SEM). 
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pre RYGB
Day 2 Day 4 Day 7 Day 42
      AUC (pmol/l) 35726 (3191) 50227 (6493) 50121 (5242) 60599 (6312) 51428 (6555)
  Δ AUC (pmol/l) 14623 (5463) 14724 (4612) 24573 (5280) 18492 (5534)
  Δ AUC (%) 47 (17) 52 (16) 85 (23) 73 (27)
p 0.018 0.007 0.0004 0.032
post RYGB
 
 
Table 5-1:  Total tGLP-2-IR AUC (0-180) and postoperative change (Δ AUC) 
 
n=16 
Values are mean (SEM)                  
Total AUC ANOVA: p=0.04         
p= paired student t–test (total AUC pre vs. post RYGB) 
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Figure 5-3:  Postoperative change of tGLP-2-IR AUC (0-180) (% change from pre-RYGB)  
n=16                        
Values represent mean (SEM)                  
**p<0.01, *p<0.05 (paired student t–test, total AUC pre vs. post RYGB)      
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Altered acute postprandial response after RYGB in diabetic subjects  
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Figure 5-4:  tGLP-2-IR meal profiles pre-and post RYGB; diabetic and non-diabetic subjects  
n=8 for each group           
Values represent the mean (SEM) 
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pre RYGB
Day 2 Day 4 Day 7 Day 42
AUC All 35726 (3191) 50227 (6493) 50121 (5242) 60599 (6312) 51428 (6555)
(pmol/l/180min) nonDM 33621 (3202) 62908 (9435) 53971 (7039) 66333 (6857) 49296 (4936)
DM 37831 (5567) 39132 (7323) 45721 (8080) 55582 (10316) 54412 (15101)
nonDM / DM p 0.53 0.06 0.45 0.42 0.72
Δ AUC All 14623 (5463) 14724 (4612) 24573 (5280) 18492 (5534)
(pmol/l/180min) nonDM 29848 (8215) 20351 (7063) 32369 (6352) 16312 (6655)
DM 1301 ( 2643) 8293 (5190) 17752 (7748) 22307 (10866)
nonDM / DM p 0.004 0.17 0.15 0.97
`
Δ AUC All 47 (17) 52 (16) 85 (23) 73 (27)
(%) nonDM 96 (25) 71 (26) 110 (33) 69 (37)
DM 4 (9) 30 (15) 63 (33) 81 (44)
nonDM / DM p 0.003 0.21 0.33 0.85
post RYGB
 
 
Table 5-2 Total tGLP-2-IR AUC (0-180) and postoperative change (Δ AUC) in diabetic and 
non-diabetic subjects 
n=8 for each group                
Values are mean (SEM)         
p= unpaired student t-test, diabetic vs. non-diabetic subjects 
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Figure 5-5: Postoperative change of tGLP-2-IR AUC (0-180) (% increase from pre-RYGB) in 
diabetic (empty bars) and non-diabetic (filled bars) subjects.  
n=8 for each group            
Values represent the mean (SEM)            
**p<0.01 (unpaired student t-test, diabetic vs. non-diabetic subjects) 
  170 
5.3.2 Study 2 (long term follow up) 
 
 
This study recruited six female patients with a pre-operative BMI of 48.3 ± 
1.4 kg/m2. Post-RYGB mean body weight and BMI showed significant 
reductions compared to pre-surgery values at all time points from 1 month to 
24 months. Mean weight loss at 24 months was 39.2 ± 3.6 kg (BMI of 33.9 
kg/m2; Figure 5-6). 
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Figure 5-6:  Change of BMI  
 6 female subjects following RYGB surgery.               
Values represent the mean (SEM)             
**p<0.01 (paired student t-test pre- vs. post RYGB). 
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Fasting levels of tGLP-2-IR remained constant throughout the pre- and post-
operative period (p=0.9, single factor ANOVA; Figure 5-7a).  
 
During the pre-RYGB meal, the 420 kcal nutritional stimulus did not cause 
a significant increase of the post-prandial tGLP-2-IR concentration from 
fasting at any time point (p=0.9, single factor ANOVA). The maximum peak 
occurred at 120 minutes (244±24pmol/l). The increase was equal to 15% of 
the fasting value. (Figure 5-7b, c). Following RYGB, postprandial tGLP-2-IR 
concentrations were raised compared to fasting levels at varying time-points 
between 30 and 120 minutes for up to 12 months. The maximum post-
prandial peak occurred at 30 minutes (1, 3, 12, 24 months) or 90 minutes (6 
months); with the highest value of 477±59pmol/l at 3 months (increase equal 
to 62% of the fasting value, Figure 5-7B). Postprandial profiles before and 
after RYGB (at 1, 6 and 24 months) are shown in Figure 5-7C. 
 
The area under the curve (AUC 0-180min) was calculated for every meal-
stimulated tGLP-2-IR profile. The tGLP-2-IR AUC in post-RYGB meals was 
significantly increased at 3 months and 6 months post surgery with a 
maximum AUC increase at 6 months (78% from pre-RYGB meal with a 
continued trend towards increase at 24 months (Table 5-3 and Figure 5-8). 
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Figure 5-7:  Meal related tGLP-2-IR concentration pre- and post RYGB (n=6).  
A) Fasting tGLP-2-IR 
B) Fasting and maximum tGLP-2-IR                 
Solid line; pre RYGB (p=0.2 fasting vs. max), broken lines post RYGB           
(p<0.05 fasting vs. max for all meals). 
C) Postprandial profiles pre-and post RYGB              
(shown for 1, 6 and 24 months; other time-points were omitted for clarity).  
All depicted values represent the mean (SEM). 
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pre RYGB
1 3 6 12 24
AUC 41656 (3110) 59633 (7596) 67403 (4976) 72614 (5983) 58744 (7652) 60498 (5512)
Δ AUC 17612 (7792) 25747 (5712) 30958 (6232) 17089 (8205) 15607 (5212)
Δ AUC (%) 44 (18) 66 (15) 78 (16) 45 (21) 35 (13)
p 0.087 0.006 0.004 0.092 0.058
post RYGB (months)
 
 
 
Table 5-3 Total tGLP-2-IR AUC (0-180) and postoperative change (Δ AUC) 
 
n=6 
Values represent mean (SEM)            
Total AUC ANOVA: p=0.02                
p= paired student t–test (total AUC pre vs. post RYGB) 
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Figure 5-8 Postoperative change of tGLP-2-IR AUC (0-180) (% change from pre-RYGB) 
n=6                     
**p<0.01 (paired student t–test; total AUC pre vs. post RYGB)            
Values represent mean (SEM)  
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5.4 Discussion 
 
The observation that bariatric surgical procedures, designed to bypass a 
significant portion of the intestinal tract, achieve lasting weight loss but only 
lead to modest and transient symptoms of malabsorption warrants further 
investigation. The Roux-en-Y gastric bypass (RYGB) procedure restricts the 
storage capacity of the stomach and allows undigested nutrients to bypass 
most of the stomach, duodenum and proximal jejunum. Nutrients and bilio-
pancreatic secretions are united in the distal jejunum. Consequently, 
nutrients have access to a reduced absorptive surface area of the small 
intestine. Although deficiencies in vitamins and minerals have been recorded 
(Pournaras et al. 2009), macronutrient malnutrition is a rare complication 
(Skroubis et al. 2006). Instead it is thought that a reduction in energy intake, 
mediated by gastric restriction and post-surgical alteration of gut-hormone 
secretion, is the principal mechanism of weight loss after RYGB. Increased 
secretion of the anorectic intestinal hormones PYY and GLP-1 as well as 
suppression of the gastric “hunger hormone” ghrelin have been implicated in 
decreasing appetite and calorie intake (Cummings et al. 2004). 
 
Morphological adaptation of the intestinal mucosa has been demonstrated in 
obese patients following bilio-pancreatic diversion, a similar bariatric 
procedure to RYGB, with an increase of villous height by 80% in the proximal 
and 58% in the distal ileum (Stock-Damge et al. 1986). Studies in a RYGB 
rodent model have shown increased cellular proliferation in the ileal crypts 
with increased mitoses and cellular uptake of the antibody to Ki67 (Carel Le 
Roux, unpublished data).  
 
The results of this study demonstrate a significantly enhanced post-prandial 
release of the intestinotrophic hormone GLP-2 in obese patients after RYGB. 
This effect can be demonstrated as early as 2 days following surgery and is 
still evident 24 month post surgery. There is no demonstrable change in 
fasting tGLP-2-IR concentration at any time point following RYGB surgery. 
As detailed in chapter 2 however, changes in fasting GLP-2 (1-33) 
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concentration are difficult to exclude completely with the measurement 
method used. 
 
Secretion of GLP-2 from enteroendocrine L-cells predominantly occurs in the 
distal jejunum and ileum. Nutrients are the chief secretory stimulus and 
appear to increase GLP-2 release through indirect neuro-hormonal 
mechanisms as well as direct L-cell contact (Section 1.1.4). However, bilio-
pancreatic secretions might also act as effective GLP-2 secretagogues 
(Chapter 6). 
 
It could be hypothesised that the accelerated and increased delivery of 
partially digested nutrients and/or digestive juices to the distal small bowel is 
largely responsible for the increase of postprandial GLP-2 secretion. This 
would be in keeping with findings of unchanged basal GLP-2 secretion. As 
described in Chapter 1, a small early peak of GLP-2 secretion can be 
observed under physiological conditions and is believed to be caused by 
early indirect L-cell stimulation through neuro-humoral signalling. A second, 
often more prominent peak occurs between 90-150 minutes  (Balks et al. 
1997; Xiao et al. 1999) which is thought to result from direct stimulation 
through nutrients reaching the distal intestine (Brubaker et al. 2003). In 8 
healthy volunteers consuming a 920kcal meal, peak GLP-2 concentrations 
were recorded between 90 and 240 minutes (Section 2.3). In contrast, the 
main post-prandial GLP-2 peak following RYGB surgery occurred very early 
(often 30min) after ingestion. 
 
The hypothesis that accelerated stimulation of the ileum and consequent 
release of L-cell products (GLP-1 and PYY) contribute to the effects of some 
bariatric surgery has been tested in rodent models of ileal transposition (IT). 
In this procedure, an isolated segment of ileum is transposed to the jejunum, 
resulting in an intestinal tract of normal length but an alteration in the normal 
distribution of endocrine cells along the gut. It was shown that rats with IT 
lost more weight and consumed less food than controls. Weight loss in the IT 
rats was not due to nutrient malabsorption but was thought to be caused by 
increased synthesis and release of the anorectic ileal hormones GLP-1 and 
  176 
PYY (Strader et al. 2005). Another study of ileal-jejunal transposition 
demonstrated significant increases in mucosal mass, villus height, and crypt 
depth in the transposed ileum as well as in the remainder of the small 
intestine (Tsuchiya et al. 1995). As GLP-1 is co-secreted with the 
intestinotrophic GLP-2 it is likely that GLP-2 is involved in this transposition 
hypertrophy. 
 
Physiologically, the increase of L-cell secretion in response to contact with a 
higher concentration of undigested nutrients could be interpreted as part of 
an adaptive response designed to decrease intake, slow gut motility and 
increase digestive and absorptive capacity and thus re-storing “normal 
nutrient concentration” in the L-cell environment.  
 
It is of note that there was no significant postprandial GLP-2 response prior 
to RYGB surgery. As we have previously demonstrated; GLP-2 secretion 
does not significantly vary between obese and normal weight subjects. It is 
therefore more likely that the lack of response was due to the relatively small 
calorie content of the meal. Meal related GLP-2 secretion is known to 
depend on nutrient composition and calorie content (Xiao et al. 1999). In 
keeping with this, a 500kcal test-meal of similar nutritional composition failed 
to produce a significant post-prandial response in lean or obese subjects 
(Chapter 4). 
 
Interestingly, significant disparity in the GLP-2 response between diabetic 
and non-diabetic subjects is shown early after RYGB. In contrast to the 
immediately increased postprandial GLP-2 response in non-diabetics, 
diabetic subjects demonstrated a flat postprandial meal profile, similar to the 
pre-operative response, on day 2 following surgery. Statistically there was no 
demonstrable difference between diabetic and non-diabetic subjects at any 
other time-point, however numerically this difference appeared to reduce 
only gradually until similar post-prandial secretion profiles were observed on 
day 42 (Figure 5-4, Figure 5-5; Table 5-2). 
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The secretion of glucagon-like peptides in diabetic patients has been studied 
more extensively for the insulinotropic GLP-1. Type-2 diabetic patients have 
a significantly reduced GLP-1 response to a test meal, compared with non-
diabetic controls (Vilsboll et al. 2001; Vilsboll et al. 2003). It is thought that 
the lower GLP-1 response seen in diabetic patients is probably a 
consequence of type-2 diabetes rather than a primary defect, as normal 24-
hour plasma concentration profiles are observed in first-degree relatives of 
patients with type-2 diabetes (Nyholm et al. 1999). In identical twins, 
discordant for type 2 diabetes, only the diabetic twin has decreased GLP-1 
levels (Vaag et al. 1996). GLP-1 is cleared at similar rates in type-2 diabetic 
patients and healthy subjects, indicating that the decreased GLP-1 
concentrations in type-2 diabetics are not attributable to differences in 
elimination (Vilsboll et al. 2003). In our cohort, a difference in post-prandial 
GLP-2 secretion between diabetic and non-diabetic patients can not be 
shown in the pre-RYGB meal. This is probably due to the relatively small 
caloric stimulus. Early (on day 2) after bypass surgery, an adaptive 
postprandial GLP-2 increase occurs in non-diabetics only. In diabetic 
subjects this early adaptive response appears to be absent. However, 
postprandial GLP-2 secretion becomes comparable to that of non-diabetics 
within days. These results suggest that gastric bypass surgery is able to 
restore a normal L-cell response in diabetics. As this will also result in 
increased release of GLP-1, this mechanism is likely to contribute towards 
the improved glucose homeostasis known to occur following gastric bypass. 
 
The GLP-2 related increase of intestinal mass is accompanied by enhanced 
intestinal digestive and absorptive functional capacity (Section 1.1.7). The 
reported increased proliferative activity and documented enhanced intestinal 
mass in humans and rats following intestinal bypass surgery may therefore 
partly explain the scarcity of calorie malabsorption associated symptoms 
after RYGB. Given the well known potent intestinotrophic properties of GLP-
2, the finding of increased GLP-2 levels post RYGB strongly suggests its 
contributing role. However, proof of a causative relationship would require 
studies using GLP-2 blockade or GLP-2 receptor deficiency models.  
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There have been concerns that high concentrations of growth factors like 
GLP-2 may stimulate malignant growth (Section 1.1.9). A decrease in the 
incidence of cancer has been reported after bariatric surgery and specifically 
no difference in bowel cancer incidence was noted (van der Woude 2007). 
Cancer of the small bowel is very rare and although exogenous GLP-2 
treatment can exert proliferative effects on the large bowel (Drucker et al. 
1997) it has not been investigated, whether stimulation of endogenous GLP-
2 secretion through bariatric procedures also increases crypt cell proliferation 
in the large intestine.  
 
Summary: An exaggerated GLP-2 response to nutrient ingestion can be 
demonstrated as early as 2 days following RYGB. Elevation of this growth 
factor may lead to adaptive changes in the intestinal mucosa that account for 
the restoration of intestinal function within months after malabsorptive 
bariatric surgery. 
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Chapter 6 
 
 
 
 
Glutamine and bile acid induced 
glucagon-like peptide-2 secretion 
from L-cells 
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6.1 Introduction 
 
Glucagon-like peptide-2 (GLP-2) is a potent intestinotrophic hormone that 
plays an important role in intestinal adaptation following injury or disease. 
Intake of nutrients is the main stimulus for GLP-2 secretion although the 
precise mechanisms of its release from enteroendocrine L-cells in the distal 
small bowel and colon are incompletely understood (Section 1.1.4). Certain 
dietary components may exert specific effects on structural and functional 
characteristics of intestinal adaptation. In this context the amino acid 
glutamine, a vital energy source for enterocytes, has generated interest. In 
rat models of small bowel resection and TPN induced mucosal atrophy; 
parenteral glutamine supplementation has been shown to improve the 
adaptive response (Tamada et al. 1993; Schroder et al. 1995). In patients 
with short bowel syndrome a glutamine enriched diet may enhance 
adaptation in conjunction with exogenous growth hormone (Zhou et al. 
2005). These effects might be mediated through glucagon-like peptide 
secretion. Cell culture experiments have suggested that glutamine stimulates 
GLP-1 secretion from L-cells (Reimann 2004). There is also recent in vitro 
evidence that bile acids play a role in the release of glucagon-like peptides. 
Expression of bile acid surface receptor TGR5 has been described in L-cell 
models (Katsuma et al. 2005).  
 
As a therapeutic agent, GLP-2 has shown potential as an adjunct in the 
treatment of short bowel syndrome and inflammatory bowel disease. Its 
positive effects on bone metabolism, intestinal barrier function, splanchnic 
perfusion and mucosal healing could be utilised to expand therapeutic 
applications to other causes of intestinal injury (Section 1.1.8). Stimulation of 
endogenous GLP-2 secretion might benefit patients in whom intestinal 
mucosal regeneration is impaired. This study aimed to evaluate the direct 
effect of glutamine and bile acids on GLP-2 secretion from enteroendocrine 
L-cells using the GLUTag cell culture model. A rodent model of papilla of 
Vater transposition was used to investigate the effect of bilio-pancreatic 
secretions on GLP-2 release in vivo. 
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6.2 Methods 
 
6.2.1 Cell culture 
 
These experiments were conducted at the Cambridge Institute for Medical 
Research and Department of Clinical biochemistry, Addenbrooke’s Hospital, 
Cambridge, UK in collaboration with Dr Fiona Gribble, who supervised the 
design of the study. Preparation and incubation of the cell cultures was 
performed by Miss Helen Parker. Cell culture analysis with 
radioimmunoassay and data interpretation was performed by the author. 
 
GLUTag cells were cultured in Dulbecco's modified Eagle's medium (DMEM, 
5.6mM glucose) supplemented with 10% (v/v) FCS, 100µg/ml streptomycin, 
100 u/ml penicillin and 4mM glutamine. They were incubated at 37ºC, 5% 
CO2 and the culture medium was changed every 3 days. When reaching 
~70% confluence (~every 5 days) cells were trypsinised with 1X trypsin-
EDTA, diluted and reseeded. For secretion experiments, cells were plated in 
24-well culture plates coated with Matrigel (BD Bioscience, UK) and allowed 
to reach 60% confluence (at least 24hrs). Before the experiment, cells were 
washed twice with saline buffer containing (in mM) 138 NaCl, 5.6 KCl, 4.2 
NaHCO3, 1.2 NaH2PO4, 2.6 CaCl2, 1.2 MgCl2, 10 HEPES and 0.1% BSA. 
Experiments were performed by incubating the cells with test reagents (as 
listed in Table 6-1) and 0.1mM Diprotin A in 500µl of buffer for 2hrs at 37°C. 
LCA was prepared as a 1000x stock solution in ethanol. Other agents were 
dissolved directly in the buffer. At the end of the incubation period the media 
was collected and centrifuged to remove floating cells. Supernatants were 
immediately frozen and stored at -70°C until analysis.  
 
Secretion was normalised to the baseline release in glucose free medium 
measured in parallel on the same day.  
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6.2.2 Ampulla of Vater transposition in rodents  
 
This study was performed in collaboration with Dr Carel Le Roux who 
developed the experiment. Animal work was performed by Ms Sandra 
Shurley at Northwick Park Hospital under a licence issued by the Home 
Office UK. Plasma sample analysis with radioimmunoassay and data 
interpretation was performed by the author. 
 
Sixteen adult male Wistar rats were randomised to either sham operation or 
duodenal translocation. The animals received 0.35 ml hypnorm and 0.35 ml 
diazepam intra muscularly before the procedure. The hair on the ventral 
surface was removed with an electrical shaver and the skin cleaned with 
Chlorhexidine. A longitudinal abdominal incision of 5 cm was made and the 
exposed bowel covered with wet gauze. Intestinal transposition involved 
excision of a duodenal segment containing the Ampulla of Vater, which 
allows drainage of both bile and pancreatic juices, and anastomosis to the 
ileum (10 cm proximal to the caecum). The first part of the duodenum and 
the first part of the jejunum was then re-anastomosed. The sham operation 
consisted of transsection of the proximal and distal parts of the duodenum 
and re-anastomosis. Post operatively gentamicin 8 mg/kg and caprofen 0.01 
mL was administered intraperitoneally as prophylaxis for postoperative 
infection. One rat in the transposition group died. Rats were housed 
individually and received a normal diet of chow and water ad libitum. The 
animals were sacrificed 4 weeks post-operatively. 3 cm of un-stretched 
terminal ileum was collected and weighed. Mixed arterial and venous blood 
was collected into lithium-heparin tubes containing 5000 Kallikrein inhibitor 
units (0-2 ml) aprotinin, immediately spun down at 1600g and stored at -70° 
until analysis.  
 
6.2.3 Radioimmunoassay 
 
Total GLP-2-IR was measured using antiserum FT-17as described in 
chapter 2. Antiserum FT-17 reacts 100% with human GLP-2. Cross-reaction 
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with GLP-1 is less than 0.1%. There is no cross-reaction with any other 
known gastrointestinal or pancreatic hormone (Appendix 1). FT-17 detects 
intact GLP-2 (1-33), its primary degradation product GLP-2 (3-33) and major 
proglucagon fragment (MPGF). Detection limit was 25pmol/l; intra-assay CV 
8.3%.  
 
6.2.4 Statistics 
 
Cell culture results are presented as fold increase versus control (mean ± 
SEM). Significance relative to secretion in the absence of nutrients was 
assessed using Student’s one-sample t test. Difference in secretory 
response between nutrients was assessed with two-tailed student t-test for 
independent samples. GLP-2 plasma concentration and TI weight in the 2 rat 
groups are presented as mean (SEM). Groups were compared using the 
two-tailed student t-test for independent samples. A p-value of less than 0.05 
was considered statistically significant for all statistical calculations. 
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6.3 Results 
 
The release of GLP-2 from GLUTag cells in response to glutamine and bile 
acids was investigated. GLP-2 secretion following incubation with glucose 
and glucose/forskolin/IBMX was examined as positive control. The secretory 
response to the different reagents is summarized in Table 6-1. 
 
Maximum stimulation of the cAMP/PKA pathway with glucose/forskolin/IBMX 
led to a 17.5 fold increase of GLP-2 in the culture medium. Glutamine 
(10mmol/l) increased the GLP-2 concentration in the culture medium 2.18 
fold. This response tended to be higher compared to stimulation with glucose 
(2 or 10 mmol/), however this difference was not significant (Figure 6-1).  
 
GLP-2 release in response to bile acids was diverse. DCA and LCA 
significantly increased GLP-2 secretion at 30mcM (2.36 and 1.96 fold 
respectively) but not at 1 mcM concentration. There was no difference in 
potency between DCA and LCA. There was a trend for GLP-2 secretion to 
increase after incubation with 30 mcM CDCA. DHCA and HDCA had no 
secretory effects (Figure 6-2 a). Addition of low dose glucose (2mmol/l) to 
either DCA or LCA had an additive effect on GLP-2 secretion compared with 
glucose or bile acids alone (Figure 6-2 b). 
 
Rats with transposition of bilio-pancreatic drainage to the ileum had an 
approximately 2-fold elevation of fasting GLP-2 plasma levels compared with 
sham operated controls: 83.3 pmol/l (74.2-112.6) vs. 165.6 pmol/l (134.2-
183.0); p=0.04 (Figure 6-3a). The bowel mucosa distal to the anastomosis 
was noted to be hypertrophic on post-mortem examination. Medium wet 
weight of the terminal ileum (3cm segment) was greater in the transposition 
group compared with the sham-operated group: 310g (255-315) vs. 200g 
(170-205) respectively; p=0.0006 (Figure 6-3b). 
 
 
 
  185 
Test Reagent  Concentration Wells Change SEM p
(mmol/l) (n) (fold control)
Glucose+ 10
Forskolin+ 0.01 4 17.5 3.6 0.02
IBMX 0.01
Glucose 2 8 1.77 0.11 0.0002
10 6 1.88 0.19 0.005
Glutamine 10 10 2.18 0.17 0.0001
DCA 0.001 6 1.13 0.14 0.42
DCA 0.03 10 2.36 0.23 0.0002
LCA 0.001 6 1.06 0.12 0.6
LCA 0.03 12 1.96 0.19 0.0003
CDCA 0.001 4 1.01 0.12 0.97
CDCA 0.03 4 1.27 0.24 0.35
HDCA 0.03 4 0.60 0.04 0.003
DHCA 0.03 3 0.72 0.11 0.12
 
Table 6-1:  Secretory responses of GLUTag cells 
tGLP-2-IR, measured in culture medium after 2-hour incubation with the test 
reagents and compared with control cultures, containing no active reagents 
Statistical significance was assessed using one-sample t test.              
(IBMX: 3-isobutyl-1-methylxanthine; LCA: lithocholic acid; DCA deoxycholic acid; 
CDCA: chenodeoxycholic acid; HDCA: hyodeoxycholic acid; DHCA dehydrocholic 
acid). 
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Figure 6-1:  GLP-2 response to glutamine (solid bar) in comparison to glucose (empty bars), 
stimulation with IBMX (dotted bar, secondary y axis) and controls (dotted line). 
Results are presented as mean ± SEM.              
The number of wells is indicated above each bar.        
Significance of change relative to secretion in the absence of nutrients           
*p<0.05, **p<0.01, ***p<0.001 (Student’s one-sample t test) 
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Figure 6-2:  GLP-2 response bile acids (BA) in comparison to glucose (empty bars) and. 
controls (dotted lines).The number of wells is indicated above each bar. Results are 
presented as means ± SEM. 
 
A: Bile acid response: DCA deoxycholic acid; LCA lithocholic acid; CDCA 
chenodeoxycholic acid; HDCA hyodeoxycholic acid; DHCA dehydrocholic acid; BA 
concentration (30µmol/l).                   
Significance of change relative to secretion in the absence of nutrients           
**p<0.01; ***p<0.001 (Student’s one-sample t test) 
 
B: Additive effect of co-stimulation with glucose: Combination of low dose 
glucose (Glc; 2mM/l) and bile acids (BA; 0.03mM/l) promotes stronger GLP-2 
secretion from GLUTag cells than either agent alone.                 
Statistical significance was assessed using two tailed student-t test                 
(** p<0.01: increase vs. glucose; # p<0.05; ## p<0.01: increase vs. BA 
alone) 
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Figure 6-3:  Ampulla of Vater (AoV) transposition in rats 
Week 4 post AoV transposition to the distal ileum versus sham operated controls.  
A: Plasma tGLP-2-IR concentration  
B: Weight of a 3cm unstretched segment of terminal ileum (TI)  
Values are mean (SEM)                               
** p<0.01; ***p<0.001 (two tailed student-t test) 
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6.4 Discussion  
 
It has been demonstrated that glutamine and bile acids are effective GLP-2 
secretagogues in vitro, using the GLUTag L-cell model. 
 
Because enteroendocrine L-cells represent only a small proportion of 
epithelial cells and are difficult to isolate in purity, GLUTag cells were used to 
investigate the L-cell secretory response. This cell line is a well-recognized 
L-cell model, derived from a colonic tumour in a transgenic mouse 
expressing SV 40 large T antigen. These cells express the glucagon gene 
and secrete the glucagon-like peptides in a regulated manner and are 
therefore frequently utilized for the analysis of GLP-1 and GLP-2 
secretagogues (Drucker et al. 1994).  
 
Proglucagon gene expression in the intestine has been shown to be 
regulated by a cAMP-dependent pathway in rodent tissue culture (Drucker et 
al. 1989). Work on GLUTag cell cultures has provided additional evidence 
that cAMP elevation also directly triggers GLP-1 release and enhances the 
secretory response to other stimuli by modulating hyperpolarisation-activated 
currents and the background potassium current (Simpson et al. 2007). In 
keeping with these results this study shows that forskolin and 
phosphodiesterase inhibitor IBMX, commonly used to maximise intracellular 
cAMP accumulation, also led to a substantial increase in GLP-2 
concentration in the culture medium, indicating that the cAMP pathway in the 
cultured cells was intact. 
 
Glutamine is not only a key metabolic fuel for enterocytes, it has also been 
shown to regulate the expression of many genes related to metabolism, 
signal transduction, cell defence and repair (Curi et al. 2005). In animal 
models, glutamine improves intestinal morphology in parenteral nutrition 
induced mucosal atrophy (Schroder et al. 1995) and enhances adaptation 
after massive intestinal resection (Tamada et al. 1993). These findings have 
encouraged glutamine supplementation in patients with short bowel 
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syndrome where it has shown to be of possible clinical benefit when used in 
combination with low-dose human growth hormone and a modified diet 
(Zhou et al. 2005). Other potential clinical uses of glutamine include intensive 
care settings, where it might reduce serious sepsis (Andrews et al. 2002). 
Glutamine supplementation might also reduce complications following 
haematopoietic stem cell transplantation in children (Kuskonmaz et al. 2008).  
 
The mechanisms of glutamine action in the intestine are poorly understood. 
It is demonstrated here that Glutamine is a GLP-2 secretagogue in vitro. It 
could therefore be hypothesised that the intestinotrophic properties of 
glutamine might in part be mediated through the release of GLP-2. Increased 
secretion of glucagon-like peptides following glutamine supplementation 
might also be relevant in the treatment of sepsis as GLP-2 has been shown 
to reduce bacterial translocation and boost immune responses in rats 
(Chance et al. 2001; Kouris et al. 2001), whereas GLP-1 improves glycaemic 
control in animal models and human clinical studies (Todd et al. 2007). 
Glutamine induced secretion of GLP-2 from L-cells has not yet been 
described. Reimann et al. have previously demonstrated that glutamine 
dose-dependently triggers and potentiates secretion of GLP-1 from GLUTag 
cells (Reimann et al. 2004). This data is strengthened by the documentation 
of co-secretion of GLP-2. To optimize substrate delivery to the cultured cells, 
pharmacological concentrations of glutamine (10mmol/l) were used in this 
study. However, Reiman et al have previously shown that glutamine-induced 
GLP-1 secretion from GLUTag cells also occurs at 1mmol/l (Reimann et al. 
2004), which resembles the physiological extracellular concentration of 
glutamine (0.7 mmol/l) (Newsholme et al. 2003) more closely.  
 
The essential role of bile acids for the absorption of dietary lipids is well 
described. More recently it has become apparent that bile acids are also 
signalling molecules, influencing bile acid synthesis, lipid metabolism and 
energy homeostasis (Houten et al. 2006) and may confer gut mucosal 
protection against bacteria (Hofmann et al. 2006). Bile acids regulate 
expression of various transport proteins and enzymes through binding and 
activating nuclear receptors such as farnesoid X receptor α. It is now 
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understood that bile acids are also ligands for a membrane based G-protein-
coupled receptor; TGR5. TGR5 has been identified in the L-cell models STC-
1 and GLUTag. Its activation induces rapid intracellular cAMP accumulation 
(Maruyama et al. 2002; Kawamata et al. 2003). 
 
Increased gut glucagon-like immunoreactivity after exposure of a canine ileal 
loop to bile and following intracolonic infusion of deoxycholic acid in humans 
has previously been reported (Namba et al. 1983; Adrian et al. 1993). More 
recently bile acid mediated stimulation of GLP-1 secretion though TGR5 was 
demonstrated in STC-1 cultures (Katsuma et al. 2005). Since GLP-1 and 
GLP-2 are co-secreted it could be assumed that GLP-2 release will follow 
the same pattern in this cell line. The results of the work presented here 
support this data by demonstrating bile acid induced GLP-2 secretion in an 
alternative L-cell model.  
 
It has been noted that the agonistic activities of bile acids on the TGR-5 
receptor appear to increase in accordance with hydrophobicity (Kawamata et 
al. 2003). The findings of this study are consistent with this. Strongly 
hydrophobic bile acids like LCA and DCA acted as GLP-2 secretagogues 
whilst hydrophilic bile acids like HDCA and DHCA elicited no measurable 
response. Low concentration (1mcM) DCA and LCA failed to stimulate 
quantifiable secretion, in keeping with the dose dependent response 
previously described for GLP-1 (Katsuma et al. 2005). A stimulatory effect on 
glucagon-like peptide-1 secretion from GLUTag cells has been described for 
other hormones that act via G-protein coupled receptors, coupled to 
adenylate cyclase. Glucose-dependent insulinotrophic peptide (GIP) and 
pituitary adenylate cyclase-activating polypeptide (PACAP) dose-
dependently trigger GLP-1 release in the presence of 10 mmol/l glucose, 
with a maximum stimulation of 1.8- to 2-fold (Simpson et al. 2007). The 
magnitude of this response compares with the documented increase of GLP-
2 in response to bile acid stimulation.  
 
Effects on cell cultures might not always indicate physiological relevance as 
pathways identified in vitro, might be overridden by other regulatory signals. 
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A contributory role of bile acids in intestinal growth and adaptation in vivo is 
controversial. Small intestinal mass remained unchanged in response to bile 
infusion in pythons, an established model of intestinal adaptation (Secor et 
al. 2002). In rat models of small intestinal resection, additional diversion of 
biliary juices did not hamper development of compensatory hypertrophic 
changes in the small intestine (Fenyo 1977; Ulshen et al. 1984). 
Nonetheless, an increase of mucosal mass in distal ileal segments following 
transplantation of the duodenal papilla into the ileum has been previously 
described (Weser et al. 1977). This is in keeping with the observations in our 
rat model. Hypertrophic distal ileal mucosa was noted in all the rats following 
the diversion of bilio-pancreatic juices to the distal ileum that contains a large 
proportion of L-cells. There was a 50% increase in weight in the terminal 
ileum. We have also shown that this is associated with higher levels of 
plasma GLP-2. It is therefore conceivable that, whilst the adaptive response 
following intestinal resection might be chiefly dependent on other stimuli like 
nutrient exposure, bilio-pancreatic secretions are also capable of inducing 
local intestinal hypertrophy, possibly mediated through stimulation of GLP-2 
release. Alternatively, the increased release of GLP-2 might be explained by 
delivery of greater amounts of poorly digested foods to the distal L-cells. 
 
In vivo, L-cells are exposed to a large variety of nutritional, hormonal and 
neural stimuli. It is likely that some of these have additive or even synergistic 
effects. In this study the combined stimulation of GLUTag cells with glucose 
and bile acids was more effective than with either agent alone. When 
exploring augmentation of endogenous GLP-2 secretion for therapeutic 
purposes, combined agents might therefore prove more effective. General 
caution should be exercised in the long-term use of intestinal growth factors. 
Stimulatory effects on colonic proliferation and a possible role in colon 
carcinogenesis has been described for bile acids (Reddy et al. 1977; Lapre 
et al. 1992) and GLP-2 (Thulesen et al. 2004; Masur et al. 2006).  
 
Summary: Glutamine and bile acids stimulate secretion of GLP-2 from L-
cells in several experimental models. Diversion of bilio-pancreatic secretions 
to the distal ileum is associated with increased plasma GLP-2 and local 
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intestinal hypertrophy in rats. It is proposed that the intestinotrophic 
properties of these substances might in part be mediated through the release 
of GLP-2. 
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Chapter 7 
 
 
 
 
Final discussion and conclusions 
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The link between increased secretion of glucagon-related peptides and the 
development of intestinal villus hyperplasia was first established in 1971, in a 
case report of patient, presenting with an “enteroglucagon”-producing renal 
tumour and massive small bowel enlargement (Gleeson et al. 1971). In a 
landmark study more than 20 years later, Daniel Drucker and colleagues 
were able to link these potent intestinotrophic properties to glucagon-like 
peptide 2 (GLP-2) (Drucker et al. 1996). Although basic research into the 
physiological role of GLP-2 has been hampered by difficulties in developing 
effective GLP-2 deficiency models, there is rapidly growing understanding of 
the central role of GLP-2 for intestinal growth and adaptation. The most 
recent scientific progress relates to the identification of downstream 
mediators of GLP-2 action, in particular the pivotal role of IGF-1.  
 
The ability to determine GLP-2 concentration in tissue and bodily fluids 
accurately has furthered the understanding of GLP-2 secretion and actions 
and given insights into the regulation of intestinal adaptation to injury or 
disease. It has also paved the way towards exploration of therapeutic GLP-2 
supplementation in a variety of intestinal conditions, culminating in a recent 
large scale clinical trial of GLP-2 in patients with short bowel syndrome. 
However, measurement methods for GLP-2 are not widely available and 
commercial assays are often poorly validated.  
 
This thesis has shown that a radioimmunoassay using antiserum FT-17 
provides a sensitive and specific method for the measurement of GLP-2 in 
plasma samples and tissue extracts. Although the antiserum is not specific 
for measurement of biologically active GLP-2 (1-33), accurate estimations of 
active GLP-2 concentrations can be made when the secretory response to a 
physiological stimulus is measured. The finding that fasting t-GLP-2-IR 
concentrations do not correlate well with active GLP-2 (1-33) concentration is 
very important in the interpretation of study results. The poor correlation of 
results obtained when using a commercially available GLP-2- ELISA kit in 
comparison with the current gold-standard method of measurement (GLP-2-
RIA using antiserum 92160), emphasises the need to validate any analytical 
method in order to interpret test-results accurately.  
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Alteration of gut hormone secretion from enteroendocrine L-cells has been 
demonstrated in a variety of pathological conditions, in particular following 
intestinal resection. In keeping with previous studies, it has been 
demonstrated here that secretion of proglucagon derived peptides (GLP-1 
and GLP-2) as well as PYY is reduced in patients with short bowel syndrome 
and jejunostomy. However, it has been shown for the first time that SBS 
patients with a retained colon, despite increased L-cell secretion of PYY, can 
be GLP-2 deficient. This has led to the conclusion that, despite their co-
localisation in enteroendocrine L-cells, the production and/or secretion of 
PYY and proglucagon derived peptides may be regulated differentially and 
could vary depending on the residual intestinal anatomy. Following intestinal 
resection, an adaptive increase of PYY secretion might mainly occur in the 
colonic L-cells, whereas L- (or other endocrine) cells in the residual jejunum 
might be primarily responsible for the adaptive increase in GLP-1 and GLP-2 
that was previously shown in this patient group (Jeppesen et al. 2000). 
These results would tie in with the relatively novel concept of multipotent 
enteroendocrine cells that produce peptides according to stimuli in the 
metabolic or biochemical milieu (Theodorakis et al. 2006). 
 
A similar disparity between regulation of PYY and glucagon-like peptide 
secretion may also occur in obesity. The results presented in this thesis 
show that, in contrast to the previously demonstrated attenuated 
postprandial PYY response in the obese (Le Roux et al. 2006), no reduction 
of glucagon-like peptide secretion is found. However, the limited subject 
number might have concealed a small concentration difference between 
obese and normal weight subjects.  
 
Measurement of gut hormone secretion in patients following gastric bypass 
procedures has revolutionized our understanding of the mechanisms of 
weight loss following bariatric surgery. It is now thought that, in addition to 
malabsorption of nutrients due to reduced surface area, a gut hormone 
mediated decrease of appetite and energy intake, is a major contributor to 
achieving sustained weight reduction. Results presented in this thesis 
document for the first time an exaggerated GLP-2 response to nutrient 
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ingestion as early as 2 days following RYGB that is sustained for at least 2 
years. It is hypothesised that the elevation of GLP-2 may lead to adaptive 
changes in the intestinal mucosa that account for the restoration of intestinal 
function after malabsorptive bariatric surgery. The interesting additional 
finding of an apparently delayed adaptive response in diabetic subjects 
deserves further investigation as the resolution of type-2 diabetes has been 
closely linked with increase of glucagon-like peptide secretion.  
 
Enhancing endogenous GLP-2 secretion might be an effective therapeutic 
strategy for patients in whom intestinal mucosal regeneration is impaired. 
This thesis demonstrates that glutamine and bile acids stimulate secretion of 
GLP-2 from model L-cells and proposes that the intestinotrophic properties 
of these substances might in part be mediated through the release of GLP-2. 
However, the limited interpretability of results obtained in artificial cell 
models, which might not always indicate physiological relevance, has to be 
taken into consideration. 
 
Far from simply being a place of nutrient digestion and absorption, the 
gastrointestinal tract is increasingly appreciated as an important endocrine 
(and immunological) organ. Although so far mostly studied in isolation, it is a 
fundamental consideration that GLP-2 will act in concert with other gut 
hormones. The mechanisms of such interaction constitute an important field 
of future research in order to understand the physiological consequences 
and maximise the benefits of therapeutic GLP-2 supplementation. 
 
In the development of future treatments for intestinal failure, GLP-2 might 
become instrumental in the development of tissue engineered neo-intestine. 
Although still experimental, this technique emerges as a possible alternative 
to long-term parenteral nutrition or intestinal transplantation. The response of 
tissue-engineered neo-intestine to exogenous GLP-2 includes mucosal 
growth and enhanced SGLT-1 expression (Ramsanahie et al. 2003). 
Measurement of GLP-2 in neo-intestine could serve as marker of 
enteroendocrine differentiation. 
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Finally; it has been very exciting to witness the progress of GLP-2 from 
relative obscurity to its recognition as an important physiological mediator 
and promising therapeutic agent. I hope that my work has contributed 
towards the understanding of this interesting peptide. 
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Appendix 1: Cross-reactivity of antiserum FT-17  
 
 
0
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%
 b
in
d
in
g
GLP-2 standard
  
GLP-2 (fmol) GLP-2 (pmol) % binding
0 0 71.8
1 0.001 67.9
2 0.002 65.6
3 0.003 62
5 0.005 53.1
10 0.01 34.2
15 0.015 24.4
20 0.02 20.5
30 0.03 15.8
50 0.05 13.1
100 0.1 10.8  
 
 
% binding % binding % binding
Peptide concentration (1pmol) (10pmol) (100pmol)
alpha CGRP 72.2 70.6 71.1
AVP 69.5 70.1 70.5
Bombesin 69.5 68.7 70
CRF 71.2 71.4 70.7
Galanin 68.5 70.3 70.3
GIP 71 70.2 65.7
GLP-1 65.5 38.4 12.6
Glucagon 69.9 68.7 69.4
GRF 70.9 70 69.8
LH-RH 68.8 67.5 70.5
Neurotensin 70.9 69.2 71.2
NPY 69.1 68.8 73.6
PACP 70.4 71.5 72.6
PHM 72.3 72.7 75.4
PYY 65.4 67.8 69.3
Secretin* *70.3 *70.1 *70
VIP 71.5 71.9 71.4  
 
 
 
FT-17 RIA: GLP-2 standard curve and cross-reactivity of with other peptide hormone standards. 
Minimal cross-reactivity of with GLP-1 (0.01%) is demonstrated. Laboratory data from Prof. M. Ghatai 
1997 (unpublished).               
* Tested standard concentrations of secretin are 0.2pmol; 2pmol and 20pmol. 
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Appendix 2: Solutions 
 
 
 Dextran coated charcoal: 
2.4g of charcoal and 0.24g of dextran were added to 100ml of phosphate 
buffer with gelatine and mixed for twenty minutes at 4oC 
 
 Phosphate buffer (GLP-2 and PYY): 
48g of Na2HPO4.2H2O, 4.13g KH2PO4, 18.61g EDTA 
(C10H14H2O8Na2.2H2O, 2.5g NaN3 are dissolved in 5l of distilled water that 
had been boiled and allowed to cool, the pH was measured to confirm it was 
7.4±0.1. The buffer was stored at 4oC 
 
 Veronal buffer (GLP-1) 
10.1g of Barbitone Sodium (C8H12N2O3) and 0.5g of NaN3 are dissolved in 1l 
of distilled water that had been boiled and allowed to cool. Solution was 
titrated with concentrated HCL until pH was 8.0 and stored at 4oC 
 
 Sephadex G50: 
8g fine grade Sephadex G-50 beads (diameter: 20-80μm) (Sigma), 2ml 100x 
TE and 0.1ml 20% SDS are added to 200ml water and autoclaved to expand 
beads. Column buffer was 0.06 M phosphate buffer containing 0.2 M NaCl 
and 0.3% BSA 
 
 Freeze-dry solution 
12.5g Lactose, 3ml BSA (30%), 0.5g citric acid, 0.25g L-cysteine 
hydrochloride, 1.06ml formic acid and 2ml Trasylol dissolved in 250 ml 
distilled water 
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Appendix 3: Table of amino acids 
 
 
Amino Acid    Codes 
    Three letter    Single letter 
 
Glycine    Gly    G 
Proline   Pro    P 
Alanine   Ala    A 
Valine    Val    V 
Leucine   Leu    L 
Isoleucine   Ile    I 
Methionine   Met    M 
Cysteine   Cys    C 
Phenylalanine  Phe    F 
Tyrosine   Tyr    Y 
Tryptophan   Trp    W 
Histidine   His    H 
Lysine    Lys    K 
Arginine   Arg    R 
Glutamine   Gln    Q 
Asparagine   Asn    N 
Glutamic Acid  Glu    E 
Aspartic Acid   Asp    D 
Serine    Ser    S 
Theronine   Thr    T 
